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Abstract
Feline immunodeficiency virus (FIV) is a pathogenic virus that causes disease in the 
domestic cat. FIV is found worldwide and can give rise to an infection that is very similar 
to human immunodeficiency virus (HIV) and the syndrome that is aquired 
immunodeficiency syndrome (AIDS). As FIV is a significant pathogen of cats, is found 
worldwide and induces similar pathology to that induced by HIV, developing a vaccine to 
FIV would not only benefit the domestic cat population but would provide an insight into 
the requirements for a HIV vaccine. To further the research into a FIV vaccine, the main 
aim of this study was to evaluate feline CD40 ligand (CD40L) as an adjuvant in a DNA 
vaccine against FIV.
Initially, the biological activity of the previously cloned feline CD40L was demonstrated 
using proliferation assays and a CD40L feeder layer system. Once the biological activity 
of feline CD40L had been proven, a FIV DNA construct was selected for use in a DNA 
vaccine. To determine whether CD40L would enhance the immune response to FIV, an 
immunogenicity trial was conducted in mice. BALB/c mice were injected with CD40L 
DNA alone, FIV DNA alone or FIV DNA and CD40L DNA together. A control group 
was inoculated with phosphate buffered saline (PBS) only. The study demonstrated that 
CD40L enhanced the humoral immune response in mice to FIV but the results of the cell- 
mediated immune response to FIV were inconclusive.
Studies were also conducted in the cat. Specified pathogen free (SPF) cats were inoculated 
with FIV DNA alone, CD40L DNA alone, or FIV and CD40L DNA. A control group was 
inoculated with PBS only. This study demonstrated that CD40L enhanced the cell- 
mediated response to FIV, but no anti-viral antibodies were detected in any of the groups 
post-vaccination. To further test the efficacy of a CD40L adjuvanted FIV DNA vaccine, 
the vaccinated cats were challenged intraperitoneally (i.p) with the virulent FIV isolate 
FIV-Glasgow 8 (FIV-GL8). No cats developed sterilising immunity to the FIV challenge 
as all vaccinated cats became virus isolation positive; however overall the viral loads were 
lower in the FIV and CD40L vaccinated cats than in the other groups.
In the vaccine trial it was noted that there was a degree of enhancement of infection in the 
groups that were inoculated with FIV DNA or CD40L DNA alone. The final part of this 
study investigated potential modes of enhancement of FIV infection.
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Chapter One 
INTRODUCTION
1.1. Feline immunodeficiency virus
FIV is a retrovirus of the lentivirus subfamily that infects domestic cats. Closely related 
viruses infect several species of large felids, cross-reactive antibodies to a FIV-like 
lentivirus have been found in free-ranging African lions and cheetahs and also in North 
American pumas (Olmsted et al, 1992). Other lentivlral infections include visna virus in 
sheep, caprine arthritis-encephalitis virus in goats, equine infectious anaemia virus in 
horses, bovine immunodeficiency virus in cattle, simian immunodeficiency virus (SIV) in 
macaques and HIV in man (Coffin, Hughes, and Varmus 1997). FIV was first isolated in 
1986 from a pet cat in California (Pedersen et al. 1987) and was classified as a lentivirus 
due to its many characteristic properties, for example, cell tropism for T lymphocytes and 
macrophages, magnesium dependent reverse transcriptase enzyme and the induction of a 
persistent, lifelong infection in the host (reviewed in Miyazawa & Mikami 1993). Analysis 
of serum samples stored in the 1960s indicated that the virus was prevalent then (Gruffydd- 
Jones et al. 1988); moreover subsequent phylogenetic studies have suggested that it is even 
older than that (Rigby et al. 1993; Sodora et al. 1994; Bachmann et al. 1997; Carpenter et 
al. 1998). Sodora et al. (1994) determined patterns of genetic diversity by studying a 684- 
nucleotide region encompassing variable regions V3, V4 and V5 of the FIV env gene, 
when the results were compared with a SIV (SIV-AGM) it was found that SIV-AGM 
subtypes existed within clear geographic boundaries, however FIV subtypes did not 
suggesting an earlier entry into and/or the greater mobility of the host species. 
Furthermore, analysis of Kg values (proportion of the potential silent nucleotide changes 
that have occurred) demonstrated that FIV has been prevalent in cat populations longer 
than HIV-1 has been in humans. FIV is found worldwide, with the prevalence ranging 
from as little as 1% in low-risk cats in the United States and Canada to 44% of sick cats in 
Japan (reviewed in Lee et al. 2002), further evidence that FIV is relatively ancient.
In the UK, Hosie, Jarrett, and Robertson (1989) confirmed that FIV was a significant 
pathogen of cats, infecting 19% of sick cats compared to 6% of healthy cats. A more 
recent study concluded that the sero-prevalence of FIV in a group of 517 stray cats sent to 
a Royal Society for the Prevention of Cruelty to Animals (RSPCA) hospital in Birmingham
16
was 10.4% in all of the cats, 4.9% in the healthy cats and 16.7% in the sick cats (Muirden 
2002). Moreover, in agreement with Hosie, Jarrett and Robertson, Muirden also 
demonstrated that the seroprevalence of FIV was significantly higher in entire males and 
neutered males than in females, in cats over two years old compared with younger cats, and 
in cats suffering disease of non-traumatic origin rather than in healthy cats or cats suffering 
only fi'om trauma. FIV is shed in the saliva and is transmitted mainly through biting hence 
the high prevalence in male, fi-ee-roaming cats.
In a follow up study of FIV infected cats conducted in July 2000, the outcome of 32 cats 
that tested seropositive for FIV between February and June that year were categorised into 
three groups: group 1 were cats that had died or were euthanased due to the severity of 
their clinical signs; group 2 were cats that had responded to treatment but had shown at 
least one recurrence of clinical signs since their diagnosis; and group 3 were cats that 
responded well to treatment and remained free of clinical signs following the initial 
presentation (Lawson and Hosie 2001). Of the 32 cats in the survey, 53% could be 
assigned to group 1 and had either died or been euthanased following diagnosis of FIV 
infection, 25% were in group 2 and were suffering from recurring clinical signs and only 
21.9% remained symptom free and could be assigned to group 3. Therefore, it was 
concluded from these results that FIV is a significant feline pathogen and infection with 
FIV can result in severe and often fatal illness.
FIV is an important subject to study, not only because of its implications for feline health 
but also because of the similarities between this feline virus and other lentiviruses causing 
immunodeficiency, including HIV, the cause of AIDS (Willett, Flynn, and Hosie 1997). 
Therefore FIV is a useful small animal model for HIV, particularly for research into 
vaccination. At the present time, 40 million people are living with HTV/AIDS worldwide, 
of whom 37 million are adults and 2.5 million are children under the age of 15. Five 
million new infections with HIV occurred in 2003 and a total of 3 million people died from 
HIV/AIDS related causes in the same year (World Health Organisation and the United 
Nations Programme on HIV/AIDS, AIDS Epidemic Update, December 2003) 
(http://www.avert.org/worldstats.htm). It is generally accepted that vaccination is the only 
way in which the pandemic can be halted. FIV is an animal model which, in terms of 
clinical pathology and disease progression, is very similar to HIV (Johnson et al. 1994; 
Miller et al. 2000). Such similarities have promoted the use of FIV as a model for
17
identifying effective HIV vaccine strategies (Bendinelli et ai. 1995). FIV vaccines and 
treatments can be tested in the natural host and the correlates of protection may be 
identified. This exchange of ideas and data from FIV research could be vital in reaching 
the ultimate goal of a vaccine against HIV.
1.1.1, Genomic structure
The FIV genome consists of two identical molecules of single-stranded RNA. Each 
molecule is flanked by terminal non-coding sequences that include two direct repeats and a 
unique 5’ (U5) or 3’ (U3) sequence. Reverse transcription of these non-coding sequences 
generates identical structures referred to as long terminal repeats (LTRs) found at both 
ends of the DNA provirus, transcription of the provirus between the upstream U3 and the 
downstream U5 regions generates RNA with the same terminal organisation as the parental 
virus (Coffin, Hughes, and Varmus 1997).
The FIV genome contains three major coding regions, gag, pol and env. The gag gene 
encodes the matrix (MA or pl5), capsid (CA or p24) and nucleocapsid (NC or plO) 
proteins, the pol gene encodes the protease (PR pi 4), reverse transcriptase enzyme (RT or 
p62), integrase (IN or p31) and dUTPase (DU or p i5) proteins, and the env gene encodes 
the surface envelope glycoprotein (SU or gpl20) and the transmembrane glycoprotein (TM 
or gp42), see Figures 1.1 and 1.2. There are additional genes, including the rev gene, 
which is involved in transport of incompletely spliced RNA from the nucleus to the 
cytoplasm, the vif gene which controls cell free virus infectivity (reviewed in Miyazawa 
and Mikami 1993) and the orf A gene which is required for virus particle formation and 
virus infectivity (Gemeniano et al. 2003; Gemeniano, Sawai, and Sparger 2004).
1.1.2. Replication
Once the viral particle has attached to a specific receptor on a susceptible cell, the viral 
core enters the cell. In order to make the necessary proteins of progeny virions, the viral 
RNA is reverse transcribed into a linear DNA duplex, which then integrates into the hosts 
chromosomal DNA and is thereafter transcribed by the hosts own machinery. The 
integration of the proviral DNA is the basis for the life-long persistence of the virus. 
Expression of proviral genes leads to the production of progeny virions and may induce 
death of the cell.
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1.1.3. Clinical and pathological findings
CD4^ T-cells are the target of FIV during early infection in vivo but, with increased time 
after infection, CD8^ T-cells and CD21^ B-cells become infected (English et al. 1993; 
Dean et al. 1996). There are many alterations in T and B-cell function following infection, 
with a decline in CD4^ T-cells (Ackley et al. 1990; Willett et al. 1991; Hoffmann-Fezer et 
al. 1992), the expansion of a CD8^ subpopulation (expressing elevated levels of major 
histocompatibility complex [MHC] class II) (Novotney et al. 1990; Willett et al. 1993), 
reduced proliferative responses to mitogens, depressed antibody responses and 
hypergammaglobulinaemia (Ackley et al. 1990; Lin et al. 1990; Lawrence, Callanan, and 
Jarrett 1992).
The initial phase of FIV infection of cats can last from a few weeks up to a few months, 
during which time there is viral growth resulting in clinical signs such as lymphadenopathy 
and pyrexia (Yamamoto et al. 1988; Dua et al. 1994). Most cats recover from this phase 
and then enter the asymptomatic phase (the term ‘asymptomatic’ is not strictly correct for 
use with animals but has been widely adopted to describe the period during which infected 
individuals remain in good health, by analogy to the course of HIV infection in man). The 
asymptomatic phase can last for several years, during which time the virus is controlled by 
anti-FIV immune responses. However, there is a steady decline in CD4^ T lymphocyte 
numbers (Ackley et al. 1990; Willett et al. 1991; Hoffmann-Fezer et al. 1992; Etemad- 
Moghadam et al. 2001), presumably due to cell killing by the virus, and eventually the 
animal may become immunodeficient and succumb to the terminal phase of the disease, 
with clinical signs such as stomatitis/gingivitis, cystitis, chronic diarrhoea and chronic 
upper respiratory tract infections (reviewed in Bendinelli et al. 1995). Such clinical signs 
are similar to those exhibited by patients with AIDS, following infection with HIV.
The infected animal mounts humoral and cellular immune responses against the virus. 
Antibodies directed at the major core proteins and the envelope glycoproteins develop 
within 2-6 weeks of the animal becoming infected and titres remain high throughout 
infection (Hosie and Jarrett 1990; Avrameas et al. 1992; Avrameas et al. 1993). Virus 
neutralizing antibodies (VNA) are also evident from around 5-6 weeks post infection (p.i) 
(Fevereiro et al. 1991; Osborne et al. 1994; Inoshima et al. 1996; Del Mauro et al. 1998). 
Virus-specific cytotoxic T lymphocyte (CTL) responses aie also detected after infection 
and normally before the appearance of serum antibodies. Thus, Gag-specific cytotoxic
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activity is detected as early as 2 weeks p.i, followed by gMv-specific activity (Beatty et al. 
1996). The FlV-specific CTLs induced are predominantly MHC-Ï restricted. Not only are 
cytolytic cells induced but non-cytolytic anti-viral activity is also evident (Hohdatsu, 
Okubo, and Koyama 1998; Flynn et al. 1999; Choi, Flokanson, and Collisson 2000). In a 
recent study, cytolytic and non-cytolytic T-cell responses were compared in a group of cats 
experimentally infected with the FIV-GL8 isolate (Flynn et al. 2002). Virus-specific 
effector CTL responses were first detected at 4 weeks p.i, with the emergence of FIV Gag- 
specific effector CTL responses in the peripheral blood. However, suppression of FIV 
replication by non-cytolytic T-cells was apparent in all the lymphoid tissues examined as 
early as one week p.i.
1.1.4. Cell tropism and pathogenesis of FIV
The cell tropism of a virus is a vital determinant of the pathogenesis of the ensuing disease 
(Lairmore et al. 1987). FIV has been shown to infect several different cell types in vivo, 
including CD4^ and CD8^ T-cells and B-cells (English et al. 1993). To gain entrance into a 
cell, the viral SU must attach to one or more cellular receptors. Initially, it was considered 
that FIV might use the same cell receptor as HIV, namely CD4, due to the similarities in 
tropism and pathogenesis between HIV and FIV. However, although feline CD4^ cells are 
highly susceptible to FIV infection, it has been demonstrated that FIV also infects feline 
CD4“ cells, including feline fibroblasts (Yamamoto et al. 1988), macrophages (Brunner and 
Pedersen 1989) and astrocytes (Dow, Poss, and Hoover 1990). Another putative cellular 
receptor for FIV was feline CD9, after an anti-CD9 monoclonal antibody was shown to 
block infection (Willett et al. 1994). However, ftirther studies demonstrated that the 
inhibition of FIV infection by anti-CD9 antibody did not operate at the level of virus entry 
but at a subsequent stage in the virus life-cycle (Willett et al. 1997b). The primary cellular 
receptor for FIV was identified as CD 134 (Shimojima et al. 2004), during the completion 
of this thesis. GDI34 is a T-cell activation antigen and a co-stimulatory molecule. 
Furthermore, it has been demonstrated that although FIV and HIV do not use the same 
primary cellular receptor, both viruses use the same co-receptor, namely CXCR4 (Willett 
et al. 1997c; Poeschla and Looney 1998a; Egberink et al. 1999; Richardson et al. 1999). 
Willett et al. (1997c) demonstrated that cell-culture adapted strains of FIV were able to use 
the a-chemokine receptor, CXCR4 for cell fusion and later Richardson et al. (1999) 
demonstrated the use of CXCR4 by primary isolates of FIV. HIV-1 strains that replicate
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only in T cell lines, but not in macrophages or monocytes, known as T-tropic viruses, use 
CXCR4 for cell entry, while HIV-1 M-tropic (specific to macrophages and monocytes) 
viruses utilise another chemokine receptor, CCR5 (reviewed in Coffin, Hughes, and 
Varmus 1997).
As would be expected, the env gene is the primary deteiminant of cell tropism for both 
HIV and FIV. It has been shown that most primary FIV isolates do not normally grow in 
fibroblast cells of the CRFK line but replicate freely in activated peripheral blood 
mononuclear cells (PBMC). Conversely, isolates that are cell-adapted will grow in CRFK 
cells (Siebelink et al. 1995a). A glutamic acid~>lysine (E->K) mutation in the V3 
hypervariable domain of SU has been shown to be responsible for the change in tropism 
(Verschoor et al. 1995a). This amino acid substitution causes an increase in charge of the 
V3 loop. These differences in cell tropism have been associated with differences in 
virulence between isolates of FIV. In a recent study the cell tropism and virulence of three 
different molecular clones of FIV, (FIV-pF34, FIV-14, and FIV-pPPR) was investigated 
(Dean, Himathongkliam, and Sparger 1999). FIV~pF34 was shown to replicate in CRFK 
cells but not PBMC and proved least efficient for establishing persistent infection in cats, 
whereas FIV-pPPR could infect PBMC but not CRFK and was most efficient for 
production of a persistent viraemia in vivo. In addition, the molecular clone FIV-14, which 
was shown to replicate in both CRFK and PBMC induced an infection of low virulence in 
vivo.
Virulence of individual FIV isolates may play a major role in assessing the efficacy of 
vaccines. Protection with a vaccine based on FIV-Petaluma (PET) was demonstrated 
against challenge with the homologous isolate and later the heterologous FIV-Dixon isolate 
(Yamamoto et al. 1993), but these isolates of FIV are believed to be of low virulence 
compared to the primary FIV-GL8 isolate, which requires a period of adaptation for 
replication in CRFK cells. However, it is likely to be necessary for a commercially 
available vaccine to confer protection against primary, and presumably more relevant 
isolates, such as FIV-GL8. Hosie et al, (1995) conducted whole inactivated virus (WTV) 
and inactivated cell (IC) vaccine trials in the early 1990s using the FIV-GL8 isolate, but 
could not reproduce the successful results of Yamamoto et al. (1993) using a FIV-PET 
WIV vaccine. Since then, a variety of immunogens have failed to induce good protection
21
against the FIV-GL8 isolate (Hosie et al. 1992; Hosie et al. 1995; Bishop et al. 1996; Hosie 
et al. 2000; Dunham et al. 2002).
1.2. Vaccination against FIV
The genes of FIV encode proteins against which an immune response can be made. 
Vaccine trials have been conducted using a variety of immunogens, including whole 
inactivated virus (WIV), inactivated infected cells (IC), recombinant subunits, peptides, 
recombinant live viruses and DNA representing different structuial and functional FIV 
genes.
Some vaccine trials have been successful in inducing protection against FIV infection. As 
indicated above, Yamamoto et al. (1991b) demonstrated protection against the FIV-PET 
isolate of FIV using paraformaldehyde-inaetivated FIV-PET-infected FeT or FL4 cells or 
paraformaldehyde-inactivated virus from FL4 cell culture fluid (Yamamoto et al. 1991a). 
Hosie et al. (1995) confirmed the latter result In a subsequent study, Hosie et al. (1998) 
induced protection against the FIV-PET isolate by vaccinating with a DNA construct with 
an in-ffame deletion in the RT region of pol (FIVART). This construct, administered 
together with a feline gamma-interferon (IFN-y) genetic adjuvant, was the first DNA 
vaccine to confer protection against a lentivirus. However, the result of vaccination is 
often not as simple as protection or non-protection against viral challenge. There may be 
other beneficial outcomes after vaccinating against FIV, including decreased viral loads 
post challenge, slowed rate of inversion of the CD4:CD8 ratio, slowed rate of development 
of the CD8p^®  ^ cell population or even, unfortunately, enhancement of infection after 
vaccination. For this reason, more research is required to define the enhancing and 
protecting immune responses against FIV. Moreover, if a sterilising vaccine cannot be 
developed, studies into the effects of a non-sterilising HIV vaccine have demonstrated that 
it may still be very beneficial (Davenport et al. 2004). Davenport et al. (2004) used an 
epidemiological model to determine the effects of a disease-modifying HIV vaccine and 
predicted that a decrease in viral load of 1 logio copies/ml would be sufficient to reduce 
HIV-associated mortality in the first 20 years after the introduction of vaccination by 30%. 
Accompanying the variations in vaccine trial outcome are the many variations in vaccine 
trial design itself, for example, type of vaccine administered (WIV or DNA), injection site 
of vaccine (intradermal [i.d], subcutaneous [s.c] or intramuscular [i.m]) and challenge 
inoculum (biological isolates or molecular clones of FIV or natural exposure).
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1.2.1. Whole inactivated virus and infected cell vaccines
Since the discovery of FIV in 1986, many combinations of vaccine type and challenge 
inoculum have been assessed. WIV and IC vaccines have induced the greatest level of 
protection thus far. WIV vaccines have induced protection against homologous (Hosie et 
al. 1995; Yamamoto et al. 1991b) and heterologous isolates of FIV (Yamamoto et al. 
1993). The results with IC vaccines have been more variable. Protection against infection 
has been achieved using infected FeT or FL4 cells (Yamamoto et al. 1991b) and MBM 
(feline CD 3\ CD4' and CDS' PBMC) cells (Matteucci et al. 1996). In a third study, 
Bishop et al. (1996) demonstrated protection against a challenge administered soon after 
vaccination with an FL4-PET IC vaccine, but experienced later infection of FIV-PET in 
6/8 vaccinated cats at 50 weeks post-challenge. A further group tested the efficacy of an 
IC vaccine using infected CRFK cells and infected thymocytes as immunogens (Verschoor 
et al. 1995b). The cells were infected with the Dutch isolate, FIV-UTl 13. After challenge 
witli the homologous isolate, 8/10 cats vaccinated with IC vaccines became virus isolation 
positive. Nonetheless, it was shown that the cats vaccinated with infected CRFK cells had 
lower viral loads (as determined by quantitative virus isolations [QVI]) after challenge 
when compared with the unvaccinated controls, suggesting that a degree of protection had 
been achieved.
IC vaccines have also induced enhancement of infection. Karlas et al. (1998) used 
autologous fixed FIV-infected PBMC as the vaccine. The FIV isolate used to infect the 
PBMC was the molecular clone 19K1, and the challenge inoculum was the homologous 
virus. Although antibodies against Gag proteins were detected after vaccination, 
antibodies against Env proteins were not, VNA were also detected at low levels. However, 
4 weeks after challenge, vaccinated and control cats all became viraemic and, more 
alarmingly, the infection in the vaccinates was accelerated. Thus, vaccinated cats became 
viraemic a week before the controls and developed higher viral loads overall. Moreover, 
provirus was detected by PCR at 2 weeks post-challenge in vaccinated cats as opposed to 4 
weeks post-challenge in controls. Giannecchini et al. (2002) also demonstrated 
enhancement after IC vaccination with infected-autologous lymphoblasts. However, the 
same group showed promising results with an IC vaccine tested conventionally in SPF cats 
challenged paienterally (Matteucci et al. 1996) and then by contact in field cats (Matteucci 
et al. 2000), a study which was more representative of natural infection than those studies
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natural infection than those studies conducted in SPF cats. Subject cats were housed in a 
private shelter where FIV was endemic, with a prevalence of FIV infection of 29-58% over 
an 8-year observation period. Cats were able to roam freely in the areas surrounding the 
shelter. After cats were designated FIV negative, they were immunised with 6 doses of an 
IC vaccine consisting of MBM cells infected with the FIV-M2 Italian isolate over a 16 
month period and were observed for 28 months after the commencement of the study. 
Immunised cats developed both antibodies and cellular immunity to FIV, although the 
immune responses varied greatly between cats. At the end of the study 0/12 immunised 
cats had evidence of FIV infection by virus isolation and PCR in comparison with 5/14 
control cats. These data are encouraging, suggesting that a vaccine against naturally 
occurring FIV infection can be developed and evoking the question: should more vaccine 
trials be conducted in this manner? It may be that parenteral challenge delivers an 
unnaturally high dose of virus to the host or may circumvent the innate baniers to natui’al 
challenge.
1.2.2. Recombinant subunit and peptide vaccines
After initial work with WTV and IC vaccines, attention turned to recombinant subunit and 
peptide vaccines. These vaccines involved immunising animals with either FIV proteins 
expressed by recombinant viruses or bacteria, or immuno-affinity purified proteins or 
synthetic peptides. Several groups tested the efficacy of these vaccines, hoping that 
targeting the immmie system to the immunodominant epitopes of the Env protein for 
example, would enhance protection. In a previous study, Hohdatsu et al. (1993) 
demonstrated that serum antibodies against FIV envelope glycoproteins correlated with 
protective immunity. Thus, when cats were immunised with sera from FIV-PET infected 
or IC/WIV vaccinated unchallenged cats and later challenged with FIV-PET, they were 
protected. Again, in a now familiar pattern, vaccination studies with subunit and peptide 
vaccines had three general outcomes: no noticeable effect on infection, suppression of 
infection or enhancement of infection.
None of the vaccines that were studied conferred sterilizing immunity in all vaccinates, 
although some vaccinations did lead to a suppression of infection, manifesting either as a 
reduction in viral load post-challenge or by a delay in seroconversion (Hosie et al. 1996; 
Lutz et al. 1996; Tijhaai* et al. 1997; Huisman et al. 1998; Richardson et al. 1998; 
Leutenegger et al. 1998). In addition, many studies did demonstrate the induction of FIV-
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specific cell-mediated and humoral immune responses following immunization, 
particularly with peptide based vaccines (Lombardi et a l 1994; Flynn et al. 1994; Flynn et 
al. 1995b; Rigby et al. 1996; Finerty et al. 2000). Frustratingly though, none of these 
vaccines induced protection or even a significant suppression of infection when compared 
with controls. However, and perhaps more importantly, neither did they facilitate 
infection.
In contrast, enhancement of infection was observed in cats immimised with a range of 
vaccines (Hosie et al. 1992; Siebelink et al. 1995b; Flynn et al. 1997; Huisman et al. 1998). 
In one such study, Hosie et al. (1992), cats were inoculated with purified FIV virions 
incorporated into immune stimulating complexes (ISCOMS), ISCOMS containing 
recombinant FIV p24 or an IC vaccine. All of the vaccinates became infected (13/13) in 
comparison with 7/9 controls. Furthermore, the vaccinated cats were found to be virus 
isolation positive earlier than the controls. Similar problems were encountered with a 
recombinant vaccinia virus (rVV) vaccine (Siebelink et al 1995b). FIV envelope 
glycoproteins were expressed by rVV (in native form or with a deletion of the cleavage site 
between SU and TM) and were incorporated into ISCOMS. However, two weeks after 
challenge with the homologous FIV-AM19 isolate, the pro viral load proved to be 
significantly higher in the cats immunized with the r W  than in other cats immunised with 
(3-Gal-FIV Env or SIV-Env ISCOMS or PBS. In another approach, Tellier et al. (1998) 
tested the efficacy of a canarypox-based FIV vaccine. The efficacy of a HIV-1 canarypox- 
based vaccine had already been proven in macaques against a heterologous challenge with 
HIV-2 (Abimiku et al. 1995). The coding regions of the env, gag and protease genes from 
the FIV- Villefranche isolate were inserted into a canarypox virus vector (ALVAC) and the 
ALVAC recombinant (ALVAC-FIV) was then used to immunise SPF cats, with and 
without an IC vaccine boost. When challenged with a homologous subtype A virus (FIV- 
PET, which is almost identical to FIV-Villefranche), 2/3 cats inoculated with ALVAC-FIV 
alone were protected. In addition, 3/3 cats inoculated with ALVAC-FIV and who received 
an IC vaccine boost were protected. These three cats were then challenged further with the 
heterologous subtype B virus, FIV-Bangston (FIV-BANG). Partial protection was
observed, in that one of the cats remained completely virus negative. Although the other 
two cats remained virus isolation negative, FIV pro viral DNA was detected by PCR. This 
vaccine trial raises hope that vaccines could be developed that would induce a broader 
range of protection against more than one subtype of FIV.
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1.3. DNA vaccination
A relatively new concept in vaccination strategies is the use of naked DNA as an 
immunogen. DNA vaccines consist of a foreign gene, for example an FIV structural gene, 
cloned into a bacterial plasmid. The plasmid also contains an origin of replication to allow 
growth in bacteria, a selectable marker (such as antibiotic resistance), a eukaryotic 
promoter to drive expression of the gene of interest in mammalian cells (for example the 
human cytomegalovirus [CMV] promoter), and a polyadenylation signal to stabilise the 
transcribed mRNA. DNA vaccines provide a mechanism for achieving intracellular 
synthesis of antigen by the introduction of a coding sequence directly into cells, either via 
i.m or i.d inoculation or via a gene gun (whereby DNA coated gold particles are introduced 
into the epidermis). The DNA is taken up by the host cells and transcribed to mRNA, 
which is then translated into the protein of interest by the cells own machinery. The viral 
proteins are then recognised as foreign by the host cells and an immune response is 
induced against them.
DNA vaccines act like a live viral vaccine, by inducing a MHC class I restricted CD 8  ^T- 
cell response, because the immunogen is synthesised inside the cell and processed by the 
endogenous pathway. Precursor CTLs recognise viral peptides of approximately 9 amino 
acids presented on infected cell surfaces by MHC class I molecules and are activated to 
become cytolytic. DNA vaccines can also induce a MHC class II response when 
immunogens are internalised (reviewed in Robinson and Torres 1997). DNA vaccines do 
not have the major disadvantage of live viral vaccines, in that the growth of potentially 
dangerous viruses can be avoided.
Already much research has been conducted using DNA vaccination in the continued search 
for a FIV vaccine. DNA constructs that have been studied include FIV proviruses which 
have been rendered defective in various ways, with an in-frame deletion in pol (FIVART) 
(Hosie et al. 1998), a deletion in vif (FIVAviÇ (Lockridge et al. 2000), a deletion in the 
AP-1 binding site (FlVAAP-1) (Kohmoto et al. 1998) or a deletion in the integrase gene 
(FIVAIN) (Dunham et al. 2002). Other constructs that have been developed encode for 
FIV structural proteins, for example, the envelope glycoprotein and the nucleocapsid 
protein (Richardson et al. 1997; Cuisinier et al. 1997). Boretti et al. (2000) tested the 
immunogenicity of a vaccination protocol based on minimalistic, immunogenic defined 
gene expression (MIDGE) vectors coding for gpl40 (SU and the extracellular part of TM)
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and feline interleukin-12 (IL-12). The vaccine was administered by gene gun. Like most 
of the DNA vaccines studied, using this system a low level of protection was induced. On 
the contrary however, DNA vaccines, like the other vaccines studied, are also capable of 
causing enhancement of infection (Richardson et al. 1997), although the mechanism is not 
well understood.
1.3.1. Mode of action of DNA vaccines
The mechanism by which the inoculation of muscle cells (DNA vaccines are primarily 
introduced i.m) with DNA elicits an immune response is not entirely clear, but there are 
three possibilities by which antigen encoded by a DNA vaccine could be processed and 
presented to the immune system, (reviewed in Gurunathan, Klinman, and Seder 2000):-
(a) Direct priming by muscle cells.
(b) Cross-priming in which DNA is taken up by muscle cells or antigen-presenting
cells (APCs) and the secreted protein is then processed by other APCs and
presented to T-cells.
(c) Direct priming by APC for example, Langerhans cells in the case of i.d injection.
DNA vaccines have been shown to elicit both cellular and humoral immune responses. 
The predominant isotype detected after DNA vaccination in mice is IgG2a, indicative of a 
T-helper 1 (Thl) response, although other isotypes produced include IgGl, IgA and IgM. 
DNA vaccines can also induce Th2 responses in mice when using the gene gun method of 
immunisation (Feltquate et al. 1997).
There are many factors that influence the type and efficacy of the immune responses 
provoked by individual DNA vaccines in particular species of animals. It will be important 
to determine which factors work best to produce a protective immune response against 
primary field isolates of FIV (such as FIV-GL8). The factors involved include the 
promoter used to regulate viral gene expression, the mode of administration, any co­
stimulatory molecules or adjuvants included in the vaccine (most DNA vaccines developed 
to date have only been successful in terms of protection when administered in combination 
with a vector expressing a co-stimulatory molecule) and the presence of cytidine- 
phosphate-guanosine (CpG) sequences/motifs. CpG motifs are specific nucleotide 
sequences that contribute to the immunogenicity of DNA vaccines. They occur naturally
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in bacterial DNA and have many beneficial immunological effects, such as inducing 
proliferation of B-cells, induction of APCs to secrete cytokines and stimulation of T-cells. 
The immune response induced in mice by CpG motifs is characterised by the production of 
IL-6, IL-12, TNF-a and TNF-y (Klinman, Yamshchikov, and Ishigatsubo 1997).
In an attempt to define the factors influencing cellular immune responses to FIV DNA 
vaccination, Flynn et al. (2000) administered FIV-PETART to cats. Feline IFNy was 
included as an adjuvant in some groups in an attempt to boost the cell-mediated immune 
responses. The promoters used in the vaccine trial were either a human CMV promoter or 
the FIV 5’ long terminal repeat (LTR) promoter. The delivery routes of the vaccine were 
i.m and i.d. The results showed that the highest level of FIV-specific CTL activity 
occurred in cats inoculated with FIV ART + IFNy, administered i.m, with the CMV 
promoter. However, the highest level of protection was achieved using a similar construct 
but with the FIV 5’LTR promoter, again administered i.m.
The fundamental properties of a protective vaccine against FIV have not yet been 
identified. An attempt was made to define the immune correlates of protection by 
establishing an immunisation regimen that induced suboptimal protection against FIV-PET 
using a WIV vaccine (Hosie et al. 1996b). Cats were vaccinated twice with WIV as 
opposed to three times, the regime shown previously to induce protection. In a preliminary 
experiment this protocol resulted in virus isolation following challenge from 2/5 vaccinated 
cats. It was intended that a comparison of the humoral and cellular immune responses in 
the viraemic and non-viraemic cats would provide an indication of which type of response 
was required for protection. In the definitive study, only 2/10 vaccinated cats became virus 
isolation positive. Thirty-five weeks after the initial challenge, the 8 protected cats were 
then rechallenged with a higher dose of virus (FIV-PET), to assess the duration of 
immunity conferred by vaccination. After the second challenge only one of the challenged 
cats became virus isolation positive. The results of the study demonstrated that after the 
initial challenge, protection correlated positively with the VNA titre induced before 
challenge. However, the ability to resist the second challenge was more closely related to 
the initial induction of Env-specific CTL activity following vaccination. These results 
indicated that protection might be conferred by both humoral and cellular components.
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Similar correlates of immunity may not apply to the FIV-DNA vaccine systems. Thus, 
Lockridge et al. (2000) induced protection against the FIV-PPR isolate using a DNA 
vaccine that did not induce cellular responses in all of the protected cats. Only one of four 
immunised protected cats exhibited a measurable CTL response to Env and one to Gag 
post-inoculation. Conversely, Hosie and co-workers later showed that DNA vaccination 
could confer protection against a homologous FIV-PET challenge in the absence of a 
detectable antibody response (Hosie et al. 1998). However, it appears that both cellular 
and humoral immunity will be required to protect against FIV-GL8 infection and therefore 
it is important to develop vaccines that may elicit high levels of these types of immune 
responses.
1.4. CD40L
In order to extend protection against FIV-GL8, the effect of the co-stimulatory molecule 
CD40L (CD 154, gp39, T-BAM or TRAP [tumour necrosis factor related activation 
protein]), as a genetic adjuvant to a DNA vaccine was investigated. Ligation of the T-cell 
receptor (TCR) is insufficient to trigger activation of naïve T-cells and both the 
engagement of the TCR with MHC/antigen and a second signal are required for complete 
activation. This second, co-stimulatory signal takes the form of a co-stimulatory molecule, 
which is delivered by the APC to which the naïve T-cell is bound (Parham 2000). APCs 
can be distinguished from other cells by the presence of co-stimulatory molecules on their 
surfaces. The CD28/B7 receptor/ligand system is one of the dominant co-stimulatory 
pathways in the immune system and others include CD40/CD40L.
Kim et al. (1998) demonstrated in mice and chimpanzees that the efficacy of DNA 
vaccines could be enhanced by co-stimulatory molecules, using CD86 as a co-stimulatory 
molecule in a DNA vaccine against HTV-l. DNA vaccine constructs expressing HIV-1 env 
and HIV-1 gag/pol, as well as constructs expressing human CD80 and CD86 were 
prepared. CD80 and CD86 belong to the B7 co-stimulatory molecule family and blocking 
of this signal leads to T-cell anergy. A dramatic increase in CTL induction was observed 
as well as Th cell proliferation with the co-administration of the gene coding for CD86. 
This enhancement of CTL response was MHC class I restricted and CD8^ T-cell 
dependent.
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CD40L plays a role in cell-mediated immunity and is also involved in the production of 
antibodies. Since the components of a protective immune response are not known, it is 
desirable for FIV vaccines to induce both cell-mediated and humoral immunity. CD40L is 
a 33kDa type II glycoprotein of the tumour necrosis factor (TNF) family, which is 
assembled in trimers on the cell surface. CD40L was originally cloned from the murine 
EL-4 thymoma cell line (Armitage et al. 1992). A cDNA encoding CD40L was isolated 
from EL-4 cells after enrichment of the cells that bound to CD40-Fc, a biotin-labelled 
soluble fusion protein consisting of the extracellular domain of CD40 linked to the Fc 
region of human IgGl. CD40 is the receptor for CD40L and is expressed on B-cells, 
dendritic cells, endothelial cells, fibroblasts and epithelial cells. The human CD40L gene 
was isolated by screening stimulated human blood T-cell libraries with the murine CD40L 
probe (Spriggs et al. 1992; Hollenbaugh et al. 1992). The nucleotide sequences of murine 
and human CD40L (Genbank accession numbers X65453 and X67878 respectively) 
predict proteins of 260 and 261 amino acids respectively. CD40L is expressed primarily 
on activated but not resting CD4^ T-cells and is also expressed on skin mast cells, blood 
eosinophils and basophils.
1.4.1. CD40L functions in B-cell maturation
CD40L has many functions in the immune system, including the induction of B-cell 
proliferation, maturation and isotype switching, a role in tolerance at the level of the 
thymus, and in T-cell priming. The critical role of CD40L in the humoral immune 
response was confirmed by the discovery that hyper-immunoglobulin M (HIgM) syndrome 
in humans was caused by defects in the CD40L gene (Allen et al. 1993). Since the CD40L 
gene is found on the X chromosome, HIgM syndrome is a sex-linked condition and is 
characterised by increased levels of IgM and decreased amounts of all other isotypes, 
leading to increased occurrence of bacterial infections in affected individuals. CD40L 
complementary DNA from three of four patients contained mutations. The proteins 
encoded by tiiese DNAs were unable to bind the CD40 receptor or to induce proliferation 
of B-cells or IgE secretion from normal B-cells. Activated T-cells from the four affected 
patients failed to express wild-type CD40L, although their B-cells were able to respond 
normally to wild-type CD40L. These findings demonstrated that CD40L is required on 
activated T-cells to bind CD40 on B-cells to induce proliferation of B-cells, and that 
CD40L plus the cytokine IL-4 are required for the production of IgE (Spriggs et al. 1992).
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Noelle et al. (1992) demonstrated that CD40L induces B-cell maturation, proliferation and 
differentiation using monoclonal antibodies (mAb) and CD40-Ig (a soluble fusion protein 
of CD40 and human Ig). The addition of CD40-Ig to cultures of plasma membrane 
fractions from activated Th cells and B-cells caused a dose-dependent inhibition of B-cell 
RNA synthesis, whereas a control fusion protein had no effect. Figure 1.3 illustrates the 
effect of the ligation of CD40 (expressed on B-cells), by CD40L (expressed on T-cells).
CD40L interacts with IL-4 to induce production of IgE (Jabara et al. 1990; Zhang, Clark, 
and Saxon 1991; Spriggs et al. 1992) and therefore CD40L could possibly be implicated in 
the cause and treatment of allergies as IgE is produced in allergic reactions (Markert et al. 
1999; Mehlhop et al. 2000). CD40 is also expressed on carcinomas (Bussolati et al. 2002; 
Voorzanger-Rousselot and Blay 2004) and there are exciting new developments with 
regard to using CD40L as a therapy for cancer patients (Gurunathan et al. 1998; Sotomayor 
et al. 1999; Hirano et al. 1999; Kikuchi et al. 2000; Vonderheide et al. 2001). Also, 
CD40L may act directly to suppress tumour growth and indirectly to enhance anti-tumour 
immune responses (reviewed in Tong and Stone 2003).
1.4.2. CD40L functions in T-cell priming
CD40L promotes the cellular immune response by activating APCs to allow CTL priming. 
Schoenberger et al. (1998) demonstrated that CD40L expressed on CD4^ T-cells primes 
CTLs. Ligation of CD40 on APCs such as dendritic cells (DC), macrophages and B-cells 
by CD40L (expressed on activated CD4^ T-cells), greatly increases their antigen presenting 
and co-stimulatory capacity. DCs process foreign antigen and present it in a complex with 
MHC Class n  molecules to naïve antigen-specific T-cells. DCs also express B7, which 
interacts with CD28 on T-cells to cause early T-cell activation and the expression of 
CD40L by T-cells. The CD40L expressed binds to CD40 on the DCs, resulting in 
expression of T-cell stimulatory molecules such as IL-12, and upregulation of B7 
production. The expression of these molecules culminates in T-cell expansion and 
maturation into Th-cells or CTLs, as illustrated in Figure 1.4.
1.4.3. Identification of feline CD40L
A biologically active homologue of CD40L has been identified in the domestic cat (Brown 
et al. 2002). Briefly, cDNAs encoding the feline homologue of CD40L were isolated from 
mRNA from feline thymus and peripheral blood lymphocytes. Primers designed from
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regions of consensus sequence identified in the published human and murine CD40L 
sequences were used to amplify feline CD40L using the polymerase chain reaction (PCR), 
The cDNAs encoded a single open reading fiame 780bp in length giving rise to a 
polypeptide of 260 amino acids with a predicted molecular mass of 28.6kDa. The nucleic 
acid sequence of feline CD40L has been deposited in GenBank, accession number 
AF079105. The biological activity of feline CD40L was demonstrated using 3T3 cells 
(murine fibroblast cell line) (Todaro and Green 1963) stably transfected with feline CD40L 
(3T3.F154) as targets in proliferation assays and it would appear that feline CD40L has 
similar properties and functions as miuine and human CD40L. Therefore, it may have the 
potential to induce humoral and cellular immune responses if used as a co-stimulatory 
molecule in feline DNA vaccines. As described above, CD40L mediates its antiviral 
effects via interaction with CD40. In addition it may have direct antiviral activity itself, 
since Ruby et al. (1995) demonstrated that rVV that expressed CD40L were readily cleared 
from a variety of immunodeficient mice.
CD40L has been considered as an adjuvant for HIV vaccination. Ihata et al. (1999) 
conducted a study in mice whereby a plasmid expressing human CD40L and plasmids 
encoding gpl60 of HIV-HUB and HIV-1 rev were inoculated by the i.m route. Expression 
of human CD40L enhanced Thl and Th2 type cytokine production, increased the 
production of antigen-specific antibody of both IgG and IgM isotypes and induced 
delayed-type hypersensitivity and CTL activity in a dose-dependent manner.
The aim of this project was to evaluate the use of CD40L as an adjuvant for FIV DNA 
vaccination. As a preliminary, the biological activity of feline CD40L was assessed. The 
immunomodulatory capacity of feline CD40L in mice was tested and a vaccine trial against 
FIV was conducted in cats. The advantage of testing the adjuvant effects of CD40L in 
conjunction with an FIV DNA vaccine is that the FIV cat model represents a challenge 
system in which the protective efficacy of the induced immune responses may be tested. 
Thus, research into the use of CD40L as an adjuvant in DNA vaccination is an important 
step in,the continuing search for a vaccine against FIV and HIV.
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Figure 1.1. Schematic cross section of a retrovirus particle
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Proteins encoded by the env region of the viral genome are SU and TM, the gag region of the viral genome 
encodes MA, CA and NC and the pol region encodes RT, PR, IN and DU. For details of abbreviations, see 
text. Adapted from Bendinelli et al. 1995.
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Figure 1.3. Biologicai effects of CD40 activation on different 
stages of B-cell development
..
► CD40L
► CD40
-proliferation 
-CD23 expression
-proliferation 
-differentiation 
-GC precursors
-CD80/CD86 expression
-proliferation 
-differentiation 
-isotype switching
-Ig production 
-IL6 expression
The figure illustrates the effect of CD40 ligation on B-cells with CD40L expressed on activated T-cells. The 
consequences differ depending on the stage of development of the B-cell. Transition from naïve to germinal 
centre (GC) and from GC to memory is thought to be promoted by CD40 activation. CD40 activation of 
memory B-cells either results in a new round of germinal centre reaction and/or an accelerated differentiation 
into immunoglobulin producing plasma cells. Adapted from Kooten and Banchereau 2000.
35
Figure 1.4. CD40L functions in T-cell priming
CJD40o
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p r o d u c t io n
CD40L expressed on activated CD4+ T-cells primes cytotoxic T-lymphocytes (CTL), in association with 
antigen presenting cells (APCs). Ligation of CD40 on APCs by CD40L expressed on CD4+T-cells, greatly 
increases their antigen presenting and co-stimulatory capacity. These events culminate in T-cell expansion 
and maturation into helper T-cells or CTLs.
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Chapter Two
COMMON MATERIALS AND METHODS AND 
STATISTICAL ANALYSIS
2.1. Common materials and methods
2.1.1. Cells and culture media 
2.1.1.1 Mya-1 ceils
Mya-l cells (Miyazawa et al. 1989) represent a feline T lymphocyte cell line that was 
selected for its susceptibility to FIV infection and was maintained in Roswell park 
memorial institute (RPMI)-1640 medium (Life Technologies, Paisley, UK) supplemented 
with 10% foetal calf serum (FCS), 2mM glutamine, 100 lU/ml penicillin and lOOpg/ml 
streptomycin, 5 x lO'^M 2-mercaptoethanol (complete RPMI) and 100 lU/ml human 
recombinant IL-2 (a kind gift from M. Hattori, University of Tokyo).
2.1.1.2. 3T3 cells
The murine fibroblast cell line 3T3 (Todaro et al. 1963) was maintained in Dulbecco’s 
modification of minimal essential medium (DMEM) (Life Technologies) supplemented 
with 10% FCS, 2mM glutamine, 100 lU/ml penicillin and lOOpg/ml streptomycin 
(complete DMEM). The 3T3.F154 cell line derived from the 3T3 cell line was maintained 
in complete DMEM, with the addition of 400pg/ml G418-sulphate (Geneticin, Life 
Technologies).
2.1.1.3. 293T cells
The human kidney epithelial cell line 293T (DuBridge et al. 1987) was also maintained in 
complete DMEM supplemented with 400pg/ml G418-sulphate (Geneticin, Life 
Technologies).
2.1.2. Viruses
The FIV-GL8 isolate (Hosie 1991), first isolated in 1988 was used in this study, both to 
develop a DNA vaccine and also as the challenge inoculum. The challenge virus (Hosie et 
al. 1992; Hosie et al. 1995) was prepared from the biological isolate and was previously
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titrated in vivo to establish the infective dose 50% (ID50) and 10 ID50 was used as the 
challenge inoculum.
2.1.3. DNA vaccines
2.1.3.1. CD40L DNA vaccine
For the purposes of inoculating into skeletal muscle, the feline CD40L cDNA (previously 
amplified from cDNA prepared from feline thymus using PCR) was sub-cloned into the 
VR1012 plasmid vector (Vical Inc., San Diego, CA, U.S.A), to produce VR1012.F154. 
Plasmid DNA was purified using an endotoxin free plasmid maxi kit (Qiagen, Hilden, 
Germany) and was subsequently dialysed extensively against PBS (Slide-a-Lyser, Pierce, 
Perbio Science UK Ltd, High Street, Cheshire, UK) to ensure it was safe for inoculation. 
If endotoxins aiQ not removed prior to inoculation in vivo, the recipients can suffer from 
pyrexia. Therefore, to confirm that the DNA was endotoxin free, endotoxin testing was 
conducted using a Limulus Amebocyte Lysate (LAL) gel clot endotoxin testing kit 
(Bio Whittaker Walkersville, MD) and demonstrated that the endotoxin content of the DNA 
was sufficiently low for use as a DNA vaccine. Endotoxin levels < 5 Endotoxin Units/ml 
were considered acceptable (Q-One Biotech Ltd., Glasgow, UK).
2.1.3.2. FIV DNA vaccine
Plasmid DNA was purified using double caesium chloride-ethidium bromide gradient 
centrifugation, butanol extraction and ethanol precipitation. To prepare large scale plasmid 
preparations, 500ml cultures of E.coli containing the plasmid DNA were centrifuged at 6K 
for 15 minutes and the supernatant discarded. The bacterial pellet was resuspended in 
50ml of solution I (see Appendix B) and incubated on ice for 30 minutes, 80ml of solution 
II (see Appendix B) was then added and incubated on ice for a further 15 minutes. To this 
40ml of solution III (see Appendix B) was added and incubated on ice again for 15 
minutes. This suspension was then centrifuged at 7K for 25 minutes at a temperature of 
14°C. The resultant supernatant was filtered through filter paper and 170ml of isopropanol 
was added to this, this solution was centrifuged at 7K for 30 minutes and at a temperature 
of -2°C. The resultant pellet was resuspended in 20ml Tris- Ethylenediaminetetra-acetic 
acid (EDTA) (TE, lOmM Tris/lmM EDTA). To this, 21g caesium chloride and 2ml 
3mg/ml ethidium bromide was added. This suspension was then ultracentrifuged at 55K 
overnight at 20°C. The resultant ethidium bromide stained DNA band was removed from
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the ultracentrifuge tubes with a needle and syringe. The DNA was ultracentrifuged again 
at lOOK for 4 hours at 18°C to increase purity. To extract the DNA, the ethidium bromide 
band was again removed with a needle and syringe and to this an equal volume of butanol 
was added and centrifuged at 3K for 10 minutes. This step was then repeated. To 
precipitate the DNA, 2 volumes of TE were added, a 1/10^  ^of the volume of 3M NaOAc 
was added and mixed by inverting the tube. To this, 2 volumes of 100% ethanol were 
added. This suspension was placed on ice for 30 minutes to precipitate the DNA and then 
centrifuged at 3K for 10 minutes. The DNA pellet was then washed in 70% ethanol and 
centrifuged again at 3K for 10 minutes. The supernatant was removed, the DNA pellet was 
air-dried and re-suspended in TE buffer and then dialysed extensively against PBS (Slide- 
a-Lyser, Pierce). Endotoxin testing was conducted using a LAL gel clot endotoxin kit 
(BioWhittaker) as for the CD40L plasmid. To confirm the results a DNA sample was also 
sent to the European Endotoxin Testing Service (BioWhittaker, Europe).
2.1.4. Proliferation assays
3T3 cells expressing feline CD40L (3T3.F154) and control 3T3 cells were used as target 
cells in proliferation assays. ^^Cobalt irradiated (3000 rads) 3T3.F154 and 3T3 cells were 
added in decreasing numbers (10^, 3x10 \  10\ 3x10^, 10 ,^ 300 and none) in triplicate to a 
96-well flat-bottomed plate (Falcon, Becton Dickinson Labware Europe, France, S.A). 
PBMC from a SPF cat were obtained by overlaying Ficoll-Hypaque (Pharmacia LKB, 
Biotechnology Inc., Pistcataway, NJ, USA) with a heparinised whole blood sample diluted 
1 in 4 in serum free RPMI (Life Technologies) and centrifuging at 2000rpm for 10 
minutes, after which time the PBMC had collected at the interface above the red blood 
cells and could be removed by pipetting. The PBMC were then washed in serum Jfiee 
RPMI (Life Technologies) and centrifuged again at lOOOrpm for 5 minutes. After 
centrifugation the PBMC were resuspended in complete RPMI (Life Technologies) and 10^  
cells were added to each well of the 96-well plate. The plates were incubated at 37°C in 
5% CO2 for 4 days, after which time 20pCi/well of tritiated thymidine (^H-thymidine) 
(Amersham Biosciences, Buckinghamshire, UK) was added for the final 18 hours of 
incubation. A positive control of concanavalin A (conA) (Sigma Aldrich Co Ltd., Poole, 
Dorset, UK) was included. The cells were harvested firom the 96-well plates onto 
absorbent filter-plates using the Packard Filtermate 196 (Perkin Elmer, Beaconsfield, 
Buckinghamshire, UK) and the amount of incorporated radioisotope was determined by a
39
microplate scintillation counter (Topcounter, Packard). Results are expressed as the mean 
of the triplicate value ± standard error mean (SEM) counts per minute (cpm).
2.1.5. Flow cytometry
For analysis by flow cytometry lymphocytes were stained with the appropriate antibody. 
Thus, 10  ^cells were washed in PB A (phosphate buffered saline/1% bovine serum albumin 
[BSA]/ 0.1% azide). After centrifugation at lOOOrpm for 5 minutes, the resulting cell 
pellet was resuspended in 50pl of PBA and the appropriate fluorescent conjugated 
antibody was added. Staining was conducted by incubating with the antibody for 30 
minutes at 4°C. After incubation, the cells were washed twice in PBA and resuspended in 
1ml PBA. Lymphocytes were “live-gated” on the basis of size (forward scatter) and 
granularity (side scatter) and 5000 events were collected for each sample.
2.1.6. Serology
2.1.6.1. TM and p24 ELISA
A peptide-based enzyme-linked immunosorbent assay (ELISA) was employed to 
determine titres of antibodies recognising an immunodominant epitope in the TM 
glycoprotein (CNQNQFFCK) of FIV (Avrameas et al.l993; Sibille et al. 1995). TM 
ELIS As were conducted at Companion Animal Diagnostics, Department of Veterinary 
Pathology, University of Glasgow, UK. Briefly, a 96-well ELISA plate (Greiner High 
Binding, Greiner Bio-One, Stroudwater Business Park, Glos, UK) was coated overnight 
with 500ng/well TM peptide in a volume of 100p,l Tris buffered saline (TBS), 
supplemented with 0.05% Tween 20 (TBS/Tween) at 4°C and with the plate continuously 
shaking. After washing five times in TB S/Tween, the rest of the assay was conducted at 
room temperature. Wells were blocked with lOOpl TB S/Tween, supplemented with 10% 
normal goat serum (blocking buffer) for 45 minutes and the plates were washed again. 
Dilutions of the serum samples to be tested were made in blocking buffer and 100p,l of 
sample was added per well and incubated for 30 minutes. After incubation, plates were 
washed with TBS/Tween and then incubated with biotinylated Protein A (4p,g/ml) (ICN 
Pharmaceuticals Ltd., Basingstoke, Hants.) diluted in blocking buffer for 30 minutes. The 
plates were again washed and incubated for a further 30 minutes with streptavidin-alkaline 
phosphatase, before being washed again. Alkaline phosphatase substrate tablets were
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dissolved in ethanolamine buffer and 50p,l substrate was added per well. The reaction was 
stopped after 15 minutes by adding 50pl/well of 0.5M NaOH. The optical density (OD) of 
the wells was read on a Multiskan Ascent microplate reader (Thenno Labsystems, 
Middlesex, UK) at 405nm. The assay cut-off was determined by adding 0.15 to the mean 
OD of the negative controls at a dilution of 1:5. The titre of a sample was taken to be the 
reciprocal of the highest dilution that equalled or was greater than this figure.
Antibodies recognising the FIV p24 core protein were also measuied by ELISA using a 
similar method to the TM ELISA (Reid et al. 1991) and were also conducted at Companion 
Animal Diagnostics, University of Glasgow, UK.
2.1.6.2. Immunofluorescence
Antibodies recognising FIV-infected CRFK cells were detected by an indirect 
immunofluorescence (IF) technique using fluorescein isothiocyanate (FITC)-conjugated 
anti-IgG secondary antibody. The IF technique was performed using previously prepared 
plates consisting of a 1:1 mixture of uninfected CRFK cells and CRFK cells chronically 
infected with FIV which had been fixed and stored in methanol at -20°C. 10-fold dilutions 
of the sample sei-um from 1:10 to 1:10000 were made using PBS containing 5% FCS and 
25pi of each sample was added to the previously prepared plates. The plates were then 
incubated at 37°C in moisture chambers for 90 minutes. After incubation, the plates were 
washed with PBS for 2 minutes then rinsed in water and left to dry. 25pi of FITC- 
conjugated anti-IgG is added to each well and the plates were tiien incubated for a further 
60 minutes at 37°C. After incubation, the plates were again washed and dried and then 
examined under a UV microscope using a lOx objective. The endpoint was taken as the 
last dilution showing fluorescence. IF was conducted at Companion Animal Diagnostics, 
University of Glasgow, UK.
2.1.6.3. Western blotting
For Western blotting a cell lysate was prepared from Mya-1 cells infected vfith FIV-GL8. 
Thus, 10^  Mya-1 cells that had been infected with supernatant previously removed from 
infected Mya-1 cells, filtered and frozen, were centrifuged at lOOOrpm for 5 minutes, to 
obtain a cell pellet. The resultant cell pellet was resuspended in 50pl of lysis buffer (1% 
NP40, 150mM NaCL, lOmM Tris/HCl and 2mM HCl) and incubated for 10 minutes at 
room temperature. Following incubation, the cell suspension was centrifuged at lOOOrpm
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for 5 minutes and the resulting supernatant was removed and the pellet discarded. To 20 pi 
of the supernatant (cell lysate) 50pl of reducing sample buffer (RSB) (0.5M Tris pH 6.8, 
glycerol, 2-mercaptoethanol, 10% SDS and 0.2% bromophenol blue) was added and the 
sample was boiled for 3 minutes and then resolved on a 4-20% gradient Tris-HCl SDS 
polyacrylamide single well prep gel (SDS-PAGE) (Biorad Laboratories, Hercules, CA). 
The proteins were transferred onto a nitrocellulose membrane (Biorad), using the Biorad 
wet tank transfer system and the resultant blots were blocked overnight with 0.5% non-fat 
milk powder in PBS (blocking buffer). Blots were cut into 2mm strips and incubated for 2 
hours at room temperature with mouse serum or feline plasma diluted 1:10 with PBS 
supplemented with 1% non-fat milk powder and 0.5% Tween-20. Controls of known FIV- 
positive and FIV-negative cat serum were included. After incubation the strips of 
membrane were washed with 0.5% Tween-20 in PBS (washing buffer) and the feline 
plasma samples and the FIV-positive and FIV-negative samples were incubated for 1 hour 
with biotinylated protein A (ICN Pharmaceuticals Ltd.) at a concentration of 4pg/ml. The 
secondary antibody used for membranes incubated with mouse serum was a biotinylated 
anti-mouse IgG antibody (Vector Laboratories, Inc., Burlingame, CA) (Ipg/ml). After 
incubating with the secondary antibodies the membranes were washed again and incubated 
for a further hour with streptavidin-alkaline phosphatase (Bio-Rad) diluted 1 in 500 with 
PBS supplemented with 1% non-fat milk powder and 0.5% Tween-20. Membranes were 
then washed and incubated in alkaline phophatase buffer (AP buffer) (lOOmM 
diethanolamine/5mM MgCl/lOOmM NaCl, pH 9.5) for 10 minutes before staining was 
developed using AP buffer containing 5 -bromo-4-chloro-3 -indolyl phosphate (BCIP) 
(50mg/ml) (Sigma) and nitro blue tétrazolium (NBT) (50mg/ml) (Sigma).
2.1.7. Detection of a cell-mediated immune response
A proliferation assay was employed to detect T-cell proliferation in response to either FIV 
p24 core protein or WIV. Either FIV p24 core protein or WIV was added in decreasing 
concentrations (25pg/ml, 12.5pg/ml, 6.25pg/ml, 3.125pg/ml and none) in triplicate wells 
to a 96-well U-bottomed tissue culture plate (Falcon). A volume of lOOpl of each 
concentration of p24 or WIV was added per well and incubated overnight at 37°C and 5% 
CO2 . A positive control of con A (lOpg/ml) (Sigma) and a negative control of complete 
RPMI only were also included. After incubating overnight, either 2x10^ mouse spleen 
cells or feline PBMC were added to each well. The plates were then incubated at 37°C and
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5% COz for a further 3 days after which time 20pCi/well of ^H-thymidine in complete 
RPMI was added for the final 5 hours of incubation. The cells were then harvested on to 
filter plates (Packard) using the Packard Filtermate 196 and the incorporated radioactivity 
was read on a microplate scintillation counter (Topcounter, Packard). The stimulation 
index (SI) was determined firom the formula: SI = experimental count/spontaneous count. 
Spontaneous count wells included 10% FCS, which serves as an irrelevant protein control. 
A SI of > 2 was regarded as significant.
2.2. Statistical analysis
Where possible results were analysed using the software packages SigmaPlot 2001 for 
Windows version 7.0 (Copyright© 1986-2001 SPSS Inc.), and SigmaStat for Windows 
2.03 (Copyright© 1992-1997 SPSS Inc.). The Student’s t-test was used to compare two 
groups. P values <0.05 were considered significant (*) and <0.01 highly significant (**).
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Chapter Three
DEMONSTRATION OF THE BIOLOGICAL ACTIVITY OF
FELINE CD40L
3.1. introduction
After the murine (Armitage et al. 1992) and human (Spriggs et al. 1992; Hollenbaugh et al. 
1992) CD40L genes were cloned, CD40L and its receptor CD40 were shown to play an 
important part in immune regulation (Kooten and Banchereau 1996). In addition, the 
efficacy of CD40L-adjuvanted vaccines was demonstrated, including those against HIV-1 
(Ihata et al. 1999), Leishmania major (Gurunathan et al.l998), bovine herpesvirus 1 
(Manoj et al. 2003) and herpes simplex virus (HSV) type 2 (Sin et al. 2001). In order to 
determine the efficacy of a DNA vaccine against FIV adjuvanted with feline CD40L DNA, 
the feline homologue of CD40L had first to be identified and cloned and then its biological 
activity assessed. Prior to this study, the feline CD40L gene was cloned and murine 
fibroblast 3T3 cells were stably transduced with a retroviral vector expressing feline 
CD40L, enabling the cells to express CD40L on their cell surface (3T3.F154). These cells 
were used as the basis for in vitro studies of tire biological activity of feline CD40L.
To determine the biological activity of the cloned feline CD40L, proliferation assays were 
conducted whereby the results relied on the interaction between B and T-cells through 
CD40 and CD40L. Thus, feline PBMC or PBMC cell fractions were co-cultured with 
3T3.F154 cells in 96-well plates and the extent of cell proliferation was determined by 
measuring the incorporation of radiolabelled thymidine. The immunophenotype of 
proliferating cells was determined using flow cytometric analysis.
The capacity of CD40L to maintain B-cells in longer-term culture was investigated. SPF 
cat PBMC were cultured to establish whether stimulation with CD40L could maintain a 
normal feline B-cell line in culture, as CD40L expressed on human and murine T-cells has 
been shown to interact with CD40 on B-cells to cause proliferation and differentiation of 
resting B-cells (Noelle et al. 1992; Spriggs et al. 1992). Previous studies had shown that it 
was possible to maintain murine B-cells in culture by stimulating with anti-CD40 antibody 
and IL-4 (Rush and Hodgkin 2001). However, there is no record of a similar study with
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feline B-cells, Flow cytometry was performed to determine the immunophenotype of the 
cell populations that resulted from stimulation of SPF cat PBMC with CD40L.
An opportunity to include the study of neoplastic cat PBMC arose because a domestic cat 
suspected to be suffering from chronic lymphocytic leukaemia (CLL) was admitted to the 
small animal clinic at Glasgow University Veterinary Hospital. Blood was collected from 
a peripheral vein for diagnostic studies. From the leukaemic cells a B-cell line was 
established and maintained using 3T3.F154 cells as a feeder layer. This cell line was 
investigated further using flow cytometry and Southern blotting techniques. CLL is a 
disease of the bone marrow that can affect either the T or B- lymphocytes. In this case the 
cat had a B-lymphocytosis (Tebb et al. 2004). Crawford and Catovsky (1993) had 
previously demonstrated that it was possible to maintain a human leukaemic B-cell line in 
culture with IL-4 and antibodies to CD40. In these studies, a feline leukaemic B-cell line 
was maintained with CD40L stimulation alone.
3.2. Materials and methods
3.2.1. Production of a cell line stably expressing feline CD40 
Ligand
Prior to this study, feline CD40L was amplified by PCR from cDNA prepared from feline 
thymus (Brown et al. 2002). Briefly, PCR products were cloned into the pCRII cloning 
vector and several clones containing the CD40L insert were identified. Plasmid DNA from 
these clones was isolated. This DNA was then sub-cloned into the pDON-AI retroviral 
vector (Takara Bio Inc., Shiga, Japan) and transfected into the Phoenix-Eco ecotropic 
murine leukaemia virus-based packaging cell line (Nolan Laboratory, University of 
Stanford). Supernatant fluids from the transfected cells were collected 48 hours post­
transfection and used to infect the 3T3 cell line. The infected cells were cultured for a 
further 2 days before being sub-cultured and re-seeded in complete DMEM supplemented 
with 800jug/ml G418-sulphate. G418-resistant cells containing the CD40L gene, known as 
3T3.F154, were amplified and maintained in medium containing 400pg/ml G418-sulphate 
and were used for feline CD40L studies in vitro.
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3.2.2. Proliferation assays (whole PBMC and PBMC cell fractions)
The proliferation assay protocol is described in detail in section 2.1.4. The phenotype of 
the proliferating cells was determined in a parallel proliferation assay, in which a further 
10  ^ feline PBMC were cultured in each well of a 12-well plate (Falcon) with decreasing 
numbers (10^, 10^  and none) of 3T3.F154 or 3T3 cells. After 5 days in culture, PBMC 
were removed from the wells for analysis by flow cytometry and were stained with 
phycoerythrin (PE)-conjugated anti-CD5 antibody (F43, Southern Bioteclmology 
Associates Inc., Birmingham, AL 35226, USA), which is a pan-T cell marker, and FITC- 
conjugated anti-B220/CD45R antibody (RA36B2, BD PharMingen, A Becton Dickinson 
Co., San Diego, California) which is an anti-mouse B-cell antibody that has been shown 
previously to cross-react with feline B-cells (Brown et al. 2002). The data were analysed 
using WinMDI v2.8 (Dr. J. Trotter, Scripps Research Institute, La Jolla, CA, USA).
Similar proliferation assays were conducted using cell fractions of PBMC. The fractions 
were obtained by depleting B and T lymphocytes from a mixed population of PBMC using 
magnetic antibody cell sorting (MACS). To deplete B-cells, lOp.1 of anti-B220-antibody 
coated magnetic beads (MACS beads) (MACS reagents, Miltenyi Biotec, 51429 Bergisch 
Gladbach, Germany) were added for every 10  ^PBMC and the cells were incubated for 30 
minutes at 4°C in MACS buffer (PBS, pH 7.2 with 0.5% BSA and 5mM EDTA). After 
incubation, cells were washed and resuspended in 500pi MACS buffer. Cells were then 
added to a MACS separation column (Miltenyi Biotec), attached to a magnet and the B 
cell-depleted PBMC were allowed to pass through the column. The column was then 
removed from the magnet and the B cell-enriched fraction was flushed through with 
MACS buffer. To obtain the T cell-enriched and depleted fractions, the PBMC were first 
incubated with mouse anti-feline CD3 antibody (NZMI, kindly supplied by Dr. Y. 
Nishimura, University of Tokyo) for 30 minutes at 4°C. After incubation, cells were 
washed in 1ml MACS buffer, resuspended in 20pl of goat anti-mouse IgG-coated MACS 
beads (Miltenyi Biotec) and incubated for a further 15 minutes at 4*^ C, at which time the 
PBMC were washed again and resuspended in 500pl MACS buffer. The T-cell fractions 
were then obtained in a similar manner to the B-cell fractions using the MACS separation 
column. The proliferation of the different cell fractions in response to incubation with 
3T3.F154 cells was then assessed using proliferation assays as described in section 2.1.4.
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3.2.3. In vitro stimulation of SPF and CLL PBMC with feline 
CD40L
PBMC from a SPF cat were isolated from a sample of heparinised venous peripheral blood 
by centrifugation over Ficoll-Hypaque. In order to increase the number of PBMC in vitro 
for further analysis and to determine if a B-cell line could be established fr om these cells, a 
3T3.F154 cell feeder layer system was adopted (Buhmann et al. 1999). PBMC, 5 x 10  ^in 
number, were cultured either directly (CON PBMC), co-cultured with 2 x 10  ^ ^^cobalt 
irradiated (3000 rads) 3T3 cells (CON.3T3) or co-cultured with 2x10^ ^^cobalt irradiated 
3T3.F154 cells (CON.F154) in complete RPMI or in complete RPMI that had been 
conditioned by the Mya-1 cell line (Mya medium [MM]). It has been demonstrated that 
MM contains granulocyte/macrophage colony-stimulating factor, macrophage CSF, stem 
cell factor, IL-10 and TNF-a (Linenberger and Deng 1999) and these factors might 
promote the growth of noiinal and neoplastic B-cells. PBMC isolated from a cat diagnosed 
with CLL (Tebb et al. 2004) were set up in parallel, these cultures were designated CLL 
PBMC, CLL.3T3, and CLL.F154 respectively. Every 4 days the cells were transferred to 
clean flasks with a fresh feeder layer and fresh medium.
After 58 days in culture the remaining viable cell populations were separated into B-cell 
enriched and B-cell depleted populations using anti-B220 MACS beads (Miltenyi Biotec) 
as described above. B220"  ^and B220' cultures were obtained and maintained in MM for a 
further 13 days at which time cells were frozen in aliquots in liquid nitrogen, using a 
controlled rate freezer, Planer Kryo 10 Series II (PLANER pic, Sunbury, Middlesex, UK).
After 28 days in culture, IL-4 (R & D Systems Europe Ltd., Abingdon Science Park, 
Abingdon, UK) was added to the CLL.F154 cell populations at a final concentration of 
25pg/ml to determine whether stimulating the B220 enriched cell population with both 
CD40L and IL-4 would increase the number of B-cells.
3.2.4. Flow cytometric analysis of CD40L stimulated SPF cat 
PBMC and CLL PBMC
To determine the phenotype of the individual cell populations, the SPF and CLL cat PBMC 
that had been set up in culture alone or with 3T3 or 3T3.F154 cells were processed for flow 
cytometry every 7-21 days, using the methods described in section 2.1.5. Analysis was
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conducted on a Beckinan Coulter EPICS using the EXPO analysis software package 
(EXPO 32 ADC software, Beckman Coulter, Kingsmead Business Park, High Wycombe, 
Buckinghamshire, UK). Lymphoblasts and lymphocytes were “live-gated” on the basis of 
size and granularity and 5000 events were collected for each sample.
After 7 and 30 days in culture, PBMC were labelled with FITC-conjugated anti-mouse 
B220 (BD Pharmingen) and PE-conjugated anti-feline CDS (Southern Biotechnologies). 
In parallel at 7 days, PBMC were incubated with an antibody that recognises feline CD21 
(CA2.1D6, Serotec Ltd., Kidlington, UK), a marker used widely for the estimation of 
feline B-cell numbers. After incubation for 30 minutes, the cells were washed in PBA and 
incubated for a further 30 minutes with FITC-conjugated anti-mouse IgG (F0257, Sigma 
Chemical Co., St. Louis, USA). On day 16 in culture, PBMC were stained with FITC- 
conjugated anti-feline CD3 (NZMI, Dr. Y. Nishimura, University of Tokyo), PE- 
conjugated anti-feline CD5 (Southern Biotechnologies) and cy-chrome-conjugated anti­
mouse B220 (RA36B2, BD PharMingen). On days 36 and 44 in culture, PBMC were 
stained with FITC-conjugated anti-feline CD4 (VPG34, Serotec Ltd.), PE-conjugated anti­
feline CDS (VPG9, Serotec Ltd.) and cy-chrome-conjugated anti-mouse B220 (BD 
Pharmingen).
After the PBMC were separated by MACS beads into B-cell-enriched and B-cell- depleted 
populations, to determine the purity of each fraction, flow cytometry was performed on day 
64 in culture. The cell populations were stained with FITC-conjugated anti-feline CD4 
(Serotec Ltd.), PE-conjugated anti-feline CDS (Serotec Ltd.) and cy-clirome-conjugated 
anti-mouse B220 (BD Pharmingen) to identify T-cells expressing CD4 or CDS and B-cells.
3.2.5. Southern blotting
To determine the clonality of the suspected CLL cells, Ig gene rearrangements were 
investigated by Southern blot hybridisation (Southern 1975). One million cells from the 
B220 enriched cell populations that were obtained from the cultures, CON.3T3, 
CON.F154, CLL.3T3 and CLL.F154 were centrifuged at lOOOrpm for 5 minutes and DNA 
was isolated from the resulting cell pellet using a Blood DNA Kit (Qiagen). The DNA was 
digested using the Hindlll enzyme (Invitrogen Life Technologies, Paisley, UK) at 37®C 
overnight. The digested DNA was resolved on a 0.8% agarose gel alongside a IHind Iff 
marker (Invitrogen) and blotted overnight onto a Hybond membrane (Amersham
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Biosciences), using the Southern blotting upward capillary method. Blots were fixed using 
UV irradiation (Spectrolinker, Spectronics Corporation, Westbury, New York) and probed 
with a feline Cp probe (kindly supplied by Anne Terry, Molecular Oncology Laboratory, 
University of Glasgow, UK) (Terry et al. 1995). The probe was labelled with phosphorus 
32 (Amersham Biosciences) using the RadPrime DNA Labeling System (Invitrogen) and 
purified with a Pharmacia NICK Column (Pharmacia). Blots were visualised by 
autoradiography using Kodak X-OMAT-S film (Kodak, Rochester, NY, USA).
3.3. Results
3.3.1. Generation of a CD40L expressing cell line
A cell line expressing feline CD40L was required for use in interactions with cells bearing 
CD40. This was achieved using a retrovirus vector, carrying both the feline CD40L gene 
as well as a gentamycin resistance gene. In order to produce retroviral particles containing 
the CD40L gene that were capable of infecting target cells (3T3), the retroviral vector 
pDON-AI containing the feline CD40L gene was transfected into a retroviral packaging 
cell line (see Figure 3.1). The 3T3 cell-line became stably transduced, as the CD40L DNA 
was incorporated into the target cell chromosomal DNA. To ensure that only 3T3 cells 
that expressed CD40L (3T3.F154) were growing, 3T3.F154 cells were positively selected 
using G418, an aminoglycoside antibiotic (Southern and Berg 1982). To assess the 
biological activity of feline CD40L, the 3T3.F154 cells and control 3T3 cells were used as 
target cells in proliferation assays.
3.3.2. CD40L induced T and B lymphocytes to proliferate
CD40L expressed on activated Th-cells is involved in the proliferation and isotype 
switching of B-cells (Spriggs et al. 1992). Therefore, proliferation assays were conducted 
in order to assess the biological activity of the feline CD40L DNA that had been cloned.
Irradiated 3T3.F154 and 3T3 cells were added in decreasing numbers ranging from 10^  to 
none to a 96-well plate and incubated with SPF cat PBMC for 4 days. As shown in Figure
3.2. feline PBMC were induced to proliferate to a maximum value of 50958 ± SEM 5126 
cpm. This degree of proliferation was highly significant for all wells containing 3T3.F154 
cells except those containing 300 or no cells (P<0.01), Student’s t-test.
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To determine whether the cells proliferating in response to CD40L were predominantly B- 
cells, as expected, a proliferation assay was set up in parallel in a 12 well culture plate. 
After 5 days of culture, the proliferating PBMC were analysed by flow cytometry. PBMC 
were stained with antibodies recognising feline CD5 or B220. The results are shown in 
Figure 3.3. Interestingly, flow cytometric analysis demonstrated that the majority of cells 
expressed CD5 and not B220, suggesting that the predominant population after stimulation 
with CD40L comprised of T-cells expressing CD5 rather than B220^ B-cells. Therefore, 
the B-cells were possibly acting as APCs inducing T-cell proliferation that may have 
exceeded B-cell proliferation.
In order to determine whether T-cells would still proliferate in the absence of B-cells, fresh 
PBMC were obtained from a SPF cat and were separated into B-cell enriched or depleted 
(B220^ or B220' respectively) and T-cell enriched or depleted (CD3^ or CD3” respectively) 
cell fractions using MACS beads. The separated cell fractions were then incubated with 
3T3.F154. As shown in Figure 3.4, the CD3^ and B220' cell fractions did not proliferate 
markedly. By contrast, B-cells were induced to proliferate to a maximum of 36662 ± 7049 
SEM cpm when T-cells were depleted from the PBMC population (CD3 ). In addition, 
proliferation of B-cells was more evident when T-cells were depleted (CD3‘), rather than 
when the population was B-cell enriched (B220^. These results indicated that when T and 
B-cells were incubated together with CD40L, the B-cells may have acted as APCs and 
primed the T-cells resulting in T-cell proliferation. However, there was no proliferation of 
T-cells when the B-cells were no longer present to act as APCs. Furthermore, when B- 
cells were incubated alone with CD40L there was proliferation of the B-cells as CD40L 
induces proliferation of the B-cells directly. Also, it was concluded that when T and B- 
cells were incubated together with CD40L, there was some proliferation of the B-cell 
population, although the B-cell proliferation may have been masked by the relatively 
greater numbers of proliferating T-cells.
3.3.3. Long-term cultures were established
In this study, B-cells were shown to proliferate in response to incubation with CD40L for 5 
days in the proliferation assays conducted above. Therefore, further studies were 
conducted to determine whether this proliferation could be maintained longer term. SPF 
cat PBMC were cultured together with 3T3.F154 cells. As mentioned previously, PBMC 
from a cat suspected of suffering from CLL were also studied in this manner. B-CLL cells
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display low spontaneous growth in vitro and respond poorly to B-cell mitogens, such as 
lipopolysaccharide (LPS) or pokeweed mitogen (PWM) (Sadamori et al. 1983). Therefore, 
to expand the CLL cell population, enabling further analysis to be conducted, CLL PBMC 
were co-cultured (in parallel with SPF PBMC) with 3T3.F154. SPF and CLL cat PBMC 
were co-cultured with a feeder layer of irradiated 3T3 or 3T3.F154 cells in complete RPMI 
and MM. MM was used because it is rich in cytokines that were expected to aid the 
growth of B-cells (Linenberger and Deng 1999). After 58 days in culture, the only cell 
populations that remained viable were the SPF cat PBMC and CLL PBMC co-cultured 
with 3T3 or 3T3.F154 cells in MM. These cultures were then separated into B220- 
enriched or B220-depleted populations using MACS beads coated with anti-B220 
antibody, and after a further 10 days in culture, the cells were frozen and stored in liquid 
nitrogen. The cells had been successfiilly maintained in culture for a total of 68 days.
After 28 days in culture, IL-4 was added to a culture of CLL.F154 cells to determine 
whether this would assist the growtli of B-cells. Flow cytometric analysis confirmed an 
increase in B-cell number in cultures stimulated with IL-4 compared to those without IL-4 
stimulation, as shown in Figure 3.5.
SPF and CLL cat PBMC were compared in a proliferation assay to deteimine whether the 
neoplastic B-cells would respond to CD40L stimulation to a greater or lesser extent than 
normal PBMC. The results indicated that the CLL PBMC had an increased response to 
CD40L when compared with control PBMC. As shown in Figure 3.6, CLL PBMC were 
induced to proliferate to a maximum value of 54000 ± 6700 SEM cpm in the presence of 
CD40L. By comparison the SPF cat PBMC proliferated to a maximum value of 29000 ± 
3000 SEM cpm, a difference of almost two-fold. As demonstrated in the previous 
proliferation assays conducted with fi-actionated PBMC cell subpopulations, it was 
primarily the B-cells that were induced to proliferate in response to stimulation by CD40L 
and as the flow cytometrical analysis of the CLL PBMC demonstrated that the 
lymphocytosis comprised principally of B-lymphocytes (see section 3.3.4), this could 
account for the increased proliferation in response to CD40L.
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3,3.4. Flow cytometry of long-term cultures of cells activated by 
CD40L
Flow cytometry was conducted to define the cell populations that resulted from co- 
culturing SPF cat PBMC or CLL PBMC, either alone or with 3T3 or 3T3.F154 cells, in 
complete RPMI or in MM.
3.3.4.1. FACS analysis after 7 days in culture
Staining of cells at 7 days in culture with FITC-conjugated anti-B220 and PE-conjugated 
anti-CD5 antibodies demonstrated that there was a large population of blast cells 
expressing B220 in SPF cat PBMC cultures and cultures of CLL PBMC stimulated with 
feline CD40L. These blast cells are recognised as being larger and less granular than other 
lymphocytes, when size (forward scatter) and granularity (side scatter) are compared by 
flow cytometry (see Figure 3.7). As described in chapter one, the association of CD40L 
with the CD40 receptor on B-cells can result in the proliferation and differentiation of B- 
cells (see Figure 1.3). Figures 3.8 and 3.9 demonstrate that more blast cells were present in 
cultures grown in MM than in those in RPMI. In the lymphocyte populations of SPF.Fl 54 
and CLL.F154, there were more B-cells in the CLL PBMC than in the SPF cat PBMC, 
39.6% vs 4.5% (see Figure 3.7), consistent with the diagnosis of B-CLL. Very few 
lymphoblasts were stimulated by control 3T3 cells in RPMI and the lymphocyte 
populations comprised predominantly of T-cells in SPF PBMC and B-cells in CLL PBMC 
(Figure 3.10). However, the same cell populations cultured in MM contained a higher 
proportion of lymphoblasts (28% in CLL 3T3 cultured in MM compared to 5% when 
cultured in RPMI and 21% in SPF 3T3 cultured in MM compared to 2% when cultured in 
RPMI) (Figure 3.10), again demonstmting that factors in the MM stimulated the 
proliferation of lymphoblasts. CLL and SPF cat PBMC cultures that were cultured in 
RPMI alone contained very few lymphoblasts and these were stimulated to proliferate 
following the addition of MM, particularly in the CLL PBMC culture (Figure 3.10).
At 7 days in culture the cell populations were also stained with FITC-conjugated anti- 
CD21 antibody and the results confirmed that the blast population of cells in the cultuies 
SPF.Fl54 and CLL.F154 contained predominantly B-cells and that the lymphocyte 
populations were predominantly T-cells in the SPF.Fl54 culture and B-cells in the 
CLL.F154 culture (see Table 3.1). Again there were fewer lymphoblasts in 3T3 stimulated
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cells and cells cultured alone. Also, in agreement with the staining with FITC-conjugated 
anti-B220 and PE-conjugated anti-CD5 antibodies, culturing in MM increased the number 
of blasting cells in both CLL.3T3 and SPF.3T3 and PBMC cultured alone.
3.3.4 2. FACS analysis after 16 days in culture
After 16 days in culture, cells were stained with FITC-conjugated anti-CD3, PE-conjugated 
anti-CD5 and cychrome-conjugated anti-B220 antibodies. At this time point, the PBMC 
cultures in RPMI alone and those co-cultured with 3T3 in RPMI were no longer viable. Of 
the remaining cell cultures that were still viable, the percentage of lymphocytes in the cell 
populations had decreased significantly, leaving only a population of blasting cells.
SPF.Fl 54 and CLL.F154 were still composed predominantly of blasting B-cells. I
However, the percentage of T and B-cells differed depending on which medium they were 
cultured in, interestingly, the SPF.Fl54 cell population was predominantly composed of 
B220^ lymphoblasts when cutured in RPMI and CD5^ lymphoblasts when cutured in MM, 
as shown in Figure 3.11. Furthermore, MM also favoured the growth of CD5^ 
lymphoblasts in the CLL.F154 cell population. This might be accounted for by the MM 
containing a source of IE-2 (Linenberger and Deng 1999). In the SPF cat PBMC cell 
population cultuied in MM alone, although the T-cell population had some co-expression 
of CD3 and CD5, not all T-cells expressed CD3 and CD5 as expected. In the SPF.3T3 cell 
population cultured in MM, there was more co-expression of CD3 and CD5 (80% co­
expression in SPF.3T3 compared to 49% co-expression in SPF cat PBMC cultured alone)
(see Figure 3.12).
3.3.4 3. FACS analysis after 28 days in culture
After 28 days, virtually no lymphocytes remained in any culture. Lymphoblasts were 
stained with FITC-conjugated anti-B220 and PE-conjugated anti-CD5 antibodies. 
CLL.F154 and SPF.Fl54 cells cultured in RPMI, and CLL and SPF cat PBMC cultured 
alone in MM were no longer viable. Although CLL.F154 cultured in MM still contained 
mostly blasting B-cells, SPF.Fl54, SPF.3T3 and CLL.3T3 cultured in MM were now 
predominantly T-cells. Therefore, it was concluded that a CD40L feeder system was 
unable to sustain a normal B-cell population indefinitely.
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3 3.4.4. FACS analysis after MACS beads separation
CLL.F154 B220^ lymphoblasts were maintained until the end of the study at 68 days. 
Their phenotype after separation into B220 enriched and B220 depleted populations using 
MACS beads was confirmed by staining with FITC-conjugated anti-CD4, PE-conjugated 
anti-CD8 and cychrome-conjugated anti-B220 antibodies. B220 enrichment led to a less 
than two fold increase in the percentage of cells expressing B220, as shown in Figure 3.13.
3.3.5. Flow cytometric analysis reveals B220/CD5, B220/CD3 and 
CD4/CD8 dual positive cell subsets
3.3.5.1. Co-expression of B220 and CD5
After the SPF cat and CLL PBMC had been in culture with 3T3 or 3T3.F154 for 7 days, 
flow cytometric analysis revealed that the blasting B220^ cell populations were also 
expressing CD5 (see Figures 3.9 and 3.14). It could be argued that this dual expression 
was due to activation of the B-cells by CD40L, however, figure 3.15 demonstrates that in 
CLL PBMC cultured alone, tlie lymphoblasts also co-expressed B220 and CD5. hi 
addition, as the SPF.Fl54 B-cell lymphocytes were not co-expressing CD5, it is possible 
that the co-expression of B220 and CD5 on CLL B-cell lymphocytes was due to the 
particular immunophenotype of these neoplastic cells (see Figure 3.14). CLL and SPF cat 
PBMC that were cultured alone in RPMI had very few lymphoblasts that were increased 
by culturing in MM, more markedly in the CLL PBMC culture where there was a large 
increase in blasting cells and also an increase in co-expression of B220 and CD5 in 
lymphocytes and lymphoblasts compared to the corresponding culture containing SPF 
PBMC (see Figures 3.15 and 3.16). This increase in co-expression in CLL B-cells could 
be due to their immunophenotype, the fact that there was a higher percentage of B-cells in 
the CLL PBMC compared with the SPF cat PBMC (so that co-expression was easier to 
detect), or the higher state of activation of these neoplastic cells compared with normal B- 
cells. After 28 days in culture the co-expression of B220 and CD5 was restricted to 
CLL.F154 cultured in MM, since B-cell growth was no longer sustained in the other cell 
cultures.
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3.3.5 2. Co-expression of B220 and CD3
A cell subset co-expressing B220 and CD3 was revealed after 16 days of culture when 
lymphoblasts were stained with FITC-conjugated anti-CD3, PE-conjugated anti-CD5 and 
cychrome-conjugated anti-B220 antibodies. This subset was evident in cultures that 
contained B220^ cells and was more obvious in CLL PBMC cultures, due to their higher 
numbers of B220'^ cells (see Figure 3.17). Therefore, it is tempting to speculate that this 
B220/CD3 dual expressing cell population was the result of co-culturing B and T-cells.
3.3.5 3. Co-expression of CD4 and CD8
At days 36-64 in culture the remaining populations of cells (SPF.Fl54, CLL.F154, 
SPF.3T3 and CLL.3T3 cultured in MM) were defined more specifically using antibodies 
recognising feline CD4, CD8 and B220. The SPF.Fl54 cells were defined as a blasting T- 
cell population, which consisted of mainly CD8^ cells with an unusual sub-population of 
CD4/CD8 dual positive cells, see Figure 3.18. The CLL.F154 cells were still mainly a 
blasting B220^ cell population, with the remainder of cells being either CD4^ or CD8^. 
Similarly, SPF.3T3 and CLL.3T3 cells were CD8^ with the same CD4/CD8 dual positive 
subset in both cell populations as the SPF.Fl54 cells. This CD4/CD8 co-expression is not 
normally observed in feline lymphocytes and could be due to the activation state of the T- 
cells. However, as the population is also seen in the 3T3 stimulated cells, it is more likely 
that this co-expression is due to prolonged culture of the T-cells. Unfortunately, this 
hypothesis cannot be confirmed, as CD4 and CD8 staining was not conducted prior to 36 
days in culture. It is interesting that this CD4/CD8 co-expression was not observed in the 
CLL.F154 population. This could be due to the small numbers of T-cells present in this 
culture,
3.3.8. No immunoglobulin gene rearrangement was detected in 
neoplastic B cells
To determine if the CLL PBMC were monoclonal, a Southern blot was performed using 
DNA prepared from the B220 enriched fi'action of CLL PBMC that had been stimulated 
with CD40L. As shown in Figure 3.19, the analysis revealed the presence of a single 
7.5Kb fi:agment, in both the control and the CLL sample. Therefore, it could be concluded 
that there was either no re-arrangement of the IgH gene in the expanded B-cell population 
or if there was, the DNA fragment was the same size as the germ line fragment, which
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might occlude the re-arranged gene band. The expansion of a monoclonal population with 
rearranged immunoglobulin genes would have resulted in the appearance of a second band 
with a different molecular weight to the germ line fragment. Failure to detect any IgH 
gene re-arrangement, therefore, would suggest that the chronic lymphocytic leukaemia was 
not clonal.
3.4. Discussion
This study confirms that the feline CD40L gene that was cloned is biologically active and 
therefore might be valuable as an adjuvant for a FIV DNA vaccine. Flow cytometric 
analysis of PBMC proliferating in response to CD40L demonstrated that the majority of 
cells expressed CD5, consistent with T-cell expansion. However, these cells did not 
respond as well to CD40L in the absence of B220^ cells, possibly because T-cells require 
B-cells to act as APCs in order for them to proliferate. The B-cells were most likely 
activated by a foreign antigen in the culture medium such as a component of foetal calf 
serum.
SPF cat PBMC were maintained for 68 days by culturing in the presence of CD40L- 
expressing 3T3 cells. At first B-cells were induced to blast by CD40L. However, the cell 
population ceased to contain predominantly blasting B-cells after 28 days in culture when 
T-cells made up the predominant cell population. Consistent with earlier findings (Rush 
and Hodgkin 2001), this study confirmed that B-cells do not require constant stimulation 
from CD40L to enable them to blast, but they do require continued bursts of stimulation. 
Thus, when PBMC that had previously been cultured with 3T3 expressing CD40L were 
cultured alone for a period of time, their immunophenotype was unaltered. Rush and co­
workers used an anti-CD40 antibody and IL-4 to stimulate murine B-cells. IL-4 was added 
to our CLL PBMC cultures, but not to our SPF cat PBMC cultures. Therefore, further 
studies will be required to determine whether IL-4 could have sustained the SPF B-cell 
population indefinitely.
CLL PBMC were maintained for 68 days and at this time were still predominantly a 
blasting B-cell population. Previous studies (Kitada et al. 1999; Granziero et al. 2001) 
have demonstrated that the stimulation of B-CLL cells with CD40L may up-regulate 
inhibitor of apoptosis proteins. This could account for the maintenance of a neoplastic B-
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cell population obtained from the CLL cat but not a normal B-cell population derived from 
a SPF cat.
After SPF cat or CLL cells had been cultured with CD40L-expressing cells or normal 3T3 
cells, several different cell subsets were identified upon analysis by flow cytometry, 
including a B220/CD5 co-expressing cell population. B-cells can express the T-cell 
marker, CD5, upon activation and therefore a degree of expression of CD5 in B-cells 
stimulated with CD40L might be expected. However, this B220^/CD5^ immunophenotype 
was also detected in PBMC that were cultured with normal 3T3 cells or cultured alone. 
The B220^/CD5^ immunophenotype was more evident in the CLL PBMC than in the 
control SPF cat PBMC. It has been shown in human B-CLL that the typical 
immunophenotype is CD19\ CD20^, C D 2 l\ sig and CDS’*" (Freedman et al. 1987). In the 
same study, normal B-cells were induced to express CD5 by activating with 12-0- 
tetradecanoylphorbal-{3-acetate (TPA). In cattle, CD5^ B-cells are found normally in 
peripheral blood and spleen, and the number of CD5^ B cells was found to be increased in 
cattle infected with Trypanosoma congolense (Naessens and Williams 1992). This 
increase in CD5^ B-cells could to be related to the excessive activation of the humoral 
component of the immune system by the Trypanosome.
After prolonged culture with CD40L-expressing 3T3 cells and normal 3T3 cells, a degree 
of co-expression of CD4 and CD8 on T-cells was also demonstrated. In man, immature 
thymic T lymphocytes acquire both CD4 and CD 8 molecules prior to the expression of 
surface CD3. With maturation, T-cells lose either the CD4 or CD 8 antigen to gain a 
mature peripheral T-cell phenotype, either CD4^ CD8" or CD4 CD8^, associated with 
helper or cytotoxic T-cell functions respectively. The finding of CD4*’"®^ ^CD8‘^ '"' T-cells 
has been reported in swine, chickens, monkeys, rats and humans (as reviewed in 
Zuckermann 1999). However, the CD4^™CDS'^”®''^  immunophenotype has been recorded 
less often (Sullivan et al. 2001). Sullivan and co-workers showed that this dual expression 
resulted following activation of CD8^ cells by co-stimulation with staphylococcal 
enterotoxin B and anti-CD3/CD28 antibodies. However, it may also result from prolonged 
culture of CD8^ and CD4^ cells. Further immunophenotypic studies will be required to 
determine whether the CD4/CD8 dual expressing cell subset that arose in cell populations 
cultured with CD40L were doublets (a CD4 expressing cell and a CD8 expressing cell 
joined together), or a distinct CD4 cell population that was induced to express CDS.
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Figure 3.1. Production of 3T3 cells stably transfected with feline 
CD40 ligand
pDON-AI
VSVEnv
MuLV
Murine leukemia 
packaging cell line
CD40L
The pDON-Al vector contains T  (psi; the extended viral packaging signal), but not the structural genes 
necessary for viral particle formation and replication (gag, pol and emi). Therefore, when this vector is 
transfected into the murine leukaemia virus-based packaging cell line containing those genes, RNA from the 
vector is packaged in an infectious but replication incompetent retrovirus particle. By infecting a target cell 
with the virus particles produced, the target gene can be integrated into the target cells chromosomal DNA. 
Modified from www.Stanford.edu/group/nolan/retroviral-systems/phx.html.
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Figure 3,2. Proliferation of PBMC in response to 3T3 cells stably 
expressing feline CD40L (3T3.F154)
mock transfected 3T3 
CD40L transfected 3T360000 -
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300100000 30000 10000 3000 1000 none
no. of 3T3 cells
Proliferative response of feline PBMC induced by 3T3 cells expressing feline CD40 ligand (3T3.F154) (®), 
compared to mock transfected 3T3 cells (o). PBMC induced to proliferate to a maximum of 50958 +/- SEM 
5126 counts per minute (cpm) by 3x10'  ^3T3.F154 cells. ** The difference between the two groups is highly 
significant P=0,001, P=0.0008, P=0.003, P=0.0004 and P=0.001 respectively (Student’s t-test).
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Figure 3.3. Flow cytometric analysis of proliferating PBMC
a.) 3T3 cells b.) 3T3.F154
100
B220*œ«s 
CDS* cells
80 -
60 -8iI 40
20 -
10® 1(fnone
100
B220*ce«s 
CDS* cells
80 -
60-
40-
20 -
icf 10* 1(f 1(fnone
No. of mock transfected 3T3 cells Noof3T3.F154oells
a)PBMC stimulated with mock transfected 3T3 cells or b) with CD40L transfected cells (3T3.F154). PBMC 
were stained with PE-conjugated anti-CD5 and FITC-conjugated anti-B220 antibodies.
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Figure 3.4. Proliferation of PBMC cell fractions in response to 
CD40L
35000 3T3 + 8220+ve cells 
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B220 enriched PBMC (B220 ) were induced to proliferate to a maximum of 29252 ± 2500 SEM cpm by 
3T3.F154 cells (A). However, PBMC depleted of CD3 positive cells (CD3 ) were induced to proliferate to a 
maximum of 36662 ± 7049 SEM cpm by 3T3.F154 cells (B). ** When the proliferation of B220^ cells in 
response to 3T3.F154 cells was compared with the proliferation of B220' cells in response to 3T3.F154 cells 
it was highly significant, P=0.00001, PM).0006 and P=0.00005 respectively. Similarly the difference 
between CD3 cells proliferation and CD3^ cells proliferation in response to 3T3.F154 cells was also highly 
significant, P=0.01, P^O.00007, P=0.00004 and P=0.002 respectively.
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Figure 3.5. Flow cytometric analysis after addition of IL-4 to CLL 
PBMC co-cultured with CD40L (CLL.F154)
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(A) CLL.F154 culture without IL-4. (B) CLL.F154 culture after the addition of IL-4 for 7 days. The 
addition of IL-4 increased the B220^ cell population and decreased the CD8 cell population. Cells were 
stained with PE-conjugated anti-CD8 and cychrome-conjugated anti-B220 antibodies.
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Figure 3.6. Comparison of CLL cat PBMC and SPF cat PBMC 
proliferation in response to CD40L
70000 3T3 + SPF PBMC 
3T3.F154 + SPF PBMC 
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CLL cat PBMC and SPF cat PBMC were incubated with mock transfected 3T3 cells and 3T3.F154 cells. 
CLL PBMC were induced to proliferate to a maximum of 54 000 ± 6700 SEM cpm. * The difference in 
proliferation of CLL cat PBMC and SPF cat PBMC was highly significant at 3x1 O'* and lO'* 3T3.F154 cells, 
P=0.01 (Student’s t-test).
Figure 3.7. FACS analysis of SPF and CLL PBMC co-cultured with 
CD40L
SPF and CLL cat PBMC cultured in RPMI and stimulated with CD40L (SPF.Fl54 and CLL.F154 
respectively) were stained with FITC-conjugated anti-B220 and PE-conjugated anti CD5 antibodies after 7 
days in culture. Stimulation of SPF and CLL PBMC with CD40L results in the production of lymphoblasts 
(BLASTS). The lymphoblasts of both SPF and CLL PBMC co-express B220 and CD5. The SPF.Fl54 
lymphocytes (LYMPH) predominantly expressed CD5, however the CLL.F154 lymphocytes also co­
expressed B220 and CD5.
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Figure 3.8. FACS analysis of CLL PBMC co- cultured in RPMI and 
MM with CD40L (CLL.F154)
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The dotplots demonstrate that the CLL.F154 cell population cultured in MM has more lymphocytes 
(LYMPH) and lymphoblasts (BLASTS), than the corresponding CLL.F154 cell population cultured in RPMI.
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Figure 3.9. FACS analysis of SPF.Fl54, SPF.3T3, CLL.F154 and 
CLL.3T3 cultured in RPMI and MM
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FACS analysis of lymphoblasts stained with PE-conjugated anti-CD5 and FITC-conjugated anti-B220 
antibodies revealed co-expression of B220 and CD5. This co-expression is more evident in cultures 
stimulated with CD40L. SPF and CLL PBMC co-cultured with 3T3 in MM display an increased number of 
CD5 cells when compared with the corresponding cell populations cultured in RPMI.
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Figure 3.10. Flow cytometric analysis of CLL and SPF PBMC 
cultures at 7 days
A) RPMI-7 days C) RPMI-7 days
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Cell populations were stained with PE-conjugated anti-CD5 and FITC-conjugated anti-B220 antibodies. SPF 
and CLL PBMC co-cultured with CD40L contained predominantly B220' lymphoblasts, however SPF 
PBMC cultures also had a large population of CD5^ lymphocytes. Conversely the lymphocytes in CLL 
PBMC cultures expressed B220. MM promoted the growth of lymphoblasts, in SPF and CLL PBMC 
cultures.
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Figure 3.11. Flow cytometric analysis of CLL and SPF PBMC 
cultures at 16 days
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Cell populations were stained with PE-conjugated anti-CD5 and FITC-conjugated anti-B220 antibodies. 
After 16 days, the SPF.Fl54 cell population in RPMI remained similar to at 7 days. The CLL.F154 cell 
population in RPMI showed a decrease in B220 lymphocytes and an increase in CD5 lymphocytes. MM 
still supported the growth of lymphoblasts, however these were no longer predominantly B220 in SPF.Fl 54 
cells. CLL.3T3 cells were now predominantly a T-cell population, nd- not done, as cells were no longer 
viable.
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Figure 3.12. FACS analysis of SPF PBMC after 16 days in culture
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Lymphoblasts were stained with FITC-conjugated anti-CD3 and PE-conjugated anti-CD5 antibodies. (A) 
SPF PBMC cultured alone in MM. (B) SPF PBMC cultured with 3T3 cells in MM, showing a decrease in 
CD5^ and CD3^ individual cell populations, but an increase in the CD5/CD3 dual positive subset.
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Figure 3.13. FACS analysis post-separation of CLL.F154 into 
B220 enriched and B220 depleted cell populations using MACS 
beads
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Cells were stained with PE-conjugated anti-CD8 and cychrome-conjugated anti-B220 antibodies. (A) B220- 
depleted population. (B) B220-enriched population. FACS analysis demonstrates that cell depletion using 
MACS beads does not result in a pure cell population.
Figure 3.14. Dual expression of B220 and CDS in SPF and CLL 
PBMC co-cultured with CD40L in RPMI and MM
Cells were stained with FITC-conjugated anti-B220 and PE-conjugated anti-CD5 antibodies. FACS analysis 
demonstrated a sub-population of CD5 B-cells in the SPF.F154 lymphoblasts and in the CLL.F154 
lymphoblasts and a smaller population of CD5^ B-cells in the CLL.F154 lymphocytes. MM promoted this 
dual expression in CLL.F154 cells.
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Figure 3.15. FACS analysis of CLL PBMC cultured alone in RPMI 
and MM
CLL PBMC were stained with FITC-conjugated B220 and PE-conjugated CD5 antibodies. The production of 
lymphoblasts (BLASTS) was increased by culturing in MM and the co-expression in lymphoblasts of B220 
and CD5 was also increased by culturing in MM.
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Figure 3.17. FACS analysis of CLL and SPF PBMC cultured alone 
at day 16
CLL PBMC in MM at day 16
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Cells were stained with FITC-conjugated anti-CD3 and cychrome-conjugated anti-B220 antibodies. FACS 
analysis revealed co-expression of CD3 and B220, which was more evident in the CLL PBMC culture.
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Figure 3.18. FACS analysis of SPF and CLL PBMC co-cultured 
with CD40L and control 3T3 in MM
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Cells were stained with FITC-conjugated anti-CD4 and PE-conjugated anti-CD8 antibodies. FACS analysis 
revealed a sub-population of CD4/CD8 co-expressing cells, in the SPF.F 154, SPF.3T3 and CLL.3T3 cell 
populations, but interestingly not in the CLL.F 154 cell population.
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Figure 3.19. Southern blot analysis of B-CLL lymphoblasts
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Hind III digested DNA from the CLL cells (lane 1) or control PBMC (lane 2) was screened with a probe 
specific for immuno globulin Cp heavy chain. A 7.5kb band was detected in both lanes, indicative of 
immunoglobulin genes in the germline con-figuration. "^XHind III marker
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Table 3.1. CD21 expressing lymphocytes and lymphoblasts
Cell % % %CD21 %CD21
populations Lymphocytes Lymphoblasts expressing expressing
________________________  lymphocytes lymphoblasts
SPF,F154 8.4 40.1 1.9 93.5
(RPMI)
CLL.F154 5.7 35.8 56.5 96.6
(RPMI)
SPF.F154 4 50.2 5.5 75.7
(MM)
CLL.F154 8.9 49.3 73.7 95.2
(MM)
SPF.3T3 45.3 1.8 23.2 58.3
(RPMI)
CLL.3T3 65.9 1,7 61 64.1
(RPMI)
SPF.3T3 27.1 29.4 40 13.6
(MM)
CLL.3T3 37.6 21.7 71.4 17.1
V
(MM)
SPF 48.4 2.1 12.1 31.6 3
(RPMI)
CLL 59.1 3.3 18.8 25.5 1
(RPMI)
SPF 33.9 13.1 29.9 14.7
(MM)
CLL 41.8 24.9 74.3 20.9
(MM) „'i
FACS analysis of SPF and CLL cat PBMC at 7 days in culture. Cells were stained with FITC-conjugated 
anti-CD21 antibody.
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Chapter Four
ENHANCING THE IMMUNE RESPONSE AGAINST FIV IN 
MICE WITH FELINE CD40L
4.1. Introduction
The realisation that naked DNA could be used to induce immune responses was almost 
accidental. Wolff et al. (1990) discovered that the injection of mice intramuscularly with 
naked DNA resulted in long-term reporter gene expression in transfected muscle fibers. It 
was subsequently shown that if the DNA plasmid encoded an antigenic protein, such as 
human growth hormone, immune responses could be induced in the mouse against the 
protein (Tang, DeVit, and Johnston 1992). The ability of proteins encoded by DNA 
plasmids to induce a protective host immune response was then established using an 
influenza virus model, again in the mouse (Ulmer et al. 1993). This study confirmed the 
potential for the use of naked DNA as a vaccine. Since then, the immune stimulating 
potential of injecting DNA plasmids encoding different pathogens into mice has been 
studied extensively. Pathogens have included HIV, hepatitis B virus, measles virus, bovine 
herpesvirus type 1, murine leukaemia virus and rabies virus (reviewed in Davis and 
McCluskie 1999).
In order to induce an effective immune response, several stimulatory signals are required. 
The primary signal is provided by the vaccine antigen itself and secondary signals are 
provided by co-stimulatory molecules or cytokines. Several novel approaches have been 
taken to provide such secondary signals in order to improve the efficacy of DNA 
vaccination. The immune stimulating capacity of DNA vaccines administered in 
conjunction with plasmids encoding co-stimulatory molecules has been studied in the 
mouse (Iwasaki et al. 1997; Davis et al. 1997; Kim et al. 1998). Many studies have been 
conducted more specifically with the co-stimulatory molecule, CD40L (Mendoza, 
Cantwell and Kipps 1997, Gurunathan et al. 1998, Ihata et al. 1999, Burger, Mendoza and 
Kipps 2001, Sinetal. 2001).
In the cat, the potency of FIV DNA vaccines has been enhanced with the addition of 
plasmids encoding cytokines (Hosie et al. 1998; Boretti et al. 2000; Leutenegger et al. 
2000; Hanlon et al. 2001; Dunham et al. 2002). DNA vaccination has been successful in
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protecting cats against FIV challenge when FIV DNA plasmids have been administered 
with plasmids encoding cytokines, including IFN-y (Hosie et al. 1998), IL-12 and IL-18 
(Dunham et al. 2002). This, combined with the success of plasmids encoding co­
stimulatory molecules inducing immune responses in the mouse model, warranted further 
research into the use of co-stimulatory molecules as novel adjuvants in DNA vaccination 
against FIV. In this study, the effect of immunising with the feline co-stimulatory 
molecule CD40L on the immune response to FIV was investigated in the mouse.
Female BALB/c mice were inoculated with feline CD40L DNA and FIV DNA together. 
Controls of either FIV or CD40L DNA alone and PBS alone were included. Because FIV 
is not infectious in mice, the aim of the study was not to challenge the immunised animals, 
but to examine the immune response against FIV that was elicited by the DNA vaccine. 
After three inoculations, serum samples were tested for anti-viral antibodies by Western 
blotting, ELISA and IF and splenocytes were assessed for the ability to proliferate in 
response to FIV p24 and WIV.
The ability of feline CD40L to bind the murine CD40 receptor has been previously 
demonstrated in proliferation assays in which murine PBMC were induced to proliferate in 
response to 3T3 cells stably expressing feline CD40L (Brown et al, 2002).
4.2. Materials and methods 
4.2.1. Mice
Twelve female BALB/c mice, 6 to 8 weeks of age, were purchased from Harlan UK Ltd 
(Bicester, Oxford, UK) and maintained at the Diagnostics Scotland animal facility 
(Pentlands Science Park, Penicuik, UK) for the duration of the study. All procedures were 
conducted in accordance with the Animals (Scientific Procedures) Act 1986.
4.2.2. Plasmids and DNA preparation
The FIV and CD40L DNA plasmids used for inoculation in this study are described in 
Chapter 2.
4.2.3. Inoculation and blood sampling protocol
All inoculations and blood sampling were conducted at the animal facility of Diagnostics 
Scotland. Mice were randomly allocated into four groups of three mice. The mice were
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inoculated at day 7, day 14 and day 21. Each inoculation consisted of one injection in the 
quadriceps muscle of the hind leg. Per inoculation, group 1 received 50p.g of FIV DNA in 
SOfxl of PBS, group 2 received 50pg of FIV DNA and 50pg of feline CD40L DNA in 50pl 
of PBS, group 3 received 50pg of feline CD40L DNA in 50pl of PBS and group 4 received 
50pl of PBS only as a control.
Whole blood was collected into plain tubes at day 0 (pre-immune bleed), day 18 (test 
bleed) and day 28 (end of study bleed) to obtain serum samples. At the end of the study 
(day 28) spleens were collected aseptically.
4.2.4. Detection of anti-viral antibodies
Western blotting, ELISA to detect antibodies recognizing the immunodominant FIV TM 
peptide and FIV p24 and IF were conducted to determine the antibody responses made 
against FIV. See sections 2.1.6.1, 2.1.6.2 and 2.1.6.3 for a full description of these 
serological assays. Antibodies recognising FIV-infected CRFK cells were detected by an 
indirect IF technique using FITC sheep anti-mouse IgG (Diagnostics Scotland, Edinburgh, 
UK) secondary antibody.
4.2.4.1. Western blotting
Western blotting was conducted as described in Section 2.1.6.3. Blots were incubated with 
mouse serum. There were 3 samples per mouse, the first sample was taken prior to any 
DNA inoculations at day 0 (pre-immune), the second sample was taken after two DNA 
inoculations at day 18 (test) and the third sample was taken 7 days after the third and final 
DNA inoculation (day 21) at day 28 (end of study). The secondary antibody used for 
membranes incubated with mouse sera was a biotinylated anti-mouse IgG antibody (Vector 
Laboratories) used at a final concentration of 1 pg/ml.
4.2.5. Detection of a cell-mediated immune response
A proliferation assay was employed as described in Section 2.1.7. to detect T-cell 
proliferation in response to either FIV p24 core protein or WIV. Cells were obtained from 
spleens collected aseptically at the end of study (day 28) by rupturing the splenic capsule 
and teasing the cells out with a scalpel blade. The resultant cell suspension was 
centrifuged over Ficoll at 2000rpm for 10 minutes and the cells were washed and counted 
and 2x10^ spleen cells were added to each well.
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4.3. Results
4.3.1. Anti viral antibodies detected by Western blotting
The serological responses against FIV, induced by inoculating mice with FIV DNA, FIV 
and CD40L DNA and CD40L DNA alone were assessed by IF, p24 and TM ELISAs and 
Western blotting. No fluorescence was detected by IF conducted with serum samples 
collected at the end of the study after 3 inoculations. Also the antibody titres for TM and 
p24 were zero when ELISAs were performed with serum samples also taken at the end of 
the study. However, as illustrated in Figure 4.1, antibodies were detected in some serum 
samples by Western blotting. Western blotting was conducted using all 3 serum samples 
collected at day 0 (pre-immune serum), day 18 after 2 inoculations (test serum) and day 28 
after all 3 inoculations (end of study serum). Antibodies against the structural proteins of 
FIV, gpl20 and p24 were evident in group 2 (FIV and CD40L DNA) only. This would 
suggest that co-immunisation with CD40L DNA had enhanced the humoral immune 
response against FIV DNA in the mice in group 2. No bands were evident in the pre- 
immune serum samples, indicating that this enhancement of the humoral immune response 
was directly attributable to DNA inoculation.
4.3.2. No cell-mediated responses induced by DNA inoculation
Proliferation assays were performed to detect cell-mediated responses induced against FIV 
following inoculation with the DNA plasmids. As shown in Figure 4.2, there was no 
marked proliferation of spleen cells in any of the groups, vaccinates or controls, when 
tested against WIV. However, there was a response against p24 in all of the groups tested, 
including the control group (PBS only), suggesting that this response was non-specific (see 
Figure 4.2). A positive experimental control of Con A was also included and splenocytes 
from all groups of mice proliferated in response to this mitogen. Therefore, the failure of 
any groups splenocytes to respond to WIV would be a tine indicator that CD40L 
inoculation did not increase the immune response to WIV. The failure of this test to 
differentiate between proliferation of PBS control splenocytes from vaccinates splenocytes 
to FIV-p24, could be due to the splenocytes proliferating in response to the GST 
component of the FIV p24-GST fusion protein employed in this assay. However the same 
p24-GST fusion protein was used in experiments with feline PBMC and this non­
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specificity was not apparent in those results. However, it is well known that results cannot 
be extrapolated from one species to another.
4.4. Discussion
In this study the immune responses to FIV in mice inoculated with FIV DNA and CD40L 
DNA together were determined. Because the response to the antigenic protein encoded by 
a DNA plasmid alone is often weak, this study sought to increase the immune response by 
inoculating the FIV DNA in the same syringe as the co-stimulatory molecule CD40L. This 
study demonstrates the immune stimulating capacity of feline CD40L in mice.
In agreement with previous studies (Gurunathan et al. 1998; Ihata et al. 1999; Burger, 
Mendoza, and Kipps 2001), the administration of the co-stimulatory molecule, CD40L in 
conjunction with FIV DNA did enhance the humoral immune response to FIV in all three 
mice in group 2 (FIV and CD40L DNA), as demonstrated by Western blotting. However, 
there was no evidence of enhancement of the cell-mediated response against FIV when 
spleen cells were incubated with either FIV p24 or WIV to test for activated CD4^ antigen- 
specific T-cell proliferation. Helper T-cells play an important role in both humoral and 
cell-mediated immunity, via expansion of antigen-stimulated B-cells and CD8^ T-cells. 
Previous studies (Gurunathan et al. 1998; Ihata et al. 1999; Burger, Mendoza, and Kipps 
2001; Sin et al. 2001) have all shown an increase in cell-mediated immunity with the 
administration of CD40L. Sin et al. (2001) demonstrated that the protection induced in 
mice against a lethal dose of HSV was elicited by a DNA vaccine co-inoculated with 
CD40L DNA and was due to an increase in cellular immunity as demonstrated by T-eell 
proliferation and enhanced production of IL-2 and IFN-y. Therefore, tlie immune response 
induced was predominantly a Thl response. Thl responses are thought to drive induction 
of cellular immunity, whereas Th2 immune responses preferentially drive humoral 
immunity. Interestingly, Sin et al. (2001) did not demonstrate an enhancement in humoral 
immunity. There was no increase in antibodies to HSV when serum was tested by ELISA. 
Sin et al. (2001) postulated that this could be due to the CD40L used in their study being 
membrane-anchored, thereby specifically targeting the cellular immune response, without 
enhancing the magnitude of the humoral immune response. However, the CD40L used in 
the present study was also membrane bound and yet appeared not to target the cellular 
immune response. Differences in the immune responses elicited between the different
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studies might be due to differences in volume of DNA injected, promotor used, site of 
injection or breed and age of mice.
In this study, a humoral response against FIV was elicited in mice inoculated with FIV and 
CD40L DNA together, whereas FIV DNA alone did not induce a humoral immune 
response as determined by ELISA, IF and Western blotting. A FlV-specific cell-mediated 
immune response was not detected in any of the mice inoculated with FIV DNA alone or 
FIV and CD40L DNA together, however the method used to detect cell-mediated 
responses requires further optimisation. Further studies may involve chromium release 
assays for the detection of CTLs.
Figure 4.1. Anti-viral serological responses
Antibodies against the structural proteins of FIV could be detected in mouse sera by Western blotting. (A) 
group 1 (FIV DNA only) and group 2 (FIV and CD40L DNA), (B) group 3 (CD40L DNA only) and group 4 
(PBS control). The pre-immune, test and end of study serum samples were tested (lanes I, 2 and 3 in each 
mouse respectively, except for mouse 1 and 2 in group I, where there are no test serum samples). Specific 
bands were only evident in serum samples from the mice in group 2. Samples from mouse I and mouse 3 in 
group 2 demonstrated reactivity against gp 120 in the end of study samples and the end of study sample from 
mouse 2 in group 2 appeared to demonstrate reactivity against a protein corresponding to p24. The 
reactivities observed in groups 1 and 3 could be non-specific as binding was evident in the pre-immune serum 
samples (which were collected prior to inoculation) and similarly bands in group 4 could be non-specific as 
bands were evident in the pre-immune serum samples and group 4 were inoculated with PBS. Known FIV 
+ve and -ve feline serum samples were used as controls.
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Figure 4.2. Proliferation of splenocytes in response to p24 and 
WiV
FIV only FIV and CD40L CD40L only PBS control
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FIV only FIV and CD40L CD40L only PBS control
B
Mouse splenocytes obtained post mortem were incubated with FIV p24 and WIV to detect any cell-mediated 
immune response post vaccination. Graph (A) demonstrates a non-specific response to p24 (25pg/ml) as the 
PBS control vaccinates proliferated to high levels in parallel with the study vaccinates. Graph (B) 
demonstrates a failure of any of the vaccinates to respond to WIV. A SI of ^  was regarded as significant.
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Chapter Five
EVALUATION OF FELINE CD40L AS AN ADJUVANT IN A 
DNA VACCINE AGAINST A VIRULENT ISOLATE OF FIV
5.1. Introduction
A number of vaccine trials have been successful in inducing protection against FIV 
infection, initially using WIV and inactivated IC vaccines (Yamamoto et al. 1991b; 
Yamamoto et al. 1993) and then DNA vaccines (Hosie et al. 1998; Lockridge et al. 2000; 
Boretti et al. 2000; Dunham et al. 2002). Protection has been restricted largely to 
challenge viruses of low virulence, such as FIV-PET and similar vaccine prepmations did 
not protect against the more virulent primary FIV-GL8 (Hosie et al. 1992). It is likely that 
it will be necessary for a commercially available vaccine to confer protection against more 
virulent, and presumably more relevant primary isolates, such as FIV-GLS and FIV-UTl 13 
that have so far proved resistant to vaccine induced protection (Hesselink et al. 1999).
Both humoral and cell-mediated immunity have been implicated in protection associated 
with WIV vaccines (Hosie and Flynn 1996b) and therefore both are considered important 
in protecting against virulent strains of FIV. When cats immunised with FIV-PET WIV 
were challenged with FIV-GL8, although not protected from infection, suppression of viral 
load post challenge was seen (Hosie et al. 1995; Hosie et al. 2000). In contrast, when a 
similar study was conducted using DNA vaccines (Hosie et al. 2000), there was no 
suppression of viral load when cats immunised with a FIV-PET DNA vaccine were 
challenged with FIV-GL8. These findings suggested that the broader spectrum of immune 
responses elicited by the WIV vaccine was beneficial in controlling the FIV-GL8 
challenge.
Such success as has been achieved with FIV DNA vaccines has been dependent on co­
administration of plasmids encoding cytokines, which act as immune-stimulating 
adjuvants. Therefore, in this study the effect of immunising cats with a FIV DNA vaccine 
together with a co-stimulatory molecule, feline CD40L, to act as an adjuvant, was 
investigated. It was hoped that by inoculating with a plasmid encoding FIV-GL8 pro virus 
together with a plasmid encoding feline CD40L, that CD40L would encourage both
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cellular and humoral immune responses, which might provide protection against the FIV- 
GLS challenge.
Prior to this study, the feline CD40L gene was cloned and 3T3 cells were transduced so 
that a cell line expressing CD40L on the cell surface was developed. In order for the 3T3 
cells to stably express CD40L, they were infected with supernatant from the Phoenix-Eco 
ecotropic murine leukaemia virus-based packaging cell line (previously transfected with 
the pDON-AI retroviral vector with a feline CD40L insert, pDON-AI.F154). In Chapter 3, 
the establishment of the in vitro biological activity of the cloned feline CD40L using 3T3 
cells stably transfected with CD40L was reported. However, this study required that feline 
CD40L be in a plasmid vector suitable for use as a DNA vaccine. The plasmid chosen was 
VR1012; the VR1012 plasmid has previously been shown to promote DNA expression in 
skeletal muscle, the preferred route of immunisation of DNA vaccines and the route used 
in this study (Hartikka et al. 1996). In order to assess the biological activity of the VR1012 
plasmid with a CD40L insert (VR1012.F154) which would be used as the DNA vaccine, 
3T3 cells were transiently transfected with VR1012.F154 and a proliferation assay was 
conducted using the methods described previously.
A FIV-GL8 DNA construct was then selected from a panel of FIV DNA constructs 
following a comparison of the expression of FIV structural proteins using Western blotting. 
Once the biological activity of the CD40L plasmid had been assessed and the FIV DNA 
construct selected, the required amounts of both DNA plasmids were prepared for 
vaccination and the immune responses elicited in cats by an FIV DNA vaccine with and 
without the inclusion of CD40L as a genetic adjuvant were studied. SPF cats were 
inoculated with FIV DNA alone, FIV DNA and CD40L DNA, CD40L DNA alone or PBS 
only as a control. To test the efficacy of immunisation, animals were challenged with the 
biological isolate of FIV-GL8 by i.p inoculation. Following challenge several parameters 
were monitored including; viral load, proviral load, CD4:CD8 ratio, CD 8(1^ °^  cell numbers 
and haematology to determine the effect, if any, of CD40L as an adjuvant.
5.2. Materials and methods
6.2.1. Production of the CD40L DNA vaccine
Please see Section 2.1.3.1.
87
5.2.2. Demonstration of the biological activity of the CD40L DNA 
vaccine, VR1012.F154
To assess the biological activity of the VR1012.F154 plasmid prior to use as a DNA 
vaccine, 3T3 cells were transiently transfected using the Superfect reagent (Qiagen) with 
VR1012.F154 or with empty plasmid (VR1012). Circular tissue culture plates 10cm in 
diameter (Becton Dickinson), were seeded with 10  ^ 3T3 cells and incubated overnight at 
37°C in an atmosphere of 5% CO2 , to allow the 3T3 cells to establish themselves. The 3T3 
cells were then rinsed in serum-free DMEM and incubated with lOpg of the plasmid DNA 
and 60pl Superfect reagent in 3 ml of serum-free DMEM for 3 hours at 37°C in an 
atmosphere of 5% CO2 . After this time, the cells were again rinsed in serum-free DMEM 
and then returned to the incubator in fresh complete DMEM for a further 2 days, at wliich 
point they were 90% confluent. To determine the efficiency of transfection, control plates 
of 3T3 cells were transfected with LacZ and subsequently stained with X-gal, The 
transiently transfected 3T3 cells were then used as target cells in proliferation assays, as 
described previously in section 2.1.4. Briefly, irradiated (3000 rads) VR1012.F154 cells 
and mock transfected 3T3 cells were added in decreasing numbers in triplicate wells of a 
96-well flat bottom plate. SPF cat PBMC (10^ in number) were added to each well and the 
plates were incubated at 37°C in an atmosphere of 5% CO2 for 4 days, after which time 
20pCi/well of ^ H-thymidine was added for the final 18 hour s of incubation. The cells were 
harvested from the plates onto absorbent filter plates and the radioactivity incorporated into 
the cells was measured on a microplate scintillation counter.
5.2.3. Expression of FIV proteins by FIV DNA constructs
The expression of FIV proteins in vitro by FIV DNA constructs was investigated by 
transfecting 293T cells as described above and performing Western blotting with an anti- 
FIV cat serum, as described in section 2.1.6.3, to enable the selection of a construct 
suitable for use as a DNA vaccine. The DNA constructs investigated are listed in Table 
5.1. Briefly, 293T cells were seeded at 1.5 x 10  ^cells/well in a 6-well poly-l-lysine coated 
tissue culture plate (Becton Dickinson) and transfected with 2pg of FIV plasmid DNA 
construct using the Superfect reagent (Qiagen). After 3 days, 1ml of culture fluid was 
removed from each well and tested for FIV p24 antigen, using a commercial FIV antigen 
ELISA (IDEXX), and RT activity was measured using a LentiRT assay (Cavidi Tech AB, 
Uppsala, Sweden). Also at 3 days post transfection, cell lysates were made from the
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transfected 293T cells. RSB was added to the lysates, which were then boiled for 3 
minutes and resolved on a 4-20% gradient Tris-HCl SDS-PAGE (Biorad). Transfer was 
performed onto a nitrocellulose membrane (Biorad), which was blocked overnight and then 
incubated for 2 hours at room temperature with FIV-positive cat serum or anti-Env 
monoclonal antibody (vpg71.2) (Willett et al. 1997a) diluted 1:10 with PBS supplemented 
with 1% non-fat milk powder and 0.5% Tween-20. Following incubation, the membranes 
stained with FIV-positive cat serum were washed and incubated for 1 hour with 
biotinylated protein A (ICN Pharmaceuticals Ltd.) at a concentration of 4|Lig/ml. The 
secondary antibody used for membranes incubated with vpg 71.2 was a biotinylated anti­
mouse IgG antibody (Vector Laboratories) (Ipg/ml), After incubating with tlie secondary 
antibodies the membranes were washed again and incubated for a further hour with 
streptavidin-alkaline phosphatase (Bio-Rad). Membranes were then washed and incubated 
in AP buffer for 10 minutes before bound antibody was detected using 10 ml AP buffer 
containing BCIP (Sigma) (50mg/ml) and NBT (Sigma) (50mg/ml).
5.2.4. Production of the FIV DNA vaccine
The CT5bG8MApol plasmid was selected from 5 FIV DNA constructs investigated for use 
as a FIV DNA vaccine. This plasmid consists of the 34TF10 (FIV PET) molecular clone 
of FIV (Talbott et al. 1989) with the U3 element within the 5’ LTR deleted by fusing the 
human CMV immediate early gene promoter to the R repeat, forming the CT5 plasmid 
(Poeschla, Wong-Staal, and Looney 1998). CT5b is a modification of CT5 in which the 
SV40 T-antigen binding site is inserted downstream of viral sequences to permit T antigen- 
dependent plasmid amplification. The CT5b plasmid was kindly supplied by Dr E.M. 
Poeschla and was developed fijrther by Dr B.J. Willett, at the University of Glasgow. The 
modified CT5b plasmid was derived by digesting CT5b Avith P a d  and Nde enzymes (New 
England Biolabs (UK) Ltd., Hitchin, Herts, UK) to remove the pol and env genes of 
34TF10, which were replaced by the pol and env genes of the GL8 molecular clone of FIV 
(Hosie et al. 2000) (CT5bG8M). A 397bp deletion in pol in CT5bG8MApol rended/s this
Iplasmid replication defective and hence non-infective. Dr. B.J Willett, University of 
Glasgow, kindly supplied the CT5bG8MApol plasmid.
Plasmid DNA was purified using double caesium chloride-ethidium bromide gradient 
centrifugation, butanol extraction and ethanol precipitation (see section 2.1.3.2).
;
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5.2.5. Immunisation of cats
A group of fifteen, 11-week-old SPF cats was obtained from a certified breeder and housed 
by Biological Services, University of Glasgow. Animal care and husbandry was conducted 
under the Codes of Practice published by the Home Office. All procedures were conducted 
in accordance with the Animals (Scientific Procedures) Act (1986).
The cats were randomly allocated into three groups of four (groups 1-3) and one group of 
three cats (group 4). Each group was vaccmated at 0, 3 and 6 weeks. Each vaccination 
consisted of 4 individual injections (one in each of the gastrocnemius muscles and one in 
each of the quadriceps muscles of the hind limb). Group 1 received lOOpg of FIV DNA in 
200pl of PBS per injection. Group 2 received lOOpg of FIV DNA and lOOpg of feline 
CD40L DNA in 200pl of PBS per injection. Group 3 received lOOpg of feline CD40L 
DNA in 200pl of PBS per injection and group 4 received 4 x 200|l i 1 injections of PBS only 
as a control. Cats were challenged 3 weeks after the third vaccination, at week 9, by i.p 
injection of 10 ID50 of the biological isolate of FIV-GL8, which had been previously 
titrated in vivo.
5.2.6. Isolation of FIV
Peripheral venous blood samples were collected into EDTA tubes at 3, 6, 10 and 13 weeks 
after challenge for isolation of FIV. PBMC were obtained by overlaying Ficoll-Hypaque 
with whole blood diluted 1 in 4 in serum-fi-ee RPMI and centrifiiging at 2000rpm for 10 
minutes. In T25 cell culture flasks (Coming), 10  ^PBMC were co-cultured with 10  ^Mya-1 
cells. The media were refreshed on day 4 and culture fluids were tested at day 7 by FIV 
p24 antigen ELISA (IDEXX). Positive cultures were discarded and negative cultures were 
maintained for a further seven days, when culture fluids were tested again.
5.2.7. Measurement of viral and proviral loads
Plasma samples and PBMC pellets from whole blood collected on the day of challenge and 
3, 6, 10, 13 and 15 weeks post challenge were analysed by real time PCR to determine 
viral and proviral loads. Peripheral lymph node (PLN) and mesenteric lymph node (MLN), 
as well as spleen and thymus were collected aseptically at post mortem examination (15 
weeks post challenge) into RPMI containing 100 lU/ml penicillin and lOOpg/ml 
streptomycin. The tissues were teased apart with scalpel blades and the resultant cell
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populations were centrifuged at lOOOrpm for 5 minutes. Spleen cells were centrifuged 
over Ficoll to remove red blood cells and therefore obtain splenocytes. These cell pellets 
were analysed for FIV proviral loads. FIV proviral load was measured by quantitative 
real-time PCR (Leutenegger et al. 1999). Viral loads were measured in plasma samples by 
quantitative reverse transcriptase-PCR (Klein et al. 2001). Dr. Dieter Klein conducted 
viral and proviral load measurements at The University of Vienna.
MLN cells obtained at necropsy were added in decreasing numbers (10\ 3x10^, 10 ,^ 3x10
5.2.8. Quantitative virus isolations
10 \  30, 10, 3, 1 and none) to a 96-well tissue culture plate (Becton Dickinson) and co­
cultivated, in 8 replicate wells, with 10  ^ Mya-1 cells/well. The plates were incubated at 
3TC  in an atmosphere of 5% CO2 for 14 days and half of the medium was removed and 
replenished every 4 days with complete RPMI supplemented with IL-2. Culture fluids 
were collected on day 14 and tested for FIV p24 by ELISA. The 50% endpoint (the 
dilution of MLN cells at which 50% of the wells containing MLN and Mya-1 cells were 
positive for FIV p24) was calculated using the method of Reed and Muench (1938).
5.2.9. Analysis of cell-mediated immune responses
A proliferation assay as described in Section 2.1.7. was employed to detect lymphocyte 
proliferation in response to either FIV p24 core protein or WIV. PBMC collected post U* 
vaccination, post 2"  ^vaccination or on the d.o.c were added to the proliferation assays.
5.2.10. Serology
5.2.10.1. Immunofluorescence
Antibodies recognising FIV-infected CRFK cells were detected by an indirect IF technique 
as described in section 2.1.6.2. FITC goat anti-feline IgG secondary antibody was used to 
detect feline antibodies (prepared by Mr. T. Dunsford, Retrovirus Research Laboratory, 
University of Glasgow),
5.2.10.2. Flow cytometry
Flow cytometry was also used to detect FIV anti-Env antibodies in plasma collected on the 
d.o.c. Thus, 10  ^ Mya-1 cells infected with FIV-GL8 were removed from culture and 
incubated with plasma samples for 30 minutes at 4°C in Falcon 2054 tubes. After washing
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twice in PBA the ceils were incubated witli FITC-conjugated goat anti-feline IgG for a 
further 30 minutes at 4°C. The cells were then washed twice in PBA, resuspended in 1ml of 
PBA and analysed on an EPICS Elite flow cytometer (Beckman-Coulter) using the EXPO 
analysis software package. For each sample 10000 events were collected.
5.2.10.3. Western blotting
Plasma samples collected prior to the vaccination and up to 15 weeks post challenge 
were assayed for anti-FIV antibodies by Western blotting, as described in Section 2.1.6.3. 
Briefly, a cell lysate was prepared from Mya-1 cells infected with FIV-GL8 and resolved 
on a 4-20% Tris-HCl SDS-PAGE (Biorad). Proteins were transferred to a nitrocellulose 
membrane (Biorad), which was blocked overnight. The membrane was cut into 2mm 
strips, which were incubated with each of 9 plasma samples and a positive and a negative 
control serum for two hours at room temperature. Staining was conducted using 
biotinylated protein A (ICN) as the secondary antibody.
5.2.10.4. ELISA
A peptide-based ELISA was employed to determine titres of antibodies recognising an 
immunodominant epitope in the TM glycoprotein (CNQNQFFCK), using the method 
described previously in section 2,1.6,1. Antibodies recognising the FIV p24 core protein 
were also measured by ELISA. TM and p24 ELISAs were conducted by Matt Colder, 
Companion Animal Diagnostics, University of Glasgow.
5.2.10.5. Virus neutralising antibody activity
Plasma samples collected on the d.o.c and 6 and 13 weeks post challenge were tested for 
VNA. Eight-fold dilutions of plasma were set up in quadruplicate in a 96-well flat- 
bottomed tissue culture plate (Falcon). The biological isolate of FIV-GL8 was diluted to 
10 TCIDso/ml and 50pl was added to each well containing plasma samples. Plasma 
samples and virus were incubated for 1 hour at 4°C. After incubation, 10^  Mya-1 cells in 
lOOjLil of complete RPMI were added to each well. The plates were incubated at 37°C in an 
atmosphere of 5% CO2 for 7 days. After 4 days, lOOpl of culture fluid was removed, 
discarded and replaced with fresh medium. At 7 days, 20pl of culture fluid was removed 
and RT activity was measured. The dilution of plasma at which 50% of RT activity was 
neutralized was calculated using the method of Reed and Muench (1938).
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6.2.11, Analysis of lymphocyte subpopulations by flow cytometry
EDTA blood samples, 1ml in volume, were subjected to ammonium chloride lysis to 
obtain peripheral blood leucocytes. Thus, 1ml of 0.4% paraformaldehyde in PBS was 
added to 1ml of whole blood and incubated at room temperature for no more than 4 
minutes. To this suspension, 25ml of pre-warmed (37°C) ammonium chloride/Tris (0.88% 
ammonium chloride/0.01 M Tris-HCL pH 7.4) was added to lyse the red blood cells and the 
suspension was then centrifuged at lOOOrpm for 5 minutes. The resultant leucocyte cell 
pellet was washed in PBA and resuspended in 200pi of PBA. The leucocytes were divided 
into 4 groups and labelled with antibodies by incubating for 30 minutes at 4”C with 5 pi of 
antibody. Group 1 was labelled with FITC-conjugated mouse anti-feline CD4 (Vpg 34, 
Serotec) and PE-conjugated mouse anti-feline CD8ap (Vpg 9, Serotec) antibodies. Group 
2 was labelled Avith FITC-conjugated anti-feline CD3 (NZMI, Dr. Y. Nishimura, 
University of Tokyo) and PE-conjugated mouse anti-feline CD4 (Fe 17, Southern 
Biotechnology) antibodies. Group 3 was labelled with FITC-conjugated anti-feline CD3 
(NZMI, Dr. Y. Nishimura) and PE-conjugated mouse anti-feline CD8aP (Vpg 9, Serotec) 
antibodies and Group 4 was labelled with FITC-conjugated anti-feline CD8a (12A3, 
kindly provided by Dr. M. Shimojima, University of Tokyo) and PE-conjugated anti-feline 
CD8P (FT2, Southern Biotechnology) antibodies. After incubation, the cells were washed 
tAvice with PBA, resuspended in a final volume of 1ml of PBA and analysed on an EPICS 
Elite flow cytometer (Beckman-Coulter) using the EXPO analysis software package. 
Lymphocytes were ‘dive-gated” on the basis of size and granularity and 5000 events were 
collected for each sample with the exception of group 4 for wliich 10000 events were 
collected because of the small number of gated cells,
5.2.12. Haematology
Peripheral venous blood samples (200pi in volume) were collected into EDTA at 6 and 3 
weeks prior to challenge, on the d.o,c, and 3, 6, 10, 13 and 15 weeks post challenge and 
were subjected to haematological analysis. The haematological parameters analysed were 
red blood cell count (RBC), haemaglobin (Hb), haematocrit (HCT), mean cell volume 
(MCV), mean cell haemaglobin (MCH), mean cell haemaglobin concentration (MCHC), 
white blood cell count (WBC), and counts of neutrophil, lymphocyte, monocyte, 
eosinophil and basophil numbers.
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5.3. Results
6.3.1. VR1012.F154 induces proliferation of feline PBMC in vitro
Prior to its use as an adjuvant in vivo, the activity of the feline CD40L DNA intended for 
use in the vaccine inoculum was assessed in vitro using proliferation assays. 3T3 cells 
were transiently transfected with CD40L DNA (VR1012.F154) and then used as target 
cells for proliferation of feline PBMC. Thus, 10^  PBMC from an SPF cat was incubated 
with irradiated 3T3 cells, either transiently expressing CD40L or mock transfected. As 
shown in Figure 5.1, feline PBMC were induced to proliferate to a maximum value of 7028 
± 664 SEM cpm by VR1012.F154, confirming the biological activity of the CD40L DNA 
construct. The proliferation of PBMC induced by 3T3 cells expressing CD40L at 10 ,^ 
3x10* and 10* 3T3 cells was highly significant and significant at 3x10^ 3T3 cells, when 
compared with the proliferation of PBMC induced by mock transfected 3T3 cells at these 
numbers (Student’s t-test).
5.3.2. Selection of a FIV DNA construct for vaccination
To investigate the effect of CD40L as a DNA adjuvant, a FIV DNA construct suitable for 
use as a DNA vaccine was first selected. 293T cells were transfected with FIV DNA 
constructs including the CT5bG8MApol plasmid, which was eventually selected for use as 
a FIV DNA vaccine. At 3 days post-transfection, cell lysates were made and Western 
blotting was performed to examine the proteins that were expressed. Env expression from 
the DNA constructs was compared on the basis of staining with anti-Env monoclonal 
antibody vpg 71.2 and pooled FIV-positive cat serum. Strong expression of the envelope 
protein was deemed to be of value as it is recognised to contain B-cell epitopes (Lombardi 
et al. 1993) important in the humoral immune response. It has also been shown that the 
induction of Env-specific CTL as part of the cellular immune response is an important 
outcome of vaccination (Flynn et al. 1996). Fuifhermore, in a previous study of HIV 
vaccination in chimpanzees, protection jfrom HIV-1 infection was associated with the 
generation of antibodies directed against the third variable domain (V3) of the HIV-1 
gpl20 Env glycoprotein (Emini et al. 1992). The CT5bG8MApol plasmid was selected for 
use as a DNA vaccine as Western blotting confirmed strong expression of FIV proteins in 
vitro, especially the Env proteins TM and SU, as shown in Figure 5.2.
__
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At 3 days post-transfection, culture fluids were tested for FIV p24 and RT activity. The 
CT5bG8MApol plasmid was positive for p24, but negative for RT activity due to the 397bp 
deletion in pol, thus confirming that the plasmid was replication incompetent and therefore 
safe for use as an immunogen.
5.3.3. Virus was isolated from all of the cats post challenge
In the light of these findings, a vaccine was prepared comprising the CT5bG8MApol 
plasmid and cats were inoculated with CT5bG8MApol alone, CT5bG8MApol with CD40L, 
CD40L alone and PBS. Cats were given three doses of vaccine and then challenged with 
10 IDso FIV-GL8 i.p. To determine whether the DNA vaccine induced protection against 
the challenge, virus isolation was conducted post challenge. At weeks 3,6, 10 and 13 post 
challenge, PBMC were isolated from peripheral venous blood samples and 10^  PBMC 
were co-cultivated with 10  ^Mya-1 cells. After 7 and 14 days culture fluids were tested for 
FIV p24 core protein by ELISA, At week 3 post-challenge, all cultures were postive for 
FIV p24, however, 2/4 cats in group 1 (A723 and A724) and 1/4 cats in group 2 (A728) 
remained negative until day 14 whereas the other cultures were positive for p24 by day 7 in 
culture, suggesting that the cats which yielded positive cultures later had lower viral loads. 
At week 6, 1/4 cats in group 1 (A723) remained negative for p24 until day 14 in culture, 
however all other cats were positive at day 7. At weeks 10 and 13 post-challenge all 
cultures were positive by day 7, indicating that inoculation with the DNA vaccine, with or 
without CD40L did not induce sterilising immunity against the homologous FIV-GL8 
challenge.
5.3.4. CD40L adjuvanted FIV DNA vaccine reduces viral loads
To monitor the progression of infection and to determine whether feline CD40L DNA 
immunisation, while not having induced sterilising immunity, may have led to decreased 
viral and proviral loads post challenge, viral and proviral loads were measured in each cat 
at intervals ftom the d.o.c to 15 weeks after challenge (see Table 5.2). Plasma viral RNA 
loads have been shown previously to be a good indicator of disease progression (Diehl et 
al. 1996; Goto et al. 2002). Plasma viral loads were highest overall in group 3 (CD40L 
DNA only), and lowest in group 2 (FIV + CD40L DNA), as shown in Figure 5.3. These 
results indicate that immunisation with the combination of FIV and CD40L DNA may 
have led to decreased viral loads, whereas CD40L DNA alone may have enhanced
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infection, since the viral loads in group 3 were gieater than those of the controls. In 
particular, Cat A731 (group 3), had a very high peak viral load of > 10^  virions/ml of 
plasma.
The proviral loads reflected the viral loads, being highest in the cats in group 3, as shown 
in Figure 5.3. Interestingly, the proviral loads were lowest in the control group, group 4 
(PBS). The proviral loads measured in the cats in group 2 were most similar to those of the 
control cats, indicating that the combination of CD40L with FIV DNA did not lead to the 
increased level of infection detected in a proportion of the cats inoculated with either FIV 
or CD40L DNA alone. In group 3, cat A729 developed a very high peak proviral load of 
182914 provirus copies/10  ^cells.
Proviral loads in tissues collected post mortem demonstrated a similar pattern to PBMC 
proviral loads. Overall, group 3 had the highest loads in all tissues sampled (PLN, MLN, 
spleen and thymus) except for PLN where loads were broadly similar amongst the groups, 
although the loads in group 1 were slightly higher, as shown in Figure 5.4. Viral loads did 
not correlate with proviral loads in individual cats, consistent with previous findings 
(Pistello et al. 1999). In agreement with the virus isolation findings (section 5.3.3), the 
viral loads of group 3 and group 4 were higher at week 3 post-challenge than those of 
groups 1 and 2. Viral loads also peaked earlier in groups 3 and 4 than in groups 1 and 2 
(see Table 5.2.). Therefore, virus was more readily detected in groups 3 and 4 by virus 
isolation. No virus or provirus could be detected in d.o.c samples, which also confirmed 
that the FIV DNA construct was non-infective.
5.3.5. Low viral levels were detected in MLN
Infectious viral burdens were quantitated by conducting quantitative virus isolations (QVI) 
with cells from MLN collected post mortem at 15 weeks post challenge. Lower levels of 
virus were detected in group 2 (FIV and CD40L DNA) and group 4 (PBS) than in groups 1 
(FIV DNA) and 3 (CD40L DNA), see Figure 5.5. The virus levels detected in MLN by 
QVI correlated in some (but not all) cats with MLN proviral loads at week 15 post­
challenge. When viral levels in MLN were compared with PBMC proviral loads, cats 722 
and 729 (groups 1 and 3 respectively) displayed the highest infectious virus levels in MLN 
and also had the highest PBMC proviral loads in their respective groups.
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mediated responses against FIV before challenge. These studies were also conducted in an 
attempt to establish whether the reduced viral loads in group 2 (FIV and CD40L DNA) 
could be associated with cell-mediated immunity. PBMC collected after the first, second 
and third vaccinations were recovered from liquid nitrogen and set up in 96-well plates 
with either p24 antigen or WIV. PBMC were shown to proliferate in response to both p24 
and WIV, as shown in Figure 5.6, In group 1, (FIV DNA only), cats A723 and A724 
displayed significant proliferative responses to p24 post first vaccination. Both of these 
cats had low viral and proviral loads, whereas the other 2 cats in the group which did not 
respond well developed higher viral and proviral loads post challenge. This result is 
consistent with a role for cell-mediated immunity in controlling the challenge virus. In 
group 2, no cat responded to p24 and WIV following the first vaccination, although 2/4 
responded after the second vaccination. In this group all of the cats except A726 had low 
viral loads and 2/4 had low proviral loads. These data are consistent with CD40L acting as 
an adjuvant to enhance the cell-mediated immune response. In Group 3 (CD40L only), 2/4 
cats responded to p24 and 1/4 to WIV following the first and second vaccination. 
Interestingly, two of the responders in this group, A729 and A730, had the highest 
responses to 25pg/ml of p24 (SI of 7.5 and 4.5 respectively) of all the animals tested. In 
this group, the cats that responded well to p24 developed high viral and proviral loads post 
challenge and a high level of virus was detected in MLN cells (Figure 5.5). Therefore, 
although CD40L had increased the immune response, the response may not have been 
sufficiently specific to prevent or even control infection post challenge and may even have 
resulted in enhancement of infection in these cats. Moreover, the single cat that did not 
respond to p24 and WIV in group 3 (A732) had remarkably low viral and proviral loads 
post challenge, further demonstrating that CD40L immunisation could have led to 
enhancement rather than inducing protective immune responses. The results were 
unexpected after the third vaccination as only one animal responded to p24 (A724) and no 
animal responded to WIV. The control group, group 4, displayed no significant responses 
to p24 or WrV at any of the time-points assessed.
5.3.7. No anti-viral antibodies were induced by vaccination
After vaccination and before challenge, no FIV-specific antibodies could be detected by 
flow cytometry. Western blotting, ELISA or IF. The ELISA to detect antibodies 
recognising the immunodominant TM peptide or p24 antigen confirmed that there were no
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anti-viral antibodies prior to infection (Table 5.3), with the exception of two animals (A726 
and A732) that had very low antibody titres (positive results detected at plasma dilutions of 
1:10) to the TM peptide before challenge. However, this result was not confirmed by any 
other method and is likely to have been non-specific, since A732 was seronegative 3 weeks 
later. No antibodies directed against FIV-GL8 infected Mya-1 cells were detected by flow 
cytometry.
5.3.8. Seroconversion following challenge
Western blotting was performed using plasma samples collected prior to the first 
vaceination to 15 weeks post challenge to detect anti-viral antibody production against the 
major structural proteins of FIV (TM, SU, CA, MA and NC) and confirmed that no anti­
viral antibodies had been induced in any of the cats before challenge (Table 5.4).
Anti-FIV antibodies developed in the cats following challenge, and analysis of sequential 
samples enabled comparisons of the humoral response between groups to be made (Table 
5.4). In group 1, 3/4 cats developed antibodies by 3 weeks after challenge, whereas the 
control cats remained seronegative. These results are consistent with either an anamnestic 
response following challenge of the cats immunised with FIV DNA, or enhanced viral 
replication leading to a high antigenic challenge. Cat A722 developed antibodies to both 
CA and SU by 3 weeks post-challenge. In group 2, only 2/4 cats developed antibodies at 3 
weeks post-challenge (see Figure 5.7). Therefore, there was no evidence that CD40L 
enhanced the humoral immune response to FIV. In group 2, cat A726 had the greatest 
antibody response at 3 weeks post-challenge, interestingly, this cat also developed the 
highest viral and proviral loads of the group. In groups 3 and 4, there was no evidence of 
antibody production against the main structural proteins of FIV until 6 weeks post- 
challenge. A similar trend was also evident in the p24 and TM ELISAs (Table 5.3), where 
2/4 cats in groups 1 and 2 had developed antibodies to p24 by the 3rd week post challenge 
and 4/4 cats in group 1 and 3/4 cats in group 2 had developed antibodies to the TM peptide 
3 weeks after challenge. However, antibodies to p24 and the TM peptide were not detected 
until 6 weeks post challenge in groups 3 and 4, except for cat A73I which had a very low 
anti-TM peptide titre at 3 weeks post challenge.
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5.3.9. Virus neutralizing antibody activity
The virus neutralising activity of plasma collected on the d.o.c and at 6 and 13 weeks post 
challenge was assessed in Mya-1 cells. None of the d.o.c samples had detectable VNA, 
consistent witli previous studies (Cuisinier et al. 1997; Hosie et al. 1998). At 6 weeks after 
challenge, cats A721 and A722 from group 1 (FIV DNA only) had the highest VNA of 
their group, as shown in Figures 5.8 and 5.9, which correlates with their high viral loads at 
6 weeks post-challenge. In comparison, cats A723 and A724 from the same group had 
very low VNA and also very low viral loads at 6 weeks post-challenge. These results are 
consistent with the induction of increased VNA in response to increased virus replication. 
A similar pattern is evident in group 2 (FIV and CD40L DNA). However, at 6 weeks post­
challenge in groups 3 and 4, the results for individual cats do not correlate with viral loads.
At 13 weeks after challenge, the VNA had increased in all plasma samples tested (Figure 
5.9). The degree of neutralising activity did not correlate with viral loads in any of the 
groups and the viral loads in all groups were lower at 13 weeks than at 6 weeks post­
challenge. Therefore, it is tempting to speculate that the increased virus neutralising 
activity could be controlling viral replication at this time point.
5.3.10. CD4:CD8 ratio inversion was more marked in the control 
groups
Flow cytometric analysis of lymphocyte subpopulations was performed on the d.o.c to 
acquire baseline data and at 3, 6, 10, 13 and 15 weeks post-challenge to monitor the 
progression of infection. Common findings in FIV infection are an increase in the CDS(3^ °^  
lymphocyte subpopulation (Willett et al. 1993; Shimojima et al. 1998; Grandie et al. 2000) 
and a decrease in the CD4^ lymphocyte subpopulation (Willett et al. 1991; Torten et al. 
1991; Hoffinann-Fezer et al. 1992), which ultimately results in an inversion of the 
CD4:CD8 ratio (Torten et al. 1991; Lehmann et al. 1992). Although this trend was evident 
in all of the groups following challenge, the increase in the CDSp*®'^  subpopulation was 
more marked in group 3 (CD40L DNA only), as shown in Figure 5.10. This result is 
consistent with this group having an enhanced infection. Also groups 3 and 4 (PBS 
control) had the greatest inversion of the CD4:CD8 ratio, in that the mean for group 3 
decreased from 2.6 to 1.2 (a difference of 1.4) and the mean for group 4 decreased from 2.9 
to 1.3 (a difference of 1.6) see Figure 5.11. In contrast the means for groups 1 and 2
99
decreased by 0.6 and 1.1 respectively. Cat A731 in group 3 had the greatest increase in the 
CD8p'^^ subpopulation from 3 to 6 weeks post-challenge, which correlated with this cat 
having the highest viral load of its group at 3 weeks post-challenge. In group 4, cat A734 
had the most marked increase in CDSP '^^  ^ subpopulation; while it did not have the highest 
viral load of this group, it had the highest proviral load.
5.3.11. Neutropenia was detected post challenge
Routine haematology was carried out on blood samples from all cats at 6 and 3 weeks pre­
challenge, on the day of challenge and 3,6, 10, 13 and 15 weeks post-challenge. As shown 
in Appendix A., all parameters were within normal limits in all cats before challenge. The 
only parameter in which abnormalities were detected following challenge was the 
neutrophil count, as illustrated in Figure 5.12. All cats suffered from a mild neutropenia, 
which was most evident at 6 and 10 weeks post-challenge. However, in some cats 
although lower than before challenge, the neutrophil count did not decrease to outwith the 
normal range (2.5-12.5x10^/1). There was no correlation between neutropenia in individual 
cats and the type of vaccine administered. By 15 weeks after challenge, all neutrophil 
counts were again within the normal range. In the primary phase of FIV infection, a 
transient neutropenia is a common finding (Shelton, Linenberger, and Abkowitz 1991; 
Hofinann-Lehmann et al. 1995) and normal neutrophil functions are depressed (Yamamoto 
et al. 1988; Hanlon et al. 1993),
5.4. Discussion
This study demonstrated that CD40L has the potential to act as a useful adjuvant in a DNA 
vaccine, since cats co-inoculated with CD40L and FIV DNA developed lower viral and 
proviral loads post-challenge, compared to cats inoculated with FIV DNA alone. 
However, the difference in viral and proviral loads between these two groups was not 
significant. Statistical analysis between groups with such small numbers can prove 
problematic, as tliere are a limited number of tests that can be performed. Immunisation 
with CD40L DNA alone appeared to have a detrimental effect on FIV infection, as cats 
that were inoculated with CD40L DNA developed higher viral and proviral loads post­
challenge, compared to control cats.
Evaluation of the FIV DNA vaccine prior to inoculation demonstrated tliat the major 
structural proteins (including Env) were expressed well in vitro. However, the level of
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expression was unknown in vivo. Similarly, the biological activity of CD40L was 
demonstrated in vitro, but the activity in vivo was not known. Furthermore, because the 
study lasted for 24 weeks and was designed to enable the efficacy of the DNA vaccine to 
be established by challenging with virus, we were unable to determine the exact location of 
the DNA directly after inoeulation. Therefore, there was no way of knowing whether the 
inoculated DNA had gone directly into muscle or between muscle bellies. This would 
presumably have an impact on the results of the study and possibly explain inter-group 
differences. Other factors that influence the distribution of DNA post vaccination include 
the volume in which the DNA is inoculated, pre-injection of muscles with substances such 
as sucrose and bupivicaine, and also the promoter used (Davis, Whalen, and Demeneix 
1993; Fomsgaard et al, 1998). Pre-injecting the muscles with sucrose and bupivicaine 
results in damage of the muscle cells, causing immune cells to migrate to the area of 
damage and therefore enhancing the immune response to the DNA vaccine (Matzinger 
2002). In addition, whether the DNA constructs remained in the muscle after inoculation 
or whether there was migration to the local lymph nodes was unknown. The iliac lymph 
nodes that would have drained the site of inoculation were collected at necropsy for future 
investigation by PCR to detect DNA constructs. Previous studies have demonstrated that 
plasmid DNA can remain in muscle for many months after inoculation (Wolff et al. 1992) 
but can also migrate to the local lymph nodes very rapidly (Winegar et al. 1996; Dupuis et 
al. 2000).
After challenging the vaccinated cats, there was evidence of enhancement of infection in 
the group that received CD40L DNA alone (group 3). This group had higher viral and 
proviral loads than group 4 (PBS only), the control group. In addition, some cats in the 
group which received FIV DNA only (group 1), also developed higher viral and proviral 
loads than the control group, demonstrating that the FIV DNA alone vaccine may have also 
induced a degree of enhancement of infection. However, the viral and proviral loads in 
groups 1 and 3 were not statistically significantly higher than the control groups. These 
results are consistent with those of a previous vaccine trial, in which cats inoculated with 
FIV Env DNA developed high viral loads much faster than the control cats post challenge 
(Richardson et al. 1997). Enhancement of FIV infection has been encountered in other 
vaccine trials, with immunogens including FIV envelope DNA, FIV p24 ISCOMS, FIV IC 
and envelope subunit vaccines (Hosie et al. 1992; Siebelink et al. 1995b; Richardson et al. 
1997; Karlas et al. 1999; Giannecchini et al. 2002). It has been proposed that lymphoid
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cell activation following immunisation with virus or non-virus specific antigens may 
increase the number of target cells available for infection by the challenge virus 
(Richardson et al. 2002). Further analysis was conducted to characterise potential modes 
of enhancement in this vaccine study, as described in Chapter 6.
I
The mechanism by which CD40L modifies the immune response to DNA vaccination is of 
great interest. CD40L has been shown in previous studies to enhance the cellular and 
humoral immune response to gene immunization (Mendoza, Cantwell, and Kipps 1997).
Low antibody titres were recorded in two of the cats against the TM peptide before 
challenge, however cats in groups 1 and 2 developed strong serological responses after 
challenge, these responses were consistent with the increased levels of viral replication 
evident from the high viral and proviral loads that developed post challenge. At present we 
are not able to discern what proportion of these serological responses are attributable to 
either antigen stimulation as a result of viral replication or memory cells primed by DNA 
immunisation against FIV before challenge. Previous work has shown that it is not 
unusual for a DNA vaccine not to induce anti-viral antibodies prior to challenge 
(Richardson et al. 1997; Hosie et al. 1998; Dunham et al 2002) and that DNA vaccines can 
still induce protection in the absence of detectable anti-viral antibodies. The methods used 
in this study to test for anti-viral antibodies have proven to be highly sensitive in previous 
studies (Hosie and Jarrett 1990)
As CD40L is also involved in the development of cell-mediated immunity, it was 
important to study the cell-mediated immune responses developed in this trial. Preliminary 
findings indicate that the cats in group 2 (immunised with FIV and CD40L DNA) 
developed strong cell-mediated immunity to WIV and p24 following vaccination, since 
increased proliferative responses were noted against WIV and p24. As previous studies 
have indicated that protection may be associated with cell-mediated immunity, (Hosie and 
Flynnl996; Flynn et al. 1996), it is tempting to speculate that the cell-mediated response in 
the cats in group 2 could be associated with the lower viral and proviral loads that 
developed post challenge. Further studies into the cell-mediated responses induced by FIV 
and CD40L vaccination are warranted and may involve demonstrating CTL activity with 
Chromium release assays and measuring IFN y production by ELISPOT.
In conclusion, the results of this vaccine trial demonstrate that the use of CD40L as an 
effective adjuvant in a vaccine against FIV requires further optimisation. This study also
1 0 2
demonstrates the need for further analysis to define protective and enhancing immime 
responses elicited by immunisation, so that more effective FIV vaccines may be developed. 
Furthermore, it may be possible to employ the lessons leamt from the FIV system to 
contribute to the development of effective vaccine strategies against other lentiviruses 
including HIV.
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Figure 5.1. Biological activity of feline CD40 ligand DNA 
construct (VR1012.F154)
10000 VR1012
VR1012.F154
8000 -
6000 -
E8-
4000 -
2000  -
3001000100000 30000 10000 3000 none
no. of 3T3 cells
Proliferative response of feline PBMC induced by 3T3 cells expressing feline CD40 ligand (VR1012.F154) 
(•), compared to mock transfected 3T3 cells (VR1012) (o). ** The difference between the two groups is 
highly significant P=0.0003, P=0.005 and P=0.01, and * significant P=0.05 respectively (Student’s t-test).
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Figure 5.2. Comparison of FIV protein expression of FIV DNA 
constructs in vitro
(A ) 1 2 3 4 5 6
M  m
gpl60 TM 
gpl20 SU
p55 gag core 
protein
(B) 1
p24 CA
pl7/10MA/NC
gpl60 TM 
gpl20 SU
(A) Western blots were stained with pooled FIV+ve serum and (B) monoclonal anti-Env antibody, vpg 71.2. 
1, CT5bG8MApol; 2, GL8A1N; 3, CF1G8M; 4, G8M control; 5, GL8ART and 6, GL8YI. See Table 5.1 for a 
full description of the FIV DNA constructs.
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Figure 5.3. Peak viral and proviral loads post challenge
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(A) Peak viral load of individual cats in each of the vaccination groups. Viral loads expressed as virions/ml 
of plasma. (B) Peak proviral load of individual cats in each of the vaccination groups. Proviral loads are 
expressed as copies/10  ^cells. See Table 5.2 for the time points of peak loads of individual cats.
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Figure 5.5. Mesenteric lymph node cell quantitative virus 
isolations
25
20  -
ÇOQ.
C  1 0  - 0>
OI f )
PBSFIV + CD40L CD40L DNAFIV DNA
Quantitative virus isolations were performed using cells from MLN collected at the end of study (15 weeks 
after challenge). * The dilution of MLN cells at which 50% of the MLN and Mya-1 cell wells were infected 
with FIV was calculated using the method by Reed and Muench (1938) (50% endpoint).
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Figure 5.6. Stimulation indices
( a ) ______________________
(b)
Group  Lymphoproliferative response____
Postl^'vacn Post 2" vacn Post 3"^ vacn
p24 WIV p24 WIV p24 WIV
FIV DNA 2/4 0/4 0/4 0/4 1/4 0/4
FIV + CD40L DNA 0/4 0/4 2/4 2/4 0/4 0/4
CD40L DNA 1/4 0/4 1/4 0/4 0/4 0/4
PBS 0/3 0/3 0/3 0/3 0/3 0/3
Group 1 Group 2
721 p24 721 WIV 722 p24 722 WIV 723 p24 723 WIV 724 p24 724 W V
Group 3
8
7
m 6Y
i :3
E 3Ô5 2
1
0
7 2 5  p 2 4  7 2 5  w v  7 2 6  p 2 4  7 2 6  VKiv 7 2 7  p 2 4  7 2 7  v « v  7 2 8  p 2 4  7 2 8  w iv
Group 4
729 p24 729 VWV 730 p24 730 WIV 731 p24 731 VWV 732 p24 732 WIV
8
7
6
5
4
3
2
1
0
733 p24 733 WIV 734 p24 7 341MV 735 p24 735W V
(a) Lymphoproliferative responses of post 1**, 2"**, and 3"* vaccination PBMC after incubation with 25pg/ml 
of FIV p24 or WIV. The stimulation index (SI) = experimental count/spontaneous count. A SI of > 2 was 
regarded as significant. Results are presented as the number of animals with a SI of > 2/the total number of 
animals in each group, (b) Stimulation indices for all cats after the 2"** vaccination.
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Figure 5.7. Group 2 (FIV and CD40L DNA vaccine) Western blots
4
B
■r’ f
D E
gpl60 TM gpl20 SU
■ i n  p55 gag^  I  core protein
■ M— p24 CA < -  pl7/10MA/NC
Plasma samples from -9w, -6w, -3w, Ow, 3w, 6w, lOw, 13w and 15w post challenge were tested for anti-FIV 
antibodies by Western blotting, a) cat number 725, b) cat number 726, c) cat number 727, d) cat number 728, 
e) -ve and +ve controls respectively.
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Figure 5.8. VNA activity at 6 weeks post challenge
140
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<D 80 -
<z>
U llll bl
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FIV DNA FIV + CD40L CD40L DNA PBS ONLY 
DNA
VNA of each cat in the vaccinated groups at 6 weeks post challenge. * The dilution of plasma at which 50% 
of the virus was neutralised, calculated using the method by Reed and Muench (1938).
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Figure 5.9. Virus neutralising antibody titres
(A)
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PBSFIV + CD40L CD40L DNAFIV DNA
(A) VNA of each cat in the vaccinated groups at 6 weeks post challenge. (B) VNA of each cat in the 
vaccinated groups at 13 weeks post challenge. * The dilution of plasma at which 50% of the virus was 
neutralised, calculated using the method by Reed and Muench (1938).
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Figure 5.10. CD8p'°'^ group means
14 FIV DNA
FIV + CD40L DNA 
CD40L DNA 
PBS12 -
w
®  10 -  ÜI CO.
QO
*o
occ
sE
d.o.c 3 6 10 13
weeks post challenge
15
CDSp'"'^ percentages obtained from flow cytometric analysis of stained lymphocyte populations. Values 
expressed as mean ± SE. * and ** Student t-test results are shown in Table 5.5.
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Figure 5.11. CD4:CD8 ratio group means
00Qq'irQ
Ü
3.5 FIV DNA
FIV + CD40L DNA 
CD40L DNA 
PBS3.0 -
2.5 -
2.0  -
T
d.o.c 6 10 
weeks post challenge
13 15
CD4" and CD8^ percentages obtained from flow cytometric analysis of stained lymphocyte populations. 
Values expressed as mean ± SE. * and ** see Table 5.5 for Student t-test values.
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Figure 5.12. Neutrophil count group means
14
12
=38
8 -
0)c
2  -
FIV DNA
FIV + CD40L DNA
CD40L DNA 
PBS
—i— 
-6 -3 d.o.c 3 6 10 13
weeks pre- and post challenge
15
Mean neutrophil count for each group from 6 weeks prior to challenge to 15 weeks after challenge. 
Neutrophil counts expressed as neutrophils x lO’/l, normal range (2.5-12.5x10^/1).
115
Table 6.1. FIV DNA constructs investigated for use as a DNA 
vaccine
DNA construct Description
1 GL8 ART GL8  molecular clone with a 99 bp deletion in reverse
transcriptase (RT) (Hosie et al. 1998)
2 GL8 AIN GL8  molecular clone with an in-frame deletion in the integrase
gene (IN) (Dunham et al. 2002)
3 GL8 YI GL8  molecular clone with a deletion in the endocytosis signal
(Hosie et al. 2004)
4 CT5bG8MApol PET/GL8  ehimera with a deletion in the pol gene (Poeschla,
Wong-Staal, and Looney 1998)
5 CF1G8M PET/GL8  chimera with deletions in the LTRs (Poeschla, Wong-
Staal, and Looney 1998)
DNA constructs 1 and 2 were kindly supplied by Dr. S. P. Dunham, University of Glasgow. Construct 3 was 
kindly supplied by Dr. M. J. Hosie also University of Glasgow and constructs 4 and 5 were kindly supplied 
by Dr. B. J. Willett, again University of Glasgow.
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Table 5.4. Western blot analysis of plasma samples, from 9 
weeks pre-challenge to 15 weeks post challenge
(A)
Vaccine Administered Weeks pre and post challenge (week 0)______
-9 - 6  -3 0 3 6  10 13 15
0/4 0/4 0/4 0/4 3/4 4/4 4/4 4/4 4/4
0/4 0/4 0/4 0/4 2/4 4/4 4/4 4/4 4/4
0 / 4  0/4 0/4 0/4 0/4 4/4 4/4 4/4 4/4
FIV DNA
FIV + CD40L DNA 
CD40L DNA 
PBS 0/4 0/4 0/4 0/4 0/4 4/4 4/4 4/4 4/4
(B)
Week 3 post challenge Antibodies induced to
G pl60/120 P55 P24 P17/10
FIV DNA 
A721 
A722 
A723 
A724 
FIV + CD40L DNA 
A725 
A726 
A727 
A728
+
+ +
+ +
+
++
+
+
4-
(A) The number of cats that had an antibody response, over the number of cats in each gi'oup at certain time 
points as demonstrated by Western blotting. (B) of the cats that did mount an antibody response, the 
response to each FIV protein differed. At 3 weeks post challenge, not all cats in each group had an antibody 
response. + indicates a band was observed on the Western blots, ++ denotes a stronger band and therefore, a 
stronger response.
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Table 5.5. Student t-test values from comparisons of 
group means and CD4:CD8 ratio group means at 3 ,6 ,10 ,13  and 
15w p.c.
5^ °'^  CD4:CD8 ratio
.
t-test 3w 6 w lOw 13w 15w 3w 6 w lOw 13w 15w
Group1 
agamst2 0 . 8 0.09 0 . 6 0.5 0 . 8 0.4 0 . 8 0.7 0.7 0.5
Group1 
againstS 0 . 1 0 . 2 0.3 0.03* 0 . 1 0.4 0 .0 1 ** 0.005** 0 .0 2 * 0 . 1
Group1 
against4 0.03* 0.5 0.5 0.4 0.3 0.05* 0.3 0 . 1 0 . 1 0 . 1
Group2
againstS 0 . 2 0.04* 0.03* 0 .0 1 ** 0.05* 0 . 6 0 . 1 0 . 2 0 . 1 0.4
Group2
against4 0 . 1 0.3 0.3 0 . 2 0 . 2 0 . 8 0.5 0.5 0.4 0.4
Groups
against4 0 . 1 0 . 2 0 . 8 0 . 1 0.9 0 . 1 0.4 0.4 0.3 0.9
Interestingly in the CDSp'”™ comparisons most of the significant results are between gi'oup 2 (FIV and 
CD40L DNA) and 3 (CD40L DNA alone) and not group 2 and 4, (PBS only), this demonstrates the positive 
effect of CD40L as an adjuvant to a FIV DNA vaccine and the negative effect of CD40L injected alone. 
However, in the CD4;CD8 ratio comparisons a greater response to infection was seen with the FIV DNA 
alone vaccine as more significant results were gained between group 1 (FIV DNA alone) and group 3. *t-test 
value significant (P<0.05) and ** highly significant (P<0.01).
î^»
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Chapter Six 
INVESTIGATION OF ENHANCEMENT OF FIV INFECTION 
AFTER VACCINATION
6.1. Introduction
In the vaccine trial conducted in cats to assess the efficacy of a CD40L adjuvanted FIV 
DNA vaccine (Chapter 5), a degree of enhancement of FIV infection was observed in 
animals that had received feline CD40L DNA or FIV DNA alone. As 2/4 cats in the 
CD40L only group had viral loads higher than the cats in the PBS control group and 1/4 of 
the cats in the FIV DNA only group had viral loads higher than the PBS controls. 
Furthermore, 3/4 cats in the CD40L DNA only group and 2/4 cats in the FIV DNA only 
group had proviral loads higher than the PBS control group. However, 2/4 cats in the FIV 
and CD40L DNA group also had proviral loads higher than the PBS controls. 
Enhancement of FIV infection after challenge has been observed in many FIV vaccine 
trials conducted previously, including DNA vaccines, recombinant virus vaccines, IC 
vaccines and subunit vaccines (Hosie et al. 1992; Osterhaus et al. 1996; Richardson et al.
1997; Flynn et al. 1997; Karlas et al. 1999).
Enhancement of infection has also been seen in other diseases caused by retroviruses 
including the oncornavirus, feline leukaemia virus (Pedersen et al. 1986) and other y 
lentiviruses including HIV and SIV infection (reviewed in Robinson and Mitchell 1990).
The enhancement of HIV infection has given cause for concern and led to caution in 
approaches to the development of a vaccine against HIV. Other diseases where 
enhancement has been observed are feline infectious peritonitis caused by a coronavirus 
(Hohdatsu et al. 1991), yellow fever, dengue and West Nile virus, all flaviviruses (Fagbami 
et al. 1988; Halstead 1988).
One mechanism of enhancement is known as antibody-dependent enhancement (ADE) of 
viral infection. ADE of viral infection is of concern because of its suspected role in 
producing enhanced viraemias, shorter incubation times from exposure to infection and 
development of disease, and vaccination failure. Two distinct types of infection-enhancing 
antibodies have been identified. One type utilises Fc receptors found on monocytes and 
macrophages, while a second type requires complement and complement receptors
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(reviewed in Montefiori 1993). McKeating et al. (1990) demonstrated that Fc receptors on 
fibroblasts could bind and internalise HIV-1 in the presence of sub-neutralising amounts of 
antibody to HIV. However in the experiments of Yamamoto et al. (1991b), the presence of 
VNA, correlated with protective immunity rather than with enhancement of infection. 
Furthermore, this immunity could be transferred to naïve animals by passive transfer of 
plasma from protected, immunised animals (Hohdatsu et al. 1993). Therefore, there is 
clearly a balance to be reached between enhancing and protecting immune responses.
Another postulated mechanism of enhancement involves lymphoid activation and has been 
demonstrated in HIV (Douek et al. 2002) and FIV infections (Richardson et al. 2002). 
Douek et al. (2002) demonstrated that HIV-specific CD4^ T-cells are preferentially 
infected in vivo, as HIV-specific memory CD4^ T-cells in infected individuals contained 
more HIV viral DNA than other memory CD4^ T-cells at all stages of HIV disease as well 
as following viral rebound after interruptions in anti-retroviral therapy. Richardson et al. 
(2002) also demonstrated in FIV infection that rapid dissemination of virus in vivo was 
associated with the presence of Th responses prior to challenge, after vaccination with a 
FIV Env DNA vaccine. These responses were linked to increased susceptibility of 
lymphocytes to ex vivo FIV infection.
Another interesting factor that must be considered in the apparent enhancement of FIV 
infection in cats inoculated with CD40L DNA alone, is the finding that CD40/CD40L 
interactions are required for the progression of retrovirus-induced murine AIDS (MAIDS) 
(Green et al, 1996; Green, Noelle, and Green 1998), a disease that causes splenomegaly, 
lymphadenopathy, hypergammaglobulinaemia and an immunodeficiency syndrome with 
pathology in susceptible mice similar to that seen in AIDS. Furthermore CD40L has also 
been implicated in enhanced HIV infection. In a recent study, CD40L-stimulated 
macrophages were found to be more susceptible to HlV-1 entry (Bergamini et al. 2002), as 
incubating macrophages with soluble CD40L for 7 days increased the number of CD4 and 
CCR5 antibody-binding sites and the percentage of CD4 and CCR5-expressing cells. 
Infection of CD40L-stimulated macrophages with HIV-1 resulted in a marked increase of 
proviral DNA with respect to controls, as demonstrated by PCR. In addition Fong et al.
(2002) demonstrated that productive infection of plasmacytoid dendritic cells with HIV-1 
was triggered by CD40 ligation. Also in another study, CD40-CD40L interactions were 
linked with the increased susceptibility of B-lymphocytes to HTV-l infection (Moir et al.
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1999). Therefore, it is tempting to speculate that inoculation with CD40L DNA alone may 
have increased the susceptibility to FIV infection.
Enhancement of FIV infection in cats vaccinated with CD40L DNA alone may have 
resulted from an increased number or susceptibility of target cells or enhancing antibodies. 
In order to investigate further the protecting and enhancing immune responses elicited by 
the FIV and CD40L DNA vaccinations, PBMC susceptibility assays were performed. 
These assays determined whether the lymphocytes of cats in which infections were 
enhanced after challenge were more susceptible to infection before challenge. The 
percentage of lymphocytes in PBMC was assessed by flow cytometry and the number of 
PBMC that contained 2x10^ lymphocytes was incubated with F1V-GL8. After incubation, 
cells were serially diluted and co-cultured with Mya-1 cells to determine the proportion of 
infected cells. These results were examined for correlations with either neutralising 
antibody activity or cell-mediated immune responses elicited after vaccination to determine 
if enhancement could be attributed to either the humoral or cellular immune responses 
induced by immunisation.
6.2. Materials and methods
6.2.1. Susceptibility of PBMC to FIV challenge
PBMC from all cats in the vaccine trial described in Chapter 5 were isolated on Üie d.o.c 
following three inoculations and were stored in liquid nitrogen using a controlled rate 
freezer. Planer Kryo 10 Series 11 (PLANER pic). Following recovery from liquid nitrogen, 
PBMC were counted and 10  ^ PBMC were prepared for flow cytometry to assess 
lymphocyte numbers in order to ensure that equivalent numbers of lymphocytes from each 
cat were added to the susceptibility assays. PBMC were washed twice in PBA and after 
centrifugation at lOOOrpm for 5 minutes, the resultant cell pellet was resuspended in 1ml of 
PBA. Samples were analysed on an EPICS Elite flow cytometer (Beckman-Coulter) using 
the EXPO 32 ADC analysis software package (Beckman-Coulter). 5000 events were 
collected for each sample and lymphocyte numbers were enumerated based on size and 
granularity. Subsequently the number of PBMC that contained 2x10^ lymphocytes was 
incubated with 500pl of FIV-GL8  (3000 ID50, approximately 10"* TCID50) in a Falcon 2054 
tube for 1 hour at 37°C in an atmosphere of 5% CO2 . After incubation, cells were washed 
three times in PBS and added in decreasing numbers (10\ 3x10^, 10 ,^ 3x10 10 \  30, 10, 3,
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1 and none) to a 96-well tissue culture plate (Falcon). Cells were then co-cultivated in 8  
replicate wells, with 10^  Mya-1 cells/well, to determine the proportion of PBMC that 
contained infectious virus. Plates were incubated at 37“C in an atmosphere of 5% CO2 for 
7 days (medium was replenished at day 4) at which time culture fluids were tested for FIV 
p24 antigen by ELISA (IDEXX). Results are expressed as the endpoint dilution at which 
50% of the wells were infected and were calculated using the method described by Reed 
and Muench (1938).
To further investigate the relationship between the susceptibility of lymphocytes to FIV 
infection and the outcome following vaccination, further susceptibility assays were 
conducted using pre-vaccination PBMC from the three cats with the highest endpoint 
dilutions and therefore the most susceptible lymphocytes of all the cats to FIV infection 
(A721, A726 and A733) and from the three cats with the lowest endpoint dilutions and 
therefore the least susceptible lymphocytes of all the cats to FIV infection (A724, A728 
and A731) as determined by the d.o.c PBMC susceptibility assays. In this way differences 
in susceptibility between pre-immunisation and post-immunisation PBMC could be 
assessed directly.
PBMC comprise a heterogenous cell population and therefore, to ascertain whether a more 
defined cell population was more or less susceptible to FIV infection, the above assay was 
also performed with d.o.c PBMC that had either been enriched or depleted of CD4^ cells 
following incubation with a mouse anti-feline CD4 antibody (vpg34, Serotec) and goat 
anti-mouse IgG antibody-coated magnetic beads (MACS beads, Miltenyi Biotec), as 
described in section 3.2.2.
6.3. Results
6.3.1. Lymphocytes from cats vaccinated with CD40L DNA alone 
are less susceptible to FIV infection
The results from this study indicate that enhancement is not associated with increased 
activation of the cellular immune system, but with some other factor. Thus, the PBMC 
from the cats in group 3 that received CD40L DNA only and displayed a degree of 
enhancement of FIV infection after challenge did not demonstrate an increased 
suseeptibility to FIV infection, when day of challenge lymphocytes were incubated with
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FIV-GL8  and co-cultured with Mya-1 cells (see Table 6.1). However, the cats in group 3 
did demonstrate significant stimulation indices, when PBMC collected after the first or 
second vaccinations were incubated with p24 and WIV consistent with increased activation 
of the cell-mediated immune system compared with the other groups. There was some 
correlation in cats between high viral and proviral loads in groups 1 (FIV DNA only) and 
group 2 (FIV and CD40L DNA) and lymphocyte susceptibility to FIV infection, in that the 
lymphocytes from cats that had high viral or proviral loads in these groups (A721, 722 and 
726) were more susceptible to FIV infection after vaccination, as shown in Table 6.1. This 
cannot be explained completely by vaccination having increased the cell-mediated 
response to FIV, however, as cat A733 in the control group (PBS only) also demonstrated a 
correlation between viral load and PBMC susceptibility and did not demonstrate an 
increased response to p24 and WIV. A single cat, cat A726 from group 2, demonstrated 
increased lymphoid activation, susceptibility to FIV infection and high viral and proviral 
loads post challenge.
6.3.2. Vaccination has a role in increased susceptibility to FIV 
infection
The susceptibility assays demonstrated that vaccination against FIV, with a FIV DNA 
vaccine with or without CD40L as an adjuvant, did indeed affect the susceptibility of 
lymphocytes to FIV infection. The susceptibility of pre-vaccination lymphocytes from the 
three cats with the greatest susceptibility to FIV infection (A721, A726 and A733) and the 
three cats with the least susceptibility to FIV infection (A724, A728 and A731) after three 
vaccinations (as determined by d.o.c susceptibility assays) was tested, (see Table 6.1). It 
was found that in cats where there was an increase in susceptibility to FIV infection post­
vaccination, this increase in FIV infection was not evident in lymphocytes collected prior 
to vaccination. Furthermore, in cats where there was no evidence of increased FIV 
infection of lymphocytes after vaccination, there was also no evidence of a greater 
susceptibility to FIV infection in lymphocytes collected prior to vaccination.
6.3.3. CD4  ^enriched cells are not more susceptible to FIV 
infection
To assess susceptibility of a defined cell population to FIV and as CD4^ T-cells are targets 
for FIV infection, susceptibility assays were conducted with CD4-enriched and CD4-
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depleted PBMC to determine the effect on susceptibility to FIV infection. As shown in 
Figure 6.1, there was no correlation observed between the cell population and the extent of 
FIV infection in the four cats tested. In cats A722 and A726, the CD4-depleted cell 
populations were more susceptible to FIV infection, whereas in cats A727 and A733, the 
CD4-enriched cells were more susceptible. Therefore, no conelation was evident between 
the expression of the CD4 molecule and susceptibility to FIV infection. However, 
seperation of cells using MACS beads does not result in a pure cell population as 
demonstrated in Chapter 3. Thus, the cell populations being compared may still have been 
heterogenous,
6.3.4. Correlation between VNA and enhanced infection?
The enhanced FIV infection observed in cats inoculated with CD40L alone could be 
explained by sub-neutralising levels of antibody. Thus, as shown in Figure 5.8, the cats in 
group 3 that received CD40L DNA alone, all had low levels of VNA activity, as 
determined in the experiment described in chapter 5. However, cat A726, from group 2 
(FIV and CD40L DNA) that developed the highest VNA titre of its group, also had the 
highest peak viral and proviral load of its group (see Table 6.1 and Figure 5.8), suggesting 
that VNA alone were not responsible for controlling the level of viral replication post 
challenge. Furthermore, other cats in group 2 (A725, A727 and A728) with some of the 
lowest viral and proviral loads of the study also had some of the lowest VNA titres.
6.4. Discussion
The results of this study do not reveal a clear mode of enhancement of FIV infection in the 
DNA vaccine trial conducted wiüi and without CD40L as an adjuvant. Previous studies 
have demonstrated VNA activity (Siebelink et al. 1995b), CD40-CD40L interactions 
(Green et al. 1996) and lymphoid activation (Richardson et al. 2002) as modes of 
enhancement of infection of MAIDS and FIV. In the vaccine trial conducted whereby cats 
were inoculated with FIV DNA, FIV and CD40L DNA, CD40L DNA, or PBS, a degree of 
enhancement was observed in cats that were inoculated with FIV DNA alone (group 1) and 
CD40L DNA alone (group 3). Thus, viral loads in 2/4 and proviral loads in 3/4 cats in 
group 3 were greater than the PBS controls. However, the level of enhancement was less 
marked in the FIV DNA alone vaccine group, since viral and proviral loads were greater in 
only 2/4 cats compared to the PBS controls.
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In contrast to the findings reported by Richardson et al. (2002), the enhancement observed 
in this study could not be accounted for by increased lymphoid activation following 
vaccination. Cats in the CD40L only DNA group did demonstrate increased cell-mediated 
immune responses when post vaccination PBMC were incubated with FIV p24 and WIV, 
however, when day of challenge PBMC were incubated with FIV-GL8  there was no 
increase in susceptibility to infection. These conflicting results could be accounted for by 
the fact that in this study, PBMC numbers were adjusted to take into account the 
differences in percentages of lymphocytes among different cats, whereas in the lymphocyte 
susceptibility experiments performed by Richardson et al. the same total numbers of 
PBMC were used. Another factor to take into consideration is the numbers of other cell 
types that may play a role in susceptibility, such as monocytes. Therefore, although 
increased activation of the cell-mediated immune system cannot account for this increase 
in susceptibility to FIV infection, other undefined immunological events following 
vaccination can.
The possibility that VNA titres could account for the enhancement of FIV infection was 
also investigated. Cats in the CD40L DNA only group did develop low levels of VNA 
activity at 6  weeks post challenge, however, cat A726 in group 2 (FIV and CD40L DNA), 
had high VNA levels and high viral and proviral loads. The high VNA levels in this cat 
measured 6  weeks p.c could be a direct result of increased viral replication after challenge 
or may reflect that immunisation primed a VNA response. No VNA were detected in any 
of the groups in day of challenge plasma samples.
At present, no reliable systems are available to quantify or even detect FlV-enhancing 
antibodies in vitro. Therefore, this mechanism of enhancement cannot be ruled out. In this 
study VNA assays were performed using Mya-1 cells, further studies will be required to 
determine whether VNA antibodies were present in day of challenge plasma but were 
undetectable by this method. Siebelink et al. (1995b) demonstrated VNA activity in CrFK 
VNA assays and not in the feline lymphocyte assays conducted, however, the lymphocyte 
assay should be considered more relevant in terms of protective immunity against FIV 
infection, as feline lymphocytes are the natural targets for FIV infection. In a recent study, 
Giannecchini et al. (2001) demonstrated a masking of VNA phenomenon. Whilst studying 
the immune correlates of protection involved in a fixed-infected-cell vaccine, VNA were 
not thought to play an important role. However, further studies revealed that VNA were
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indeed present and that failure to detect VNA initially was due to the presence of vaccine- 
induced antibodies to cellular antigens and that these antibodies could be removed by 
adsorption with selected feline cells. Tliis phenomenon may be of relevance with respect 
to DNA vaccines.
Further studies will also be required to determine whether CD40-CD40L interactions do 
indeed increase susceptibility of cells to FIV infection as demonstrated previously in HtV- 
1 infection (Moir et al. 1999; Bergamini et al. 2002; Fong et al. 2002). It is interesting that 
in this study, the greatest level of enhancement was observed in cats immunised with 
CD40L DNA alone since previous studies have linked CD40-CD40L interactions to the 
development of MAIDS (Green et al. 1996; Green, Noelle and Green 1998). Green et al. 
(1996) demonstrated that a monoclonal antibody to CD40L inhibited the splenomegaly, 
hypergammaglobulinaemia and immunodeficiency disease state associated with MAIDS. 
In this study, mice infected with LF-BM5, an isolate of murine retroviruses were treated 
with anti-CD40L antibody (therefore preventing CD40L from interacting with CD40 on B- 
cells). This resulted in the symptoms of MAIDS being inhibited. Therefore, it is tempting 
to speculate that the increased viral and proviral loads in cats vaccinated with CD40L DNA 
may be due to increased CD40-CD40L interactions enhancing the disease process. 
Unfortunately until the mechanisms of enhancement of infection are fully understood, this 
phenomenon is a potentially fatal stumbling block in the continuing search for vaccines 
against infection with FIV and HIV.
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Figure 6.1. CD4 enriched and CD4 depleted cell susceptibility 
assays
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PBMC collected on the day of challenge from the cats in the FIV DNA vaccine trial were separated into 
CD4-enriched and CD4-depleted cell populations using magnetic antigen coated beads. Cat numbers A722, 
A726, A727 and A733 were selected as a larger number of PBMC had been collected for these cats. 
* Results are expressed as the endpioint dilution of PBMC at which 50% of the wells were infected with FIV 
and were calculated using the method by Reed and Muench (1938).
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Table 6.1. Pre-vaccination and day of challenge PBMC 
susceptibility to FIV infection
susceptibility outcome post challenge
cat number pre-vacn d.o.c peak VL peak PVL
group 1 
A721 9 160 7356 41913
A722 nd 47.5 50082 94487
A723* nd 21.5 1551 794
A724* 7.5 6 0 6 6 6
group 2  
A725 nd 13.25 959 12935
A726** 8 92 16456 50199
A727 nd 23 2701 39883 i
A728** 13.5 7.5 1144 4807 1
group 3 
A729* nd 8.5 33821
!
182914 '
A730* nd 18 12612 93937
A731 5 5 101369 45970
A732 nd 17 603 7293
group 4 
A733 5 134 27525 22223
A734 nd 27 3847 24683
A735 nd 25.5 4256 14831
Lymphocytes from cats prior to immunisation (pre-vacn) or following 3 immunisations and prior to challenge 
(d.o.c) were compared for susceptibility to infection with FIV-GL8 in vitro. These results are compared with 
the peak viral load (VL) and proviral loads (PVL) measured during the 15 weeks post challenge. VL are 
expressed as virions/ml of plasma and PVL are expressed as proviral copies/10  ^cells, nd : not determined. * 
significant stimulation index ( ^ )  to either p24 or WTV, ** significant stimulation index (>2) to both p24 and 
WIV.
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Chapter Seven 
GENERAL DISCUSSION
7.1. Aims of this study
The main aim of this study was to test the effect of using the feline homologue of the co­
stimulatory molecule CD40L as an adjuvant in a DNA vaccine against FIV infection. As a 
first step towards that goal, the biological activity of feline CD40L was demonstrated. 
Subsequently the properties of feline CD40L in vitro were investigated by monitoring the 
effect of co-cultivating feline PBMC with cells expressing CD40L and examining the 
resulting cell phenotypes by flow cytometry. In vivo studies with CD40L in both mice and 
cats were performed and finally the apparent phenomenon of enhancement of FIV 
infection following immunisation was investigated.
7.2. Feline CD40L is biologically active
When testing the biological efficacy of feline CD40L in vitro, 3T3 cells were either stably 
or transiently transfected witli feline CD40L DNA, so that CD40L was then expressed on 
the cell surface of the 3T3 cells similar to the membrane-bound expression of CD40L on 
T-cells in vivo. The 3T3 cells expressing CD40L were then used as target cells in 
proliferation assays. As described in Chapter 3, feline PBMC were shown to proliferate in 
response to feline CD40L. The biological activity of feline CD40L was further 
demonstrated when the above mentioned target 3T3 cells expressing CD40L were used as 
a feeder layer. A B-CLL cell line, derived from a blood sample taken from a cat that had 
been admitted to Glasgow University Veterinary Hospital with a suspected CLL, was 
maintained using the 3T3 eells expressing feline CD40L, whilst a control feeder layer 
consisting of mock-transfected 3T3 cells was unable to maintain the neoplastic B-cells.
7.2.1. Further studies
The activity of membrane bound CD40L was investigated, however it would be interesting 
to test the activity of soluble feline CD40L both in vitro and in vivo. Hollenbaugh et al. 
(1992) and Mazzei et al. (1995) demonstrated the biological activity of soluble CD40L and 
other studies with soluble CD40L have been conducted. Khanna et al. (1997) 
demonstrated that soluble CD40L-treated Burkitts lymphoma (BL) cells consistently 
processed endogenously synthesised viral antigens for recognition by virus-specific CTLs.
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BL is an Epstein-Barr virus-associated tumour and BL cells are known to escape CTL 
surveillance by down-regulating transporter for antigen presentation and surface MHC 
expression. However, this study showed that CD40L treatment of tumour cells might be 
used in conjunction with other immunotherapeutic protocols to prevent this down- 
regulation and thereby aid the immune system to fight the disease.
Future work could also be conducted to investigate the maintenance of a normal feline B- 
cell line using CD40L as a feeder layer and also using soluble CD40L, as in this study the 
neoplastic cell line only was maintained. Fmlher investigations to determine the cytokines 
that are required to maintain a normal B-cell line are warranted.
7.3. CD40L could be used as an adjuvant in a DNA vaccine
Once the activity of feline CD40L had been established in vitro, studies were conducted in 
vivo. Mice were inoculated with CD40L DNA alone, FIV DNA alone and CD40L and FIV 
DNA together, to determine whether CD40L enhanced the humoral and cellular immune 
responses to FIV. In a similar study cats were inoculated with the same groups of DNA, 
however in an extension to the above protocol, the outcome of an i.p challenge with the 
homologous strain of FIV was investigated in addition to the humoral and cellular immune 
responses induced by DNA vaccination.
CD40L DNA inoculation appeared to induce humoral responses in mice as measured by 
Western blotting, however this was not the case in the feline vaccine trial, where no 
antibodies were detected following immunisation and prior to challenge. In the murine 
study the method used to detect a cellular immime response gave non-specific results, 
whereas the same method gave valid results in the feline study and, as described in Chapter 
5, demonstrated that CD40L enhanced the cellular arm of the immune response against 
FIV. After the cats were challenged i.p with FIV-GL8 , the cats were monitored for 
evidence of FIV infection by virus isolation and viral and proviral loads were measured. In 
addition, flow cytometry was employed to monitor CD4;CD8 ratios and CD8 p'®'^  cell 
number counts. These results indicated that CD40L DNA, when inoculated in conjunction 
with FIV DNA, did act as an adjuvant to the FIV vaccine in some cats, as overall the cats 
in group 2 (FIV and CD40L DNA) developed lower peak viral and proviral loads than the 
cats in groups 1 and 3. Furthermore, at 6 , 10, 13 and 15 weeks p.c, the mean of the
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CDgp*ow numbers in cats in group 2  was lower than the mean of the cats in the other 
vaccine groups.
7.3.1. Further studies
In the mouse study the cellular immune response was measured using proliferation assays, 
however these proved to be non-specific. The results in the feline study were valid; 
however, further studies are required to demonstrate cellular immune responses in the 
mouse against FIV and to increase the data describing cellular immunity in the cat. One 
such study may be the conduction of CTL assays. The CTL assay has been used in 
previous FIV vaccine studies to demonstrate cellular immune responses induced in 
response to FIV vaccination (Flynn et al. 1995a; Flynn et al. 1996; Pu et al. 1999; 
Leutenegger et al. 2000). In brief, autologous skin fibroblast target cells collected prior to 
vaccination are labelled with sodium ^^chromate and then infected with recombinant 
vaccinia virus expressing either the gag or env gene of FIV. Fibroblast target cells are then 
incubated with effector lymphocytes derived from PBMC from vaccinates prior to 
challenge. After 4 hours, supernatants are removed and the sodium ^^chromate activity is 
measured. Cytotoxicity can also be measured by a lactate dehydrogenase (LDH) assay, 
whereby LDH a stable cytosolic enzyme that is released upon cell lysis is measured 
(Beatty et al. 1996; Lockridge et al. 2000) and by measuring the mitochondrial membrane 
potential, a reduction in which is an early step during CTL-mediated cell death (Hu and 
Kipps 1999; Burger, Mendoza, and Kipps2001). Burger, Mendoza, and Kipps (2001) also 
conducted studies with mice splenocytes to determine cellular immune responses. 
Splenocytes were separated into CD8  ^cells using flow cytometry and stimulated with the 
antigen (p-gal) used in the inoculations, flow cytometry was again used to assess numbers 
and therefore, detect any response to p-gal. Other methods to demonstrate cell-mediated 
immune responses are IL-2 assays, conducted using an IL-2 dependent CTL-L cell-line 
(Richardson et al. 2002) and IFN-y measurement, conducted by detecting the level of anti­
viral activity against vesicular stomatitis virus on a feline embryo cell-line (McCullough et 
al. 1986; Pu et al. 1999). IFN-y production can also be measured using ELISPOT (Sirriyah 
et al. 2004). Sirriyah et al. (2004) demonstrated that equivalent numbers of CD4^ and 
CD8  ^T-cells produced IFN-y in naïve cats, however, in FIV infected cats the number of 
CD8  ^T-cells that produced IFN-y was twice the number of IFN-y producing CD4^ T-cells.
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Some of the results from the FIV vaccine trial were inconsistent. As shown in Chapter 5, a 
cat with a high antibody titre could still have a high level of FIV infection, as indicated by 
viral load measurements. Further studies to distinguish between a) an ananmestic immune 
response generated from a previous vaccination and b) an immune response induced in 
response to biological infection would enable greater interpretation of vaccine trial data. 
These studies could involve including a marker sequence or gene product in the vaccine 
and then testing for specific antibodies, or testing for antibodies against a gene product that 
is not included in the vaccine, but that is found in the biological challenge. Thus, in the 
ART vaccine, if antibodies to RT were detected this would be indicative of an immune 
response to challenge and not an anamnestic response generated by vaccination.
Another common finding in vaccine trial results is inter-group variation. This could be due 
to the DNA inoculation site. When injecting DNA into the quadriceps and gastrocnemius 
muscles of the hind limb, unless the animal is examined immediately post mortem, there is 
no way of knowing whether the DNA has gone into the muscle belly or in-between muscle 
bellies. Previous studies (McCluskie et al. 1999; Dupuis et al. 2000) have shown that the 
vaccination site can play a large part in the ensuing immune response. Dupuis et al. (2000) 
demonstrated that only muscle cells expressed a transgene even though there was uptake of 
DNA from non-muscle cells, when DNA was injected into the tibialis anterior muscle of 
mice. McCluskie et al. (1999) conducted a large study, whereby mice and rhesus monkeys 
were inoculated in many different sites with a hepatitis B surface antigen (HbsAg)- 
encoding plasmid. This study demonstrated that out of eight sites (i.p, i.d, i.v, i.m, 
intraperineal, subcutaneous, sublingual and vaginal wall) of DNA inoculation in mice, anti- 
HbsAg antibodies were generated in only five sites of DNA inoculation. Furthermore, the 
highest levels of antibody were detected in mice injected i.m or i.v. In the monkey, two 
sites were inoculated (i.m and i.d) and both induced anti-HbsAg antibodies.
Another factor affecting individual results is the i.p challenge. If performed incorrectly, 
the challenge dose could conceivably be inoculated into the bladder or large intestine, 
presumably resulting in a lower challenge dose or a failed injection. Also, should we really 
be challenging with virus using methods more akin to natural challenge? In the wild FIV 
is transmitted via the saliva, through biting, since FIV is most common in intact adult 
males. Therefore, to simulate this, would an i.m or i.d challenge be a more effective 
method of testing vaccines for use in the field or does the i.p challenge represent a more
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stringent test for the vaccine (Rigby et al. 1997)? Rigby et al. (1997) compared the FIV 
infections that resulted after either an i.p or an i.m inoculation of virus reconstituted from 
the, F14 molecular clone of FfV-PET. It was demonstrated that there was a higher viral 
load in cats inoculated i.p than those inoculated i.m, despite the fact that the virus 
concentration in the i.m inoculum was 10 times higher than the i.p inoculum. This would 
suggest that viral challenge via the i.m route is relatively inefficient at establishing 
infection. An i.d challenge would presumably be efficient at establishing infection, as the 
skin is rich in professional APC’s that would carry the virus fi-om the skin to the local 
lymph nodes. Perhaps the lack of APC’s in muscle causes the slower rate of infection. In 
addition, as FIV is an invaluable animal model for HIV, should vaccine efficacy be tested 
by challenging using methods more akin to the natural transmission of HIV? Pistello et al.
(2003) remarkably demonstrated protection against a FIV-GL8  i.p challenge when SPF 
cats were vaccinated with a live-attenuated FIV-PET vaccine, however when challenged 
mucosally via the vagina the vaccine did not induce sterilising immunity but the FIV-GL8  
replication that ocurred in the vaccinated cats was much less than in the unvaccinated cats. 
This study provides encouragement for the development of live-attenuated FIV and HIV 
vaccines and allays some of the fears with regard to a live-attenuated HIV vaccine, as no 
vaccinated cat displayed any symptoms of disease derived from the vaccine strain of FIV.
Vaccine efficacy can be tested by different routes of challenge, as described above, and 
also by using different types of challenge inocula. The different types of inocula include: 
1) early passaged inoculum grown in primary PBMC; 2) molecularly cloned inoculum; 3) 
in vivo-derived inoculum such as plasma from FIV-infected cats and 4) contact challenges 
to stimulate natural conditions such as housing vaccinates with FIV-infected cats (reviewed 
in Uhl et al. 2002). In vivo-derived inoculum is similar to natural challenge as it contains 
quasi-species of FIV. These different types of challenge inocula and routes of transmission 
should be considered when planning future FIV vaccine trials, to optimise vaccine efficacy 
evaluation. In field-testing is likely to become important in future FIV vaccine trials and 
results may have an impact on HIV vaccine efficacy evaluation.
Finally, as with other diseases, another factor to consider is whether individual cats have 
different thresholds for infection. Animals, like humans, have different susceptibilities to 
infection depending on environment, diet and the development of their immune systems. 
Most of these factors are overcome with SPF animals that are kept in similar environments
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and have the same diets, however, an animal born with a poorly developed immune system 
could be more susceptible to infection, regardless of being vaccinated with a vaccine 
shown previously to induce protection. Moreover, an animal with a high threshold to 
infection may falsely demonstrate that a vaccine has induced protection.
7.4. Causes of enhancement of FIV infection still undetermined
In the feline vaccine trial described in this thesis, vaccination with FIV DNA alone and 
CD40L DNA alone appeared to result in enhancement of FIV infection after challenge in 
some cats, as 2/4 cats in the CD40L only group had viral loads higher than the PBS control 
group cats and 1/4 of the cats in the FIV DNA only gi’oup had viral loads higher than cats 
immunised with PBS as a control. Furthermore, 3/4 cats in the CD40L DNA only group 
and 2/4 cats in the FIV DNA only group developed proviral loads higher than the PBS 
control group cats. The investigation into this enhancement is described in Chapter 6 . In 
this study PBMC isolated after all three vaccinations but prior to FIV challenge were 
incubated with FIV-GL8 . Assays were then conducted to compare the susceptibilities of 
these cells to FIV infection. No links could be proven between susceptibility of PBMC to 
FIV infection and high viral loads post challenge. However, these studies did demonstrate 
that vaccination did indeed have an effect on susceptibility to infection, as when PBMC 
collected pre- and post- vaccinations were compared it was evident that the pre-vaccination 
PBMC were less susceptible to FIV infection.
7.4.1. Further studies
Richardson et al. (2002) demonsti'ated a link between lymphoid activation prior to 
challenge and enhancement of FIV infection post vaccination. Similar methods were 
employed to those described in Chapter 6  in this study, to detect an increased susceptibility 
of lymphocytes to FIV infection, with the exception that PBMC numbers were not adjusted 
to take into account the varying numbers of lymphocytes between cats before use in the 
susceptibility assays. In this study flow cytometry was performed to assess lymphocyte 
numbers in individual cats so that the number of PBMC used in the assays could be 
adjusted, taking the lymphocyte numbers into account. Further assays could be conducted 
using PBMC numbers not adjusted for lymphocyte counts to determine if the results would 
be more comparable to those obtained by Richardson et al. (2002). Furthermore, if 
lymphoid activation does indeed lead to enhancement of infection, it would be interesting 
to conduct further vaccine studies with varying intervals of time between the final
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immunisation and challenge, in order to examine the effect of decreasing the level of 
immune activation with time.
CD40-CD40L interactions affect the humoral and cell-mediated immune systems in many 
different ways. They are involved in the activation and differentiation of B-cells, the 
activation of T-cells via B7-CD28 interactions, CD40-CD40L interactions enable B-cells 
to increase their APC function, Th cells are primed and CTL's differentiate into memory 
cells with the help of CD40L, furthermore, CD40L also plays a role in T-cell tolerance and 
has direct anti-viral activity. All these factors would seem to make CD40L the ideal co­
stimulatory molecule to use as an adjuvant to boost the immune responses to FIV. 
However, perhaps it is this veiy broad range of effects that may have in fact led to CD40L 
DNA causing enhancement of infection, as the immune response generated was not 
specific enough to induce protection against FIV. Berlinski et al. (2002) have 
demonstrated a non-specific component of immunisation related increased susceptibility to 
FIV infection and have concluded that cats vaccinated with non-FIV specific antigens or 
even commercial feline vaccines may be more susceptible to FIV infection.
A further mode of enliancement may involve the primary receptor for FIV. As mentioned 
previously, the primary receptor for FIV has recently been identified as CD 134 (Shimojima 
et al. 2004). CD 134 (also known as 0X40) is a T-cell activation antigen and costimulatory 
molecule that is expressed primarily on CD4^ T-cells (Paterson et al. 1987; Mallett, 
Fossum, and Barclay 1990), but it has also been shown to be present on activated CD8  ^T- 
cells, B-cells and macrophages (Baum et al. 1994; Durkop et al. 1995). Therefore 
vaccination may induce an expansion of a population of cells expressing the viral receptor 
and if the immune response induced is not virus specific then vaccination may lead to 
enhancement of infection. Furthermore, signalling through CD 134 plays an important role 
in the proliferation and survival of CD4^ T-cells that have encountered antigen, CD 134 
engagement enhances expansion and migration and prevents effector T-cell apoptosis 
(Gramaglia et al. 1998), further increasing the FIV susceptible cell population. The 
eventual decline in CD4^ T-cell numbers as FIV disease progresses may be explained by 
the shift in cell tropism of the virus to CXCR4-expressing cells (CD 134-independent 
infection) in chronic FIV infection. It has been demonstrated previously that some primary 
and some cell culture-adapted strains of FIV can infect via CXCR4 alone (Lemer and 
Elder 2000). Further work in this field is warranted.
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7.5. Conclusion
In this study, the biological activity of CD40L and the effect of CD40L as a DNA adjuvmit 
have been demonstrated. Also the possible link between lymphoid activation and 
enhancement of FIV infection has been studied. Although the FIV and CD40L combined 
DNA vaccine did not induce protection against a virulent isolate of FIV, it did appear to 
increase humoral responses in the mouse against FIV and increased cell-mediated 
responses in the cat against FIV. The use of CD40L as an adjuvant also led to decreased 
viral loads following challenge and slowed the progression of disease as determined by 
CD8 p‘®^ number counts. For lentiviral vaccination, it has been proposed that instead of 
sterilizing immunity being the goal of vaccination, it may be more realistic to evaluate the 
efficacy of vaccines based on the above determinants (Davenport et al. 2004).
Further studies are indeed warranted, however, it is important not to overlook the negative 
involvement of CD40L in diseases such as HIV (Kombluth 2000), MAIDS (Green et al. 
1996) and neoplasia (Anderson et al. 2000). Both Pinchuk et al. (1994) and Tsunetsuga- 
Yokota et al. (1997) demonstrated that CD40L expression was required for full CD4^ T 
cell activation and thus, the enhanced growth of HTV-l. It would be interesting to 
determine if CD40L expression increased the susceptibility of CD4^ T cells to FIV 
infection. CD40L has also been implicated in the pathogenesis of MACDS, Green et al. 
(1996) demonstrated that antibody to CD40L inhibited the symptoms of MAIDS such as 
splenomegaly and hypergammaglobulinaemia. Furthermore, CD40L is also involved in 
autoimmunity and transplant rejection (reviewed in Grewal and Flavell 1998). However, 
this involvement may lead to therapeutic uses of anti-CD40L mAbs. Further studies are 
required to achieve the desirable balance between the negative and positive effects of 
CD40L.
In this study a DNA vaccine trial was conducted against FIV and the results raised many 
questions about the way in which this study and other FIV vaccine trial studies have been 
conducted in the past. In future, standardisation of the method of inoculation of the DNA 
vaccine, the method of challenge of FFV and the methods used to detect humoral and 
immune responses must be considered, in order for many research groups to work together 
in the continuing search for an effective FIV vaccine against field isolates and for the 
findings to be used constructively in the development of a HIV vaccine.
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Currently there is a FIV vaccine available in the USA, Fel-O-Vax FIV (Fort Dodge Animal 
Health, P.O.Box 25945, Overland Park, KS); this vaccine is based on a dual-subtype, 
subtype A FIV-PET and subtype D FIV-Shizuoka (SHI), WIV vaccine (Pu et al. 2001). It 
was hoped that by combining two different subtypes of the FIV, the protection induced 
would be against a broader range of isolates. To test this hypothesis, vaccinated cats were 
challenged with FIV-PET, the homologous isolate and FIV-BANG, a heterologous isolate. 
To further test the immunity induced, two different strengths of challenge inocula were 
used for the heterologous isolate. Four out of five dual-subtype vaccinated cats were 
protected agamst a low-dose (10 CID50) FIV-BANG challenge. However, in an additional 
study only 2/5 dual-subtype vaccinated cats were protected against a high-dose (100 
CID50) FIV-BANG challenge. Therefore, the dual-subtype vaccine did induce protection 
against a low-dose heterologous isolate challenge, but the vaccine was less efficacious 
against a high dose challenge. However, Pu and co-workers demonstrated that the dual­
subtype vaccine induced stronger immunity against the homologous challenge (FIV-PET) 
when compared to a single-subtype vaccine. Thus, 4/4 dual-subtype vaccinated cats were 
protected against FIV-PET (50 CID50) whereas, only 1/5 single-subtype vaccinated cats 
was protected against the same challenge dose. Could this be an effective strategy against 
virulent isolates in the UK? Recent results have indicated that Fel-O-Vax did not protect 
cats against challenge with the FIV-GL8  isolate (Dunham et al. 2004).
The problems involved in developing a FIV vaccine that has a broad range of protection 
against many isolates ar e similar to the problems encountered in the development of a HIV 
vaccine. Additional factors to consider are individual mutations and inter-subtype 
recombination of viruses. Therefore, it is hoped that the continued work in the field of FIV 
will assist the research into HIV vaccine development. Further studies are required to 
overcome these hurdles and hopefully the lessons learned in the FIV vaccine system will 
impact upon the future development of an effective HIV vaccine. SIV is another useful 
animal model for HIV and SIV vaccine studies also have an important role in HIV vaccine 
research; however FIV is an animal model in which the host is infected naturally and can 
suffer from immunodeficiency symptoms similar to AIDS. Therefore, the development of 
a FIV vaccine is an important step in the development of a vaccine against HIV infection.
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Appendix B. Solutions for large scale plasmid preparations
Solution 1
2g lysozyme 
3.6g glucose
20ml0.2MEDTA (pH 8)
10ml IM Tris (pH 8)
Make up to 400ml with water for 8 preparations
Solution II
25.6ml 5M NaOH 
64ml 10% SDS
Make up to 640ml with water for 8 preparations
Solution III
240ml 5M KO AC 
46ml acetic acid
Make up to 400ml with water for 8 preparations
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